Personale

Recapiti

Orario di ricevimento

Italiano

Curriculum

Pubblicazioni

Insegnamenti

English

Curriculum

Enrico MINI

Ruolo attuale:: Professore Emerito titolare di contratto di insegnamento

Recapiti

	0552758221
	enrico.mini(AT)unifi.it

Enrico MINI

Curriculum

CURRICULUM VITAE

Nome Cognome: Enrico Mini

Data di nascita: 22 febbraio 1952

Luogo di nascita: Livorno, Italia

INDIRIZZO

Sezione di Farmacologia Clinica e Oncologia

Dipartimento di Scienze della Salute (UniFI)

ISTRUZIONE

1988: Dottorato di Ricerca in Farmacologia e Tossicologia, UniFI

1980: Specializzazione in Oncologia, Università di Modena

1977: Laurea in Medicina e Chirurgia - Magna cum laude, UniFI

POSIZIONI ATTUALI

Accademiche

2011- Direttore della Scuola di Specializzazione in Oncologia Medica, UniFI

2008- Professore Ordinario di Oncologia Medica, UniFI

1992- Direttore del Laboratorio di Chemioterapia e Farmacologia Antitumorale, UniFI

Cliniche:

2014- Direttore della SOD di Oncologia Traslazionale, Azienda Ospedaliero-Universitaria Careggi (AOUC), Firenze

POSIZIONI PRECEDENTI

Accademiche:

2001-2008: Professore di Farmacologia, Dipartimento di Farmacologia, UniFI

1992-2001: Professore Associato di Farmacologia, Dipartimento di Farmacologia, UniFI

1988-1992: Professore a contratto (Chemioterapia Oncologica), Università di Ferrara

1983-1987: Professore a contratto (Farmacologia Cellulare), Università di Siena

1981-1984: Ricercatore, Dipartimenti di Medicina Interna e di Farmacologia; Yale University School of Medicine (New Haven, CT, USA)

Cliniche:

2004-2014: Direttore di Programma, c/o SOD Farmacologia Oncologica, Dipartimento Assistenziale Integrato di Oncologia, Azienda Ospedaliero-Universitaria Careggi, Firenze

1993-2004: Dirigente I livello, Servizio di Farmacologia Clinica, Azienda Ospedaliero-Universitaria Careggi, Firenze

VISITATORE OSPITE

Luglio - settembre 2010: Visiting Professor, Dipartimento di Farmacologia, Yale University School of Medicine (New Haven CT, USA)

Maggio-luglio, 1989, Settembre 1990–: Visiting Scientist, Cornell University Graduate School of Medical Sciences, Laboratory of Molecular Pharmacology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Maggio 1987, settembre-ottobre 1987: Visiting Scientist, Dipartimenti di Medicina Interna (Sezione di Oncologia Medica) e di Farmacologia, Yale University School of Medicine, New Haven CT, USA

PREMI E BORSE DI STUDIO:

1989: Premio Viviana Minozzi Bartolozzi dell’Università degli Studi di Firenze

1988-1990: Award della Lady Tata Memorial Trust (Londra)

1988: Premio Alberico Benedicenti della Società Italiana di Farmacologia (SIF) (menzione) (Milano);

1988: Borsa di studio all’estero del Consiglio Nazionale delle Ricerche (CNR), Roma/National Institute of Health (USA)

1985: Premio della International Union against Cancer (UICC) (Ginevra, Svizzera)

1982-1984: Special Fellowship della Leukemia Society of America (New York, NY, USA)

1981 ,1985, 1986: Borsa di ricerca del Consiglio Nazionale delle Ricerche (CNR) (Roma)

1981-1981: Borsa di ricerca dell’Associazione Italiana per la Ricerca sul Cancro (AIRC) (Milano)

ALTRE POSIZIONI

2015-: Delegato Ricerca Università di Firenze Dipartimento Interaziendale di Area Vasta Centro (D.I.A.V.C) per la Prevenzione, Diagnosi e Cura Malattie Oncologiche, Reg. Toscana

2015-: Membro, Unit of Translational Hematology and Oncology, Center of Excellence for the Study at Molecular Level of Chronic, Degenerative and Neoplastic Diseases to Develop Novel Therapies (DENOTHE), Università di Firenze

2015-: Membro, European Organization for Research and Treatment of Cancer (EORTC) – Lung Cancer Group

2015-: Membro, Department Committee, Dipartimento (DAI) Oncologico - AOUC

2013-: Membro e Segretario, Consiglio Direttivo, Societa Italiana di Chemioterapia (SIC)

2012-: Membro, Centro Interdipartimentale ‘Development of Mini-Invasive New Technologies in Oncological Surgery’ (COMIS)

2012-2013: Membro, Centro Interdipartimentale ‘Research on Pharmacoutilization, Pharmacoepidemiology, Pharmacovigilance and Pharmacoeconomy’ (CIRF)

2012-: Membro del Gruppo di Lavoro Farmacologia Oncologica, Società Italiana di Farmacologia (SIF)

2007-2011: Segretario e Tesoriere della Società Italiana di Chemioterapia;

2007-2013: Chairman della Cancer Section dell’International Society of Chemotherapy (ISC) (Londra)

2007-2013: Membro, Executive Committee ISC (Londra)

2005-2007: Membro, Consiglio Direttivo SIC

2005-2007: Segretario della Cancer Section ISC (Londra)

2004-2012: Membro del Comitato Tecnico Scientifico dell’Istituto Tumori Toscano (ITT), Regione Toscana

1998-: Membro dello Steering Committee, EORTC, PAN-European Trials in Adjuvant Colon Cancer (PETACC) (Brussels)

1998-: Membro, EORTC – Gastrointestinal Cancer Group

1997-2001: Membro, Consiglio Direttivo SIC

1997-2001: Membro, Consiglio Direttivo Società Italiana di Immunofarmacologia

1991-: Segretario, Gruppo Oncologico Chirurgico Cooperativo Italiano (GOCCI)

1991-1994: Segretario, Comitato Tecnico-Scientifico del Consorzio Vettori Antitumorali, Programma Nazionale Farmaci (Roma)

1987-: Membro, EORTC – Pharmacology and Molecular Mechanisms (PAMM) Group

APPARTENENZA A SOCIETÀ SCIENTIFICHE

American Society for Microbiology (ASM)

European Society of Medical Oncology (ESMO)

European Association for Cancer Research (EACR)

Associazione Italiana di Immunofarmacologia

Società Italiana di Farmacologia (SIF)

European Organisation for Research and Treatment of Cancer (EORTC)

EORTC-Pharmacology and Molecular Mechanisms (PAMM) Group

American Society of Clinical Oncology (ASCO)

American Association for Cancer Research (AACR)

Italian Association of Medical Oncology (AIOM)

Italian Society of Chemotherapy (SIC)

ATTIVITÀ EDITORIALE

Dal 2017: Editorial Board Member, Cancer Drug Resistance

Dal 2015: Associate Editor, Frontiers in Oncology

Dal 2015: Associate Editor, Frontiers in Pharmacology

2015: Host Editor della monografia "Multidrug resistance in cancer: molecular basis, pharmacological

strategies and clinical issues", Frontiers in Oncology

Dal 2015: Editorial Board Member, Oncology Research

Dal 2014: Editorial Board Member, Cell Death in Therapy

Dal 2014: Editorial Board Member, World Cancer Research Journal

Dal 2014: Editorial Board Member, European Journal of Oncology

Dal 2006: Associate Editor, Metal-Based Drugs

Dal 2002: Editor, Journal of Chemotherapy.

1997-2002: Field Editor (chemioterapia antitumorale), Journal of Chemotherapy

ATTIVITÀ DI REFEREE

Oncologia medica, farmacologia antitumorale per numerose riviste scientifiche, società scientifiche, enti nazionali ed internazionali

PRINCIPALI CONTRATTI DI RICERCA (ATTUALI E PREGRESSI)

I progetti di ricerca preclinica e traslazionale del Prof. Mini sono attualmente supportati dall'Associazione Italiana per la Ricerca sul Cancro, dalla Cassa di Risparmio di Firenze, dall'Associazione Giacomo Onlus, dal Gruppo Oncologico Chirurgico Cooperativo Italiano e da altri fondi di ricerca pubblici e privati. In precedenza il prof. Mini ha ricevuto finanziamenti per progetti di ricerca oltre che dalle suddette istituzioni anche da altre (ad esempio, Ministero dell'Istruzione, Università della Ricerca, Ministero della Salute, Consiglio Nazionale delle Ricerche, Regione Toscana, Istituto Toscano Tumori, NATO, Fédération Francophone de Cancérologie Digestive).

In particolare, il Prof. Mini ha svolto il ruolo di Investigatore Principale/Coordinatore Scientifico in 3 Progetti di Rilevante Interesse Nazionale (PRIN) (2003053403/2003, 2005065797/2005, 20084TASKL / 2008) e di ricercatore associato in 2 PRIN (9806301873_004 / 1998; n.9906278347_005 / 1999) del MIUR. Tali progetti riguardavano i meccanismi molecolari della resistenza ai farmaci nelle neoplasie gastrointestinali (principalmente il tumore del colon-retto), nuove strategie farmacologiche volte al superamento della resistenza, l'identificazione di biomarcatori potenzialmente predittivi di farmacoresistenza. Il Prof. Mini ha esperienza in studi clinici ICN-GCP e ha partecipato a numerosi studi clinici nazionali e internazionali come PI, Co-I e coordinatore nazionale.

ATTIVITÀ DIDATTICA

Attualmente il Prof. Mini tiene corsi di Oncologia Medica presso la Scuola di Scienze della Salute Umana (Medicina e Chirurgia e altri 4 programmi di Laurea in Professioni Sanitarie); un corso di Diagnostica Oncologica presso il Corso di Laurea in Biotecnologie; Corsi di Oncologia presso varie scuole di Specializzazione di Area Medica e Master, UniFI.

Precedentemente ha tenuto corsi di Farmacologia presso i corsi di laurea in Medicina e Chirurgia e Biotecnologie e presso varie scuole di Specializzazione di Area Medica (UniFI).

Dal 2011 è membro del Consiglio della Scuola di Dottorato in Farmacologia, Tossicologia e Terapie Innovative (UniFI).

Dal 1995 al 2011 è stato membro del Consiglio della Scuola di Dottorato in Fisiologia molecolare e cellulare, Farmacologia e Tossicologia (Università di Siena)

TUTORAGGIO

Il Prof. Mini ha supervisionato tesi di Dottorato di Ricerca in Farmacologia e Tossicologia, tesi di Laurea per i corsi di Medicina e Chirurgia, Biologia, Farmacia, Biotecnologie e tesi di Specializzazione in Oncologia Medica (Università degli Studi di Firenze).

LETTURE AD INVITO

Il Prof. Mini ha tenuto circa 200 relazioni su invito a congressi nazionali ed internazionali e a seminari in università italiane o estere.

PRINCIPALI INTERESSI

Meccanismi molecolari della chemioresistenza tumorale e strategie farmacologiche volte al superamento di questo fenomeno. Farmacologia degli antimetaboliti citotossici e dei farmaci a base di metalli. Farmacogenomica e farmacogenetica tumorale. Trattamento medico del tumore del colon-retto. Studi clinici in oncologia medica.

PUBBLICAZIONI

Autore di oltre 150 articoli di ricerca originali pubblicati in extenso su riviste recensite a livello internazionale e di oltre 40 rassegne, editoriali o capitoli su libri a diffusione internazionale.

ATTIVITÀ DI ORGANIZZAZIONE SCIENTIFICA

Il Prof Mini ha organizzato numerosi congressi, conferenze e convegni nazionali ed internazionali.

Enrico MINI

Pubblicazioni

Legenda

Contributo su rivista |

Articolo su libro |

Libro |

Contributo in atti di convegno (proceeding) |

Brevetto |

Curatela | Altro

Altro |

Tesi di Dottorato

Perrone, Gabriele; Rigacci, Luigi; Roviello, Giandomenico; Landini, Ida; Fabbri, Alberto; Iovino, Lorenzo; Puccini, Benedetta; Cencini, Emanuele; Orciuolo, Enrico; Bocchia, Monica; Bosi, Alberto; Mini, Enrico; Nobili, Stefania (2024). Validation of single nucleotide polymorphisms potentially related to R-CHOP resistance in diffuse large B-cell lymphoma patients. CANCER DRUG RESISTANCE, vol. 7, pp. 1-14, ISSN:2578-532X DOI

Catalano, Martina; Roviello, Giandomenico; Aprile, Giuseppe; Ramello, Monica; Conca, Raffaele; Petrioli, Roberto; Perrone, Gabriele; Ianza, Anna; Mini, Enrico (2023). Prognostic value of alkaline phosphatase and gamma-glutamyl transferase in patients with metastatic pancreatic cancer. FUTURE ONCOLOGY, vol. 19, pp. 937-946, ISSN:1479-6694 DOI

Catalano, Martina; Roviello, Giandomenico; Santi, Raffaella; Villari, Donata; Spatafora, Pietro; Galli, Ilaria Camilla; Sessa, Francesco; Conte, Francesco Lupo; Mini, Enrico; Cai, Tommaso; Nesi, Gabriella (2023). Inflammation in Urological Malignancies: The Silent Killer. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 24, pp. 866-866, ISSN:1422-0067 DOI

Cosso, Federica; Roviello, Giandomenico; Catalano, Martina; Botteri, Cristina; Comin, Camilla Eva; Castiglione, Francesca; Ferrari, Katia; Baldini, Editta; Mini, Enrico (2023). A case report of a lung cancer patient with two uncommon EGFR mutations and a review of the literature: two sides of the same coin. ANTI-CANCER DRUGS, vol. Publish Ahead of Print, pp. 1-6, ISSN:0959-4973 DOI

Catalano, Martina; Lapucci, Andrea; Nobili, Stefania; De Gennaro Aquino, Irene; Vascotto, Ismaela Anna; Antonuzzo, Lorenzo; Villari, Donata; Nesi, Gabriella; Mini, Enrico; Roviello, Giandomenico (2023). Platinum-based chemotherapy in metastatic prostate cancer: what possibilities?. CANCER CHEMOTHERAPY AND PHARMACOLOGY, pp. 0-0, ISSN:0344-5704 DOI

Rejali, Leili; Seifollahi Asl, Romina; Sanjabi, Fatemeh; Fatemi, Nayeralsadat; Asadzadeh Aghdaei, Hamid; Saeedi Niasar, Mahsa; Ketabi Moghadam, Pardis; Nazemalhosseini Mojarad, Ehsan; Mini, Enrico; Nobili, Stefania (2023). Principles of Molecular Utility for CMS Classification in Colorectal Cancer Management. CANCERS, vol. 15, pp. 0-0, ISSN:2072-6694 DOI

Catalano, Martina; Iannone, Luigi Francesco; Nesi, Gabriella; Nobili, Stefania; Mini, Enrico; Roviello, Giandomenico (2023). Immunotherapy-related biomarkers: Confirmations and uncertainties. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol. 192, pp. 104135-104136, ISSN:1040-8428 DOI

Perrone, Gabriele; Rigacci, Luigi; Urru, Sara; Kovalchuk, Sofya; Brugia, Marco; Fabbri, Alberto; Iovino, Lorenzo; Puccini, Benedetta; Cencini, Emanuele; Orciuolo, Enrico; Birtolo, Silvia; Melosi, Alessandro; Santini, Simone; Landini, Ida; Roviello, Giandomenico; Santi, Raffaella; Macciotta, Alessandra; Ricceri, Fulvio; Bosi, Alberto; Bocchia, Monica; Petrini, Mario; Mini, Enrico; Nobili, Stefania (2023). Exploratory Genome-Wide Association Analysis to Identify Pharmacogenetic Determinants of Response to R-CHOP in Diffuse Large B-Cell Lymphoma. CANCERS, vol. 15, pp. 0-0, ISSN:2072-6694 DOI

Lombardo F.; Aiolfi A.; Cavalli M.; Mini E.; Lastraioli C.; Panizzo V.; Lanzaro A.; Bonitta G.; Danelli P.; Campanelli G.; Bona D. (2022). Techniques for reconstruction after distal gastrectomy for cancer: updated network meta-analysis of randomized controlled trials. LANGENBECK'S ARCHIVES OF SURGERY, vol. 407, pp. 75-86, ISSN:1435-2451 DOI

Nobili, Stefania; Mini, Enrico (2022). Special Issue: “Gastrointestinal Cancers and Personalized Medicine”. JOURNAL OF PERSONALIZED MEDICINE, vol. 12, pp. 338-343, ISSN:2075-4426 DOI

Lavacchi D.; Landini I.; Perrone G.; Roviello G.; Mini E.; Nobili S. (2022). Pharmacogenetics in diffuse large B-cell lymphoma treated with R-CHOP: Still an unmet challenge. PHARMACOLOGY & THERAPEUTICS, vol. 229, pp. 1-16, ISSN:0163-7258 DOI Accesso ONLINE all'editore

Lulli, Matteo; Napoli, Cristina; Landini, Ida; Mini, Enrico; Lapucci, Andrea (2022). Role of Non-Coding RNAs in Colorectal Cancer: Focus on Long Non-Coding RNAs. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 23, pp. 13431-13431, ISSN:1422-0067 DOI

Tonelli F.; Di Martino C.; Amorosi A.; Mini E.; Nesi G. (2022). Surgery for ulcerative colitis complicated with colorectal cancer: when ileal pouch–anal anastomosis is the right choice. UPDATES IN SURGERY, vol. .., pp. 637-647, ISSN:2038-131X DOI

Catalano, Martina; Francesco Iannone, Luigi; Cosso, Federica; Generali, Daniele; Mini, Enrico; Roviello, Giandomenico (2022). Combining inhibition of immune checkpoints and PARP: rationale and perspectives in cancer treatment. EXPERT OPINION ON THERAPEUTIC TARGETS, pp. 1-14, ISSN:1472-8222 DOI

Dugheri, Stefano; Mucci, Nicola; Bucaletti, Elisabetta; Squillaci, Donato; Cappelli, Giovanni; Trevisani, Lucia; Bonari, Alessandro; Cecchi, Michele; Mini, Enrico; Ghiori, Andrea; Tognoni, Daniela; Berti, Nicola; Alderighi, Francesca; Li Vigni, Nicola; Orlandi, Irene; Arcangeli, Giulio (2022). Monitoring surface contamination for thirty antineoplastic drugs: a new proposal for surface exposure levels (SELs). MEDYCYNA PRACY, vol. -, pp. 1-14, ISSN:0465-5893 DOI

Linguanti, Flavia; Abenavoli, Elisabetta M; Briganti, Vittorio; Danti, Ginevra; Lavacchi, Daniele; Matteini, Maria; Vaggelli, Luca; Novelli, Luca; Grosso, Anna M; Mungai, Francesco; Mini, Enrico; Antonuzzo, Lorenzo; Miele, Vittorio; Sciagrà, Roberto; Berti, Valentina (2022). Added prognostic value of molecular imaging parameters over proliferation index in typical lung carcinoid: an [18F]FDG PET/CT and SSTR imaging study. ANNALS OF NUCLEAR MEDICINE, vol. -, pp. 1-9, ISSN:0914-7187 DOI

D'Angelo, Alberto; Chapman, Robert; Sirico, Marianna; Sobhani, Navid; Catalano, Martina; Mini, Enrico; Roviello, Giandomenico (2022). An update on antibody-drug conjugates in urothelial carcinoma: state of the art strategies and what comes next. CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol. 90, pp. 191-205, ISSN:0344-5704 DOI

Pani, L.; Cicchetti, A.; De Luca, A.; Mennini, F.S.; Mini, E.; Nocentini, G.; Racagni, G.; Jommi, C. (2022). PRICING FOR MULTI INDICATION MEDICINES: A DISCUSSION WITH ITALIAN EXPERTS. PHARMADVANCES, vol. 4, pp. 163-170 DOI

Roviello, Giandomenico; Lavacchi, Daniele; Antonuzzo, Lorenzo; Catalano, Martina; Mini, Enrico (2022). Liquid biopsy in colorectal cancer: No longer young, but not yet old. WORLD JOURNAL OF GASTROENTEROLOGY, vol. 28, pp. 1503-1507, ISSN:2219-2840 DOI

Palmieri, Valeria Emma; Roviello, Giandomenico; Catalano, Martina; D'Angelo, Alberto; Vannini, Gianmarco; Buttitta, Eleonora; Mini, Enrico (2022). Immune checkpoint inhibitor-induced neurologic toxicity: a case report and literature review. IMMUNOTHERAPY, vol. 14, pp. 505-510, ISSN:1750-743X DOI

Russo, Valentina; Lallo, Eleonora; Munnia, Armelle; Spedicato, Miriana; Messerini, Luca; D'Aurizio, Romina; Ceroni, Elia Giuseppe; Brunelli, Giulia; Galvano, Antonio; Russo, Antonio; Landini, Ida; Nobili, Stefania; Ceppi, Marcello; Bruzzone, Marco; Cianchi, Fabio; Staderini, Fabio; Roselli, Mario; Riondino, Silvia; Ferroni, Patrizia; Guadagni, Fiorella; Mini, Enrico; Peluso, Marco (2022). Artificial Intelligence Predictive Models of Response to Cytotoxic Chemotherapy Alone or Combined to Targeted Therapy for Metastatic Colorectal Cancer Patients: A Systematic Review and Meta-Analysis. CANCERS, vol. 14, pp. 4012-4049, ISSN:2072-6694 DOI

Enrico Mini, Ida Landini, Antonello Di Paolo, Gloria Ravegnini, Simona Saponara, Maria Frosini, Andrea Lapucci, Stefania Nobili (2022). Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy. In: Enrico Mini, Ida Landini, Antonello Di Paolo, Gloria Ravegnini, Simona Saponara, Maria Frosini, Andrea Lapucci, Stefania Nobili. Predictive “omic” biomarkers of drug response: Colorectal cancer as a model, pp. 199-240 Elsevier.

Roviello G.; Iannone L.F.; Bersanelli M.; Mini E.; Catalano M. (2022). The gut microbiome and efficacy of cancer immunotherapy. PHARMACOLOGY & THERAPEUTICS, vol. 231, pp. 107973-107983, ISSN:0163-7258 DOI

Catalano M.; Marini A.; Ferrari K.; Voltolini L.; Cianchi F.; Comin C.E.; Castiglione F.; Roviello G.; Mini E. (2022). Gastric and colonic metastasis from NSCLC A very unusual case report. MEDICINE, vol. 101, pp. E28249-E28249, ISSN:0025-7974 DOI

Parsa, Fatemeh Ghorbani; Nobili, Stefania; Karimpour, Mina; Aghdaei, Hamid Asadzadeh; Nazemalhosseini-Mojarad, Ehsan; Mini, Enrico (2022). Fanconi Anemia Pathway in Colorectal Cancer: A Novel Opportunity for Diagnosis, Prognosis and Therapy. JOURNAL OF PERSONALIZED MEDICINE, vol. 12, pp. 396-421, ISSN:2075-4426 DOI

Dugheri S.; Mucci N.; Mini E.; Cappelli G.; Bucaletti E.; Squillaci D.; Trevisani L.; Arcangeli G. (2022). AN UPDATE ON PERMEATION OF PROTECTIVE MEDICAL GLOVES BY ANTINEOPLASTIC DRUGS. SIGURNOST, vol. 64, pp. 341-357, ISSN:0350-6886 DOI

Lapucci, Andrea; Perrone, Gabriele; Di Paolo, Antonello; Napoli, Cristina; Landini, Ida; Roviello, Giandomenico; Calosi, Laura; Naccarato, Antonio Giuseppe; Falcone, Alfredo; Bani, Daniele; Mini, Enrico; Nobili, Stefania (2021). PNN and KCNQ1OT1 can predict the efficacy of adjuvant fluoropyrimidine-based chemotherapy in colorectal cancer patients. ONCOLOGY RESEARCH, vol. 28, pp. 631-644, ISSN:0965-0407 DOI

Rubino R, Marini A, Roviello G, Presotto EM, Desideri I, Ciardetti I, Brugia M, Pimpinelli N, Antonuzzo L, Mini E, Livi L, Maggi M, Peri A. (2021). Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy. ENDOCRINE, vol. 74, pp. 172-179, ISSN:1559-0100 DOI

Angelini, S.; Cecchin, E.; Conti, V.; Dal Piaz, F.; Filippelli, A.; Hrelia, P.; Landini, I.; Menna, P.; Mini, E.; Nobili, S.; Soledad Poetto, A.; Ravegnini, G.; Roncato, R.; Minotti, G. (2021). Therapeutic drug monitoring for the cancer patient: challenges and opportunities. PHARMADVANCES, vol. 3, pp. 592-600 DOI

Roncato, R.; Cecchini, E.; Dalle Fratte, C.; Decorti, G.; Del Re, M.; Franca, R.; Nobili, S.; Ravegnini, G.; Stocco, G.; Mini, E.; Toffoli, G.; Cancer Pharmacology Working Group, W.G. (2021). Cancer Pharmacogenetics: perspective on newly discovered and implemented predictive biomarkers. PHARMADVANCES, vol. 3, pp. 357-368 DOI

Tartarone A.; Lapadula V.; Di Micco C.; Rossi G.; Ottanelli C.; Marini A.; Giorgione R.; Ferrari K.; Catalano M.; Voltolini L.; Mini E.; Roviello G. (2021). Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer. FRONTIERS IN ONCOLOGY, vol. 11, pp. 0-0, ISSN:2234-943X DOI

Altavilla A, Mini E, Nobili S, Santarpia M (2021). Effetti collaterali dei trattamenti antitumorali: chemioterapia e terapia orale. In: Massimo Aglietta. Oncologia Medica, II edizione, pp. 66-79 Edizioni Minerva Medica spa, ISBN:9788855320948.

Peyravian N.; Nobili S.; Pezeshkian Z.; Olfatifar M.; Moradi A.; Baghaei K.; Anaraki F.; Nazari K.; Aghdaei H.A.; Zali M.R.; Mini E.; Mojarad E.N. (2021). Increased expression of vangl1 is predictive of lymph node metastasis in colorectal cancer: Results from a 20-gene expression signature. JOURNAL OF PERSONALIZED MEDICINE, vol. 11, pp. 1-22, ISSN:2075-4426 DOI

Santini D.; Stellato M.; De Giorgi U.; Pantano F.; De Lisi D.; Casadei C.; Maruzzo M.; Bimbatti D.; Naglieri E.; Buti S.; Bersanelli M.; De Vivo R.; Di Lorenzo G.; Sbrana A.; Verzoni E.; Soraru' M.; Fornarini G.; Mucciarini C.; Grillone F.; Mini E.; Vignani F.; Attademo L.; Pignata S.; Procopio G. (2021). Clinical Outcomes of Metastatic Renal Carcinoma following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO): A Meet-URO Group Real World Study (Meet-Uro 7). AMERICAN JOURNAL OF CLINICAL ONCOLOGY: CANCER CLINICAL TRIALS, vol. 44, pp. 121-125, ISSN:0277-3732 DOI

Roviello G.; Rodriquenz M.G.; Aprile G.; D'Angelo A.; Roviello F.; Nobili S.; Mini E.; Sarno I.; Polom K. (2021). Maintenance in gastric cancer: New life for an old issue?. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol. 160, pp. 103307-103315, ISSN:1040-8428 DOI

Roviello G.; Aprile G.; D'Angelo A.; Iannone L.F.; Roviello F.; Polom K.; Mini E.; Catalano M. (2021). Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand?. GASTRIC CANCER, vol. 24, pp. 765-779, ISSN:1436-3291 DOI

Catalano M.; Casadei-Gardini A.; Vannini G.; Campani C.; Marra F.; Mini E.; Roviello G. (2021). Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, vol. 14, pp. 1353-1365, ISSN:1751-2433 DOI

Lisi, L.; Cari, L.; Sorrentino, R.; Mini, E.; Fimognari, C.; Nocentini, G. (2021). IMMUNE MODULATION OF CANCER: MECHANISMS AND RESISTANCE. PHARMADVANCES, vol. 3, pp. 479-495 DOI

Pezeshkian Z.; Nobili S.; Peyravian N.; Shojaee B.; Nazari H.; Soleimani H.; Asadzadeh-Aghdaei H.; Bonab M.A.; Nazemalhosseini-Mojarad E.; Mini E. (2021). Insights into the role of matrix metalloproteinases in precancerous conditions and in colorectal cancer. CANCERS, vol. 13, pp. 6226-6245, ISSN:2072-6694 DOI

Sinicrope F.A.; Chakrabarti S.; Laurent-Puig P.; Huebner L.; Smyrk T.C.; Tabernero J.; Mini E.; Goldberg R.M.; Zaanan A.; Folprecht G.; Van Laethem J.L.; Le Malicot K.; Shi Q.; Alberts S.R.; Taieb J. (2021). Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials. EUROPEAN JOURNAL OF CANCER, vol. 144, pp. 101-112, ISSN:0959-8049 DOI

Spinelli, Sara; Mini, Enrico; Monteleone, Erminio; Angiolini, Catia; Roviello, Giandomenico (2021). ALTERTASTE: improving food pleasure and intake of oncology patients receiving chemotherapy. FUTURE ONCOLOGY, pp. 0-0, ISSN:1479-6694 DOI Accesso ONLINE all'editore

Giorgione, Roberta; Santini, Daniele; Stellato, Marco; Basso, Umberto; Bimbatti, Davide; Palmieri, Valeria Emma; Doni, Laura; Antonuzzo, Lorenzo; Bersanelli, Melissa; Buti, Sebastiano; De Giorgi, Ugo; Galli, Luca; Sbrana, Andrea; Conca, Raffaele; Carella, Claudia; Naglieri, Emanuele; Mini, Enrico; Pignata, Sandro; Procopio, Giuseppe; Roviello, Giandomenico (2021). Active therapy or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The BEYOND study (Meet-Uro 19). JOURNAL OF CLINICAL ONCOLOGY, vol. 39, pp. 319-319, ISSN:0732-183X DOI

Gasperoni, Silvia; Papi, Laura; Castiglione, Francesca; Gensini, Francesca; Sestini, Roberta; Messerini, Luca; Bartoli, Caterina; Nozzoli, Filippo; Dimarino, Michele; Cianchi, Fabio; Taddei, Antonio; Ferrara, Angelo; Calistri, Massimo; Bencini, Lapo; Perna, Federico; Catalano, Martina; Giorgione, Roberta; Winchler, Costanza; Venturi, Giulia; Mini, Enrico (2021). Germline mutations in MSH2 and ATM gene in patients with GIST (gastrointestinal stromal tumor) and second epitelial tumors. JOURNAL OF CLINICAL ONCOLOGY, vol. 39, pp. e23520-e23520, ISSN:0732-183X DOI

Dugheri S.; Mucci N.; Mini E.; Squillaci D.; Marrubini G.; Bartolucci G.; Bucaletti E.; Cappelli G.; Trevisani L.; Arcangeli G. (2021). Characterization and separation of platinum-based antineoplastic drugs by zwitterionic hydrophilic interaction liquid chromatography (Hilic)–tandem mass spectrometry, and its application in surface wipe sampling. SEPARATIONS, vol. 8, pp. 0-0, ISSN:2297-8739 DOI

Cirri, Damiano; Landini, Ida; Massai, Lara; Mini, Enrico; Maestrelli, Francesca; Messori, Luigi (2021). Cyclodextrin Inclusion Complexes of Auranofin and Its Iodido Analog: A Chemical and Biological Study. PHARMACEUTICS, vol. 13, pp. 1-10, ISSN:1999-4923 DOI

Gasperoni, Silvia; Castiglione, Francesca; Vannucchi, Margherita; Papi, Laura; Fumagalli, Elena; Manglaviti, Sara; Vincenzi, Bruno; Mazzocca, Alessandro; Nannini, Margherita; Vancheri, Giovanni; Adragna, Tommaso; Ottaviano, Margaret; Palmieri, Giovannella; Meoni, Giulia; Ribecco, Angela Stefania; Grignani, Giovanni; Tolomeo, Francesco; Tofani, Lorenzo; Paderi, Agnese; Mini, Enrico (2020). Update of NGS analysis of Italian survey of second tumors in patients with diagnosis of GIST (gastrointestinal stromal tumor). JOURNAL OF CLINICAL ONCOLOGY, vol. 38, pp. e23518-e23518, ISSN:0732-183X DOI

Roviello G.; Ramello M.; Catalano M.; D'Angelo A.; Conca R.; Gasperoni S.; Dreoni L.; Petrioli R.; Ianza A.; Nobili S.; Aieta M.; Mini E. (2020). Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer. SCIENTIFIC REPORTS, vol. 10, pp. 19281-19289, ISSN:2045-2322 DOI

Roviello G.; Fancelli S.; Gatta Michelet M.R.; Aprile G.; Nobili S.; Roviello F.; Cianchi F.; Mini E.; Lavacchi D. (2020). TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol. 152, pp. 1-9, ISSN:1040-8428 DOI

Roviello G.; Casadei-Gardini A.; Nobili S.; Mini E.; Fancelli S. (2020). Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment. JOURNAL OF ONCOLOGY, vol. 2020, pp. 1-4, ISSN:1687-8450 DOI

Catalano, Martina; Roviello, Giandomenico; Conca, Raffaele; D’Angelo, Alberto; Palmieri, Valeria Emma; Panella, Benedetta; Petrioli, Roberto; Ianza, Anna; Nobili, Stefania; Mini, Enrico; Ramello, Monica (2020). Clinical outcomes and safety of patients treated with NAb-Paclitaxel plus Gemcitabine in metastatic pancreatic cancer: the NAPA study. CURRENT CANCER DRUG TARGETS, vol. 20, pp. 0-0, ISSN:1568-0096 DOI Accesso ONLINE all'editore

Presotto EM, Rastrelli G, Desideri I, Scotti V, Gunnella S, Pimpinelli N, Vaccher E, Bearz A, Di Costanzo F, Bruggia M, Mini E, Maggi M, Peri A. (2020). Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study.. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, vol. 43, pp. 337-345, ISSN:1720-8386 DOI Accesso ONLINE all'editore

D'Angelo A.; Bagby S.; Di Pierro G.; Chirra M.; Nobili S.; Mini E.; Villari D.; Roviello G. (2020). An overview of the clinical use of cabozantinib in the treatment of advanced non-clear-cell renal cell carcinoma (NCCRCC). CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol. 149, pp. 10921-10921, ISSN:1040-8428 DOI

Roviello G.; Corona S.P.; D'angelo A.; Rosellini P.; Nobili S.; Mini E. (2020). Immune checkpoint inhibitors in pre-treated gastric cancer patients: Results from a literature-based meta-analysis. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 21, pp. 448-448, ISSN:1661-6596 DOI

Roviello G.; D'Angelo A.; Sciortino M.; Mini E.; Nobili S.; De Logu F.; Massi D. (2020). TRK fusion positive cancers: From first clinical data of a TRK inhibitor to future directions. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol. 152, pp. 0-0, ISSN:1040-8428 DOI

Giandomenico Roviello, Alberto D'Angelo, Roberto Petrioli, Franco Roviello, Fabio Cianchi, Stefania Nobili, Enrico Mini, Daniele Lavacchi (2020). Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. TRANSLATIONAL ONCOLOGY, pp. 0-0, ISSN:1936-5233 DOI

Zaanan A, Shi Q, Taieb J, Alberts SR, Meyers JP, Smyrk TC, Julie C, Zawadi A, Tabernero J, Mini E, Goldberg RM, Folprecht G, Van Laethem JL, Le Malicot K, Sargent DJ, Laurent-Puig P, Sinicrope FA. (2020). Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials. JCO PRECISION ONCOLOGY, vol. February 2020, pp. 0-0, ISSN:2473-4284 DOI

Mini Enrico; Nobili Stefania (2020). Pharmacogenetics of Cancer. CANCER DRUG RESISTANCE, pp. 0-0, ISSN:2578-532X DOI

Nobili, Stefania; Lavacchi, Daniele; Perrone, Gabriele; Vicini, Giulio; Tassi, Renato; Landini, Ida; Grosso, AnnaMaria; Roviello, Giandomenico; Mazzanti, Roberto; Santomaggio, Carmine; Mini, Enrico (2020). Vinorelbine in non-small cell lung cancer: Real-World data from a single institution experience. ONCOLOGY RESEARCH, pp. 237-248, ISSN:0965-0407 DOI

Landini, Ida; Massai, Lara; Cirri, Damiano; Gamberi, Tania; Paoli, Paolo; Messori, Luigi; Mini, Enrico; Nobili, Stefania (2020). Structure-activity relationships in a series of auranofin analogues showing remarkable antiproliferative properties. JOURNAL OF INORGANIC BIOCHEMISTRY, vol. 208, pp. 0-0, ISSN:0162-0134 DOI

Nobili S, Lapucci A, Landini I, Coronnello M, Roviello G, Mini E. (2020). Role of ATP-binding cassette transporters in cancer initiation and progression. SEMINARS IN CANCER BIOLOGY, pp. 72-95, ISSN:1044-579X DOI

Roviello G.; Roviello F.; Mini E. (2020). Perioperative chemotherapy for gastric cancer in FLOT4. THE LANCET, vol. 395, pp. e3-E3, ISSN:0140-6736 DOI

Roviello, Giandomenico; Catalano, Martina; Nobili, Stefania; Santi, Raffaella; Mini, Enrico; Nesi, Gabriella (2020). Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand?. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 21, pp. 7935-7943, ISSN:1422-0067 DOI

Maruzzo, Marco; Verzoni, Elena; Pierantoni, Francesco; Galli, Luca; Vignani, Francesca; Buti, Sebastiano; Pignata, Sandro; Zanardi, Elisa; Sbrana, Andrea; Procopio, Giuseppe; Zivi, Andrea; Zielli, Teresa; Mini, Enrico; Roviello, Giandomenico; Basso, Umberto; Zagonel, Vittorina (2020). Prognostic role of T3/T4 ratio in metastatic renal cell carcinoma (mRCC): Preliminary results of the threeFOUR multicenter study (Meet-Uro 14). JOURNAL OF CLINICAL ONCOLOGY, vol. 38, pp. e17093-e17093, ISSN:0732-183X DOI

Caraglia M.; Correale P.; Giannicola R.; Staropoli N.; Botta C.; Pastina P.; Nesci A.; Caporlingua N.; Francini E.; Ridolfi L.; Mini E.; Roviello G.; Ciliberto D.; Agostino R.M.; Strangio A.; Azzarello D.; Nardone V.; Falzea A.; Cappabianca S.; Bocchetti M.; D'Arrigo G.; Tripepi G.; Tassone P.; Addeo R.; Giordano A.; Pirtoli L.; Francini G.; Tagliaferri P. (2019). GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up. FRONTIERS IN ONCOLOGY, vol. 9, pp. 1102-1102, ISSN:2234-943X DOI

De Giorgi, Ugo; Procopio, Giuseppe; Sabbatini, Roberto; Caserta, Claudia; Mitterer, Manfred; Ortega, Cinzia; Scoppola, Alessandro; Fornarini, Giuseppe; Ferraú, Francesco; Marchetti, Paolo; Verusio, Claudio; Mini, Enrico; Bidoli, Paolo; Buti, Sebastiano; Crino, Lucio; Basso, Umberto; Frassoldati, Antonio; Bearz, Alessandra; Carteni, Giacomo; Sternberg, Cora N. (2019). Association of body mass index and systemic inflammation index with survival in patients with renal cell cancer treated with nivolumab. JOURNAL OF CLINICAL ONCOLOGY, vol. 37, pp. e16077-e16077, ISSN:0732-183X DOI

Roviello G.; Nobili S.; Mini E. (2019). A potential novel drug combination for adjuvant therapy in lung cancer: reflections on an early phase of clinical development. JOURNAL OF CHEMOTHERAPY, vol. 31, pp. 295-296, ISSN:1120-009X DOI Accesso ONLINE all'editore

Di Pierro, Giulia; Mini, Enrico; Roviello, Giandomenico (2019). Cabozantinib in advanced non-clear-cell renal cell carcinoma: is it the way clearer now?. ANNALS OF TRANSLATIONAL MEDICINE, vol. 7, pp. S229-S229, ISSN:2305-5839 DOI

Roviello G.; Corona S.P.; Nesi G.; Mini E. (2019). Results from a meta-analysis of immune checkpoint inhibitors in first-line renal cancer patients: does PD-L1 matter?. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, vol. 11, pp. 1-8, ISSN:1758-8340 DOI Accesso ONLINE all'editore

Correale, P; Staropoli, N; Pastina, P; Giannicola, R; Botta, C; Francini, E; Ridolfi, L; Mini, E; Ciliberto, D; Agostino, R M; Strangio, A; Azzarello, D; Nardone, V; Falzea, A; Tassone, P; Giordano, A; Pirtoli, L; Francini, G; Tagliaferri, P S (2019). 1204PGOLFIG chemo-immunotherapy in metastatic colorectal cancer (mCRC) patients: A fifteen year retrospective analysis. ANNALS OF ONCOLOGY, vol. 30, pp. 492-493, ISSN:0923-7534 DOI

Mini E.; Lapucci A.; Perrone G.; D'Aurizio R.; Napoli C.; Brugia M.; Landini I.; Tassi R.; Picariello L.; Simi L.; Mancini I.; Messerini L.; Magi A.; Pinzani P.; Mazzei T.; Tonelli F.; Nobili S. (2019). RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy. INTERNATIONAL JOURNAL OF CANCER, pp. 0-0, ISSN:0020-7136, Wiley-Liss Inc.: DOI Accesso ONLINE all'editore

Lavacchi, Daniele; Mini, Enrico; Roviello, Giandomenico (2019). Abiraterone plus prednisone or enzalutamide in patients with metastatic castration-resistant prostate cancer: is a question of quality?. AME MEDICAL JOURNAL., vol. 4, pp. 24-26, ISSN:2520-0518 DOI

Roviello, Giandomenico; D’Angelo, Alberto; Roudi, Raheleh; Petrioli, Roberto; Mini, Enrico (2019). Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights. JOURNAL OF ONCOLOGY, vol. 2019, pp. 1-9, ISSN:1687-8450 DOI

Tiziano Marzo, Lara Massai, Alessandro Pratesi, Matteo Stefanini, Damiano Cirri, Francesca Magherini, Matteo Becatti, Ida Landini, Stefania Nobili, Enrico Mini, Olivia Crociani, Annarosa Arcangeli, Serena Pillozzi, Tania Gamberi, Luigi Messori (2019). Replacement of the Thiosugar of Auranofin with Iodide Enhances the Anticancer Potency in a Mouse Model of Ovarian Cancer. ACS MEDICINAL CHEMISTRY LETTERS, vol. 10 (4), pp. 656-660, ISSN:1948-5875, American Chemical Society: DOI Accesso ONLINE all'editore

Zaanan, Aziz; Shi, Qian; Taieb, Julien; Alberts, Steven R; Meyers, Jeffrey P.; Smyrk, Thomas C.; Julié, Catherine; Zawadi, Ayman; Tabernero, Josep; Mini, Enrico; Goldberg, Richard M.; Folprecht, Gunnar; VAN Laethem, Jean Luc; Le Malicot, Karine; Sargent, Daniel J.; Laurent-Puig, Pierre; Sinicrope, Frank A. (2019). Is the predictive and prognostic impact of sporadic and familial microsatellite instable stage III colon cancer different? A pooled analysis of the PETACC8 and NCCTG N0147 (Alliance) trials. JOURNAL OF CLINICAL ONCOLOGY, vol. 37, pp. 3583-3583, ISSN:0732-183X DOI

Sinicrope, Frank A.; Huebner, Lucas J.; Laurent-Puig, Pierre; Smyrk, Thomas C.; Tabernero, Josep; Mini, Enrico; Goldberg, Richard M.; Folprecht, Gunnar; Zaanan, Aziz; Le Malicot, Karine; Shi, Qian; Alberts, Steven R; Taieb, Julien (2019). Relative contribution of clinical and molecular features to outcome within low and high risk T and N groups in stage III colon cancer (CC). JOURNAL OF CLINICAL ONCOLOGY, vol. 37, pp. 3520-3520, ISSN:0732-183X DOI

Auclin E, Taieb J, Lepage C, Aparicio T, Faroux R, Mini E, Folprecht G, Salazar R, Benetkiewicz M, Banzi M, Louvet C, Van Laethem JL, Tabernero J, Hickish T, de Gramont A, André T, Vernerey D. (2019). Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer: Post hoc Analysis of the MOSAIC and PETACC-8 Trials.. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, vol. 28, pp. 1153-1161, ISSN:1055-9965 DOI

Toffoli G, Innocenti F, Polesel J, De Mattia E, Sartor F, Fratte CD, Ecca F, Dreussi E, Palazzari E, Guardascione M, Buonadonna A, Foltran L, Garziera M, Bignucolo A, Nobili S, Mini E, Favaretto A, Berretta M, D'Andrea M, De Paoli A, Roncato R, Cecchin E. (2019). The genotype for DPYD risk variants in colorectal cancer patients and the related toxicity management costs in clinical practice.. CLINICAL PHARMACOLOGY & THERAPEUTICS, vol. ..., pp. 1-27, ISSN:1532-6535 DOI

Roviello G, Conter FU, Mini E, Generali D, Traversini M, Lavacchi D, Nobili S, Sobhani N. (2019). Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer.. CANCER CHEMOTHERAPY AND PHARMACOLOGY, pp. 0-10, ISSN:0344-5704

De Giorgi U.; Carteni G.; Giannarelli D.; Basso U.; Galli L.; Cortesi E.; Caserta C.; Pignata S.; Sabbatini R.; Bearz A.; Buti S.; Lo Re G.; Berruti A.; Bracarda S.; Cognetti F.; Rastelli F.; Fornarini G.; Porta C.; Turci D.; Sternberg C.N.; Procopio G.; Falcone A.; Roila F.; Cascinu S.; Tirelli U.; Giustini L.; Sobrero A.; Cappuzzo F.; Tassinari D.; Passalacqua R.; Pazzola A.; Surico G.; Maio M.; Benedetti G.; Barone C.; Adamo V.; Ricevuto E.; De Censi A.; Spada M.; Tonini G.; Pinto C.; Ciuffreda L.; Ruggeri E.M.; Bengala C.; Scotti V.; Fagnani D.; Bonetti A.; Mitterer M.; Castiglione F.; Bidoli P.; Ferrau F.; Crino L.; Frassoldati A.; Marchetti P.; Mini E.; Scoppola A.; Verusio C.; Favaretto A.; Di Costanzo F.; Fasola G.; Merlano M.; Artioli F.; Di Leo A.; Romito S.; Maestri A.; Giannitto Giorgio C.; Ionta M.T.; Verderame F.; Zampa G.; Numico G.; Minelli M.; Tagliaferri P.; Foa P.; Palmiotti G.; De Placido S.; Mattioli R.; Iuliano F.; Defraia E.; Siena S.; Clerico M.; Salvagno L.; Ceresoli G.L.; Bernardo A.; Di Lieto M.; Moroni M.; Maisano M.; Scartozzi M.; Scagliotti G.; Soraru M.; Pepe S.; Scaltriti A.; Gebbia V.; Testa E.; Lorusso V.; Bordonaro R.; De Signoribus G.; Tedde N.; Santoro A.; Francini G.; Aondio G. (2019). Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. BJU INTERNATIONAL, vol. 123, pp. 98-105, ISSN:1464-4096 DOI Accesso ONLINE all'editore

Gasperoni S, Messerini L, Fumagalli E, Manglaviti S, Vincenzi B, Mazzocca Jr. A, Pantaleo MA, Nannini M, Badalamenti G, Incorvaia L, Ottaviano M, Palmieri G, Grignani G, D'Ambrosio L, Meoni G, Paderi A, Fancelli S, Caliman E, Tofani L, Enrico Mini. (2019). Italian survey of second tumors in patients with diagnosis of GIST (gastrointestinal stromal tumor). JOURNAL OF CLINICAL ONCOLOGY, vol. 37, pp. 11032-11033, ISSN:0732-183X

De Giorgi, Ugo; Procopio, Giuseppe; Sabbatini, Roberto; Caserta, Claudia; Mitterer, Manfred; Ortega, Cinzia; Scoppola, Alessandro; Fornarini, Giuseppe; Ferraú, Francesco; Marchetti, Paolo; Verusio, Claudio; Mini, Enrico; Bidoli, Paolo; Buti, Sebastiano; Crino, Lucio; Basso, Umberto; Frassoldati, Antonio; Bearz, Alessandra; Carteni, Giacomo; Sternberg, Cora N. (2019). Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab. CLINICAL CANCER RESEARCH, vol. 25, pp. 3839-3846, ISSN:1078-0432 DOI

Roviello, G; Gatta Michelet, M R; D'Angelo, A; Nobili, S; Mini, E (2019). Role of novel hormonal therapies in the management of non-metastatic castration-resistant prostate cancer: a literature-based meta-analysis of randomized trials. CLINICAL & TRANSLATIONAL ONCOLOGY, pp. 1-7, ISSN:1699-048X DOI

Mini, Enrico; Landini, Ida; Lucarini, Laura; Lapucci, Andrea; Napoli, Cristina; Perrone, Gabriele; Tassi, Renato; Masini, Emanuela; Moroni, Flavio; Nobili, Stefania (2018). Erratum: The inhibitory effects of HYDAMTIQ, a novel PARP inhibitor, on growth in human tumor cell lines with defective DNA damage response pathways (Oncology Research 25:9 (1441-1451) DOI: 10.3727/096504017X14926854178616). ONCOLOGY RESEARCH, vol. 26, pp. 333-334, ISSN:0965-0407 DOI Accesso ONLINE all'editore

Garassino MC, Gelibter AJ, Grossi F, Chiari R, Soto Parra H, Cascinu S, Cognetti F, Turci D, Blasi L, Bengala C, Mini E, Baldini E, Quadrini S, Ceresoli GL, Antonelli P, Vasile E, Pinto C, Fasola G, Galetta D, Macerelli M, Giannarelli D, Lo Russo G, de Marinis F. (2018). Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients.. JOURNAL OF THORACIC ONCOLOGY, vol. 13, pp. 1146-1155, ISSN:1556-0864 DOI

Taieb, J; Kourie, Hr; Emile, Jf; Le Malicot, K; Balogoun, R; Tabernero, J; Mini, E; Folprecht, G; Van Laethem JL, ; Mulot, C; Bouché, O; Aparicio, T; Michel, P; Thaler, J; Bridgewater, J; Van Cutsem, E; Perkins, G; Lepage, C; Salazar, R; Laurent-Puig, P. (2018). Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.. JAMA ONCOLOGY, pp. 1-8, ISSN:2374-2437 DOI

F Ecca, E De Mattia, F Serra, R Roncato, E Dreussi, L Romanato, A Buonadonna, A De Paoli, M Berretta, E Mini, S Nobili, G Toffoli, E Cecchin (2018). Next-Generation Sequencing to Identify Rare Variants Related to FL-Toxicity. PUBLIC HEALTH GENOMICS, vol. 21, pp. 19-19, ISSN:1662-8063 DOI

Dalle Fratte C, Polesel J, Roncato R, De Mattia E, Ecca F, Bignucolo A, Garziera M, Dreussi E, Palazzari E, Buonadonna A, Guardascione M, Berretta M, Foltran L, Sartor F, D’Andrea M, Favaretto A, Mini E, Nobili S, De Paoli A, Toffoli G, Cecchin E. (2018). DPYD gene activity score (GAS) predicts dose-limiting toxicity in fluoropyrimidine-treated colorectal cancer patients. JOURNAL OF MOLECULAR AND CLINICAL MEDICINE, vol. 1, pp. 143-150, ISSN:2616-3632 DOI

Auclin, Edouard; Taieb, Julien; Lepage, Come; Aparicio, Thomas; Faroux, Roger; Mini, Enrico; Folprecht, Gunnar; Salazar, Ramon; Banzi, Maria; Louvet, Christophe; Van Laethem, Jean-Luc; Tabernero, Josep; Hickish, Tamas; De Gramont, Aimery; Andre, Thierry; Vernerey, Dewi (2018). Association of postoperative carcinoembryonic antigen (CEA) levels with survival in stage III colon cancer (CC): Post hoc analysis of the MOSAIC and PETACC-8 studies. JOURNAL OF CLINICAL ONCOLOGY, vol. 36, pp. 3568-3568, ISSN:0732-183X DOI

Garassino MC, Crinò L, Catino A, Ardizzoni A, Cortesi E, Cappuzzo F, Bordi P, Calabrò L, Barbieri F, Santo A, Altavilla G, Ambrosio F, Mini E, Vasile E, Morgillo F, Scoppola A, Bengala C, Follador A, Tedde N, Giannarelli D, Lo Russo G, Vitiello F (2018). Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program. TUMOR BIOLOGY, vol. 40, pp. 1-8, ISSN:1010-4283 DOI

Bartolini I, Ringressi MN, Melli F, Risaliti M, Brugia M, Mini E, Batignani G, Bechi P, Boni L, Taddei A. (2018). Analysis of Prognostic Factors for Resected Synchronous and Metachronous Liver Metastases from Colorectal Cancer.. GASTROENTEROLOGY RESEARCH AND PRACTICE, vol. ...., pp. 1-14, ISSN:1687-6121, HINDAWI LTD: ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND DOI

Allen WL, Dunne PD, McDade S, Scanlon E, Loughrey M, Coleman H, McCann C, McLaughlin K, Nemeth Z, Syed N, Jithesh P, Arthur K, Wilson R, Coyle V, McArt D, Murray GI, Samuel L, Nuciforo P, Jimenez J, Argiles G, Dienstmann R, Tabernero J, Messerini L, Nobili S, Mini E, Sheahan K, Ryan E, Johnston PG, Van Schaeybroeck S, Lawler M, Longley DB. (2018). Transcriptional subtyping and CD8 immunohistochemistry identifies poor prognosis stage II/III colorectal cancer patients who benefit from adjuvant chemotherapy.. JCO PRECISION ONCOLOGY, vol. ...., pp. 1-31, ISSN:2473-4284 DOI

De Mattia E, Dreussi E, Montico M, Gagno S, Zanusso C, Quartuccio L, De Vita S, Guardascione M, Buonadonna A, D'Andrea M, Pella N, Favaretto A, Mini E, Nobili S, Romanato L, Cecchin E, Toffoli G. (2018). A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy.. FRONTIERS IN PHARMACOLOGY, vol. 9, pp. 1-12, ISSN:1663-9812 DOI

Lavacchi D, Nobili S, Brugia M, Paderi A, Fancelli S, Caliman E, Vergoni F, Mini E. (2018). A case report of eyelid Merkel cell carcinoma occurring under treatment with nivolumab for a lung adenocarcinoma.. BMC CANCER, vol. 18, pp. 1-5, ISSN:1471-2407 DOI

Villanucci A, Tavella K, Vannini L, Rossi V, Nobili S, Amunni G, Mazzei T, Mini E (2018). Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors. MOLECULAR AND CLINICAL ONCOLOGY, vol. 9, pp. 635-639, ISSN:2049-9450 DOI

Gallois C, Taieb J, Le Corre D, Le Malicot K, Tabernero J, Mulot C, Seitz JF, Aparicio T, Folprecht G, Lepage C, Mini E, Van Laethem JL, Emile JF, Laurent-Puig P (2018). Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy. CLINICAL CANCER RESEARCH, vol. 24, pp. 4745-4753, ISSN:1078-0432 DOI

Magherini, Francesca; Fiaschi, Tania; Valocchia, Elisa; Becatti, Matteo; Pratesi, Alessandro; Marzo, Tiziano; Massai, Lara; Gabbiani, Chiara; Landini, Ida; Nobili, Stefania; Mini, Enrico; Messori, Luigi; Modesti, Alessandra; Gamberi, Tania* (2018). Antiproliferative effects of two gold(I)-N-heterocyclic carbene complexes in A2780 human ovarian cancer cells: A comparative proteomic study. ONCOTARGET, vol. 9, pp. 28042-28068, ISSN:1949-2553 DOI Accesso ONLINE all'editore

Zaanan, A; Shi, Q; Taieb, J; Alberts, Sr; Meyers, Jp; Smyrk, Tc; Julie, C; Zawadi, A; Tabernero, J; Mini, E; Goldberg, Rm; Folprecht, G; Van Laethem JL, ; Le Malicot, K; Sargent, Dj; Laurent-Puig, P; Sinicrope, F. A. (2018). Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.. JAMA ONCOLOGY, pp. 1-5, ISSN:2374-2437 DOI

Altavilla G, Mini E, Nobili S, Ostuni C, Santarpia M, Silvestris, F (2018). Principali effetti collaterali delle terapie mediche. In: Collegio degli Oncologi Medici Italiani. Manuale di Oncologia Medica, pp. 94-108, Torino: Edizioni Minerva Medica spa, ISBN:9788877119391.

Mini E, Nobili S, Mazzei T (2017). Farmaci antineoplastici - Farmaci immunoterapici - Anticorpi monoclonali inibitori dei checkpoints immunitari. In: Vari. Farmacologia – Principi di base e applicazioni terapeutiche - III edizione, pp. 908-910, Torino: Edizioni Minerva Medica, ISBN:978-88-7711-881-3.

Taieb, J; Balogoun, R; Le Malicot, K; Tabernero, J; Mini, E; Folprecht, G; Van Laethem, Jl; Emile, Jf; Mulot, C; Fratté, S; Levaché, Cb; Saban-Roche, L; Thaler, J; Petersen, Ln; Bridgewater, J; Perkins, G; Lepage, C; Van Cutsem, E; Zaanan, A; Laurent-Puig, P (2017). Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients. ANNALS OF ONCOLOGY, vol. 28, pp. 824-830, ISSN:0923-7534 DOI

Mini E., Nobili S., Mazzei T. (2017). Farmaci antineoplastici - Antimetaboliti. In: Vari. Farmacologia – Principi di base e applicazioni terapeutiche - III edizione, pp. 854-869 Edizioni Minerva Medica, ISBN:978-88-7711-881-3.

Tavella, K; Villanucci, A; Vannini, L; Rossi, V; Fantechi, B; Capone, G; Putignano, A L; Gensini, F; Porfirio, B; Amunni, G; Mazzei, T; Mini, E; Papi, L (2017). Retrospective analysis of 77 patients with ovarian cancer undergoing genetic testing for BRCA1 and BRCA2 mutations. ANNALS OF ONCOLOGY, vol. 28, pp. 71-71, ISSN:0923-7534 DOI

S Kovalchuk, L Rigacci, G Perrone, S Nobili, B Puccini, R Tassi, M Brugia, I Landini, L Mannelli, G Benelli, C Napoli, E Cencini, A Fabbri, L Iovino, M Petrini, S Birtolo, A Melosi, S Santini, P Bernardeschi, A Bosi, E Mini (2017). THE IMPACT OF GENETIC POLYMORPHISMS ON R-CHOP EFFICACY IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: AN INTERIM ANALYSIS OF A MULTICENTER PROSPECTIVE PHARMACOGENETIC STUDY. HAEMATOLOGICA, vol. 102, pp. 27-27, ISSN:0390-6078

Garassino, M.; Cortesi, E.; Grossi, F.; Chiari, R.; Parra, H. Soto; Cascinu, S.; Cognetti, F.; Turci, D.; Blasi, L.; Bengala, C.; Mini, E.; Baldini, E.; Gamucci, T.; Ceresoli, G.; Antonelli, P.; Vasile, E.; Pinto, C.; Galetta, D.; Macerelli, M.; De Marinis, F. (2017). MA 11.11 Italian Nivolumab Expanded Access Program in Non-Squamous NSCLC Patients: Results in Never Smokers and EGFR Positive Patients. JOURNAL OF THORACIC ONCOLOGY, vol. 12, pp. S1847-S1847, ISSN:1556-0864 DOI

Garassino, M.C.; Cortesi, E.; Grossi, F.; Chiari, R.; Soto Parra, H.J.; Cascinu, S.; Cognetti, F.; Turci, D.; Blasi, L.; Bengala, C.; Mini, E.; Baldini, E.E.; Gamucci, T.; Ceresoli, G.L.; Antonelli, P.; Vasile, E.; Pagano, M.; Macerelli, M.; Lagroscino, A.; De Marinis, F. (2017). Italian nivolumab expanded access programme in non-squamous non-small cell lung cancer patients: Real-world results in never smokers and EGFR positive patients. ANNALS OF ONCOLOGY, vol. 28, pp. 470-471, ISSN:0923-7534 DOI

Taieb, Julien; Kourie, Hampig Raphael; Emile, Jean-François; Le Malicot, Karine; Balogoun, Ralyath; Tabernero, Josep; Mini, Enrico; Folprecht, Gunnar; Van Laethem, Jean-Luc; Mulot, Claire; Bouche, Olivier; Aparicio, Thomas; Michel, Pierre; Thaler, Josef; Bridgewater, John A.; Van Cutsem, Eric; Perkins, Géraldine; Salazar, Ramon; Lepage, Come; Laurent-Puig, Pierre (2017). Association of prognostic value of primary tumor location in stage III colon cancer with RAS and BRAF mutational status. JOURNAL OF CLINICAL ONCOLOGY, vol. 35, pp. 3515-3515, ISSN:0732-183X DOI

De Giorgi, U.; Procopio, G.; Guida, A.; Bearz, A.; Buti, S.; Basso, U.; Mitterer, M.; Ortega, C.; Bidoli, P.; Ferrau, F.; Crinò, L.; Frassoldati, A.; Marchetti, P.; Mini, E.; Scoppola, A.; Verusio, C.; Fornarini, G.; Cartenì, G.; Caserta, C.; Sternberg, C.N. (2017). Inflammatory indexes strongly predict clinical outcome in patients (pts) with metastatic renal cell cancer (mRCC) treated with nivolumab: results from the Italian expanded access program (EAP). ANNALS OF ONCOLOGY, vol. 28, pp. 320-321, ISSN:0923-7534 DOI

Gallois, C.; Taieb, J.; Le Corre, D.; Le Malicot, K.; Tabernero, J.; Mulot, C.; Seitz, J-F.; Aparicio, T.; Folprecht, G.; Lepage, C.; Mini, E.; Van Laethem, J-L.; Emile, J.F.; Laurent-Puig, P. (2017). Prognostic value of methylator phenotype in stage III colon cancer treated with oxaliplatin-based adjuvant chemotherapy. ANNALS OF ONCOLOGY, vol. 28, pp. 161-161, ISSN:0923-7534 DOI

Taieb, Julien; Kourie Hampig, Raphael; Emile Jean, François; Le Malicot, Karine; Balogoun, Ralyath; Tabernero, Josep; Mini, Enrico; Folprecht, Gunnar; Van Laethem Jean, Luc; Mulot, Claire; Bouché, Olivier; Aparicio, Thomas; Michel, Pierre; Thaler, Josef; Bridgewater, John; Van Cutsem, Eric; Perkins, Géraldine; Lepage, Come; Salazar, Ramon; Laurent Puig, Pierre (2017). Prognostic value of primary tumor location in stage III colon cancer is associated with RAS and BRAF mutational status. ANNALS OF ONCOLOGY, vol. 28, pp. 142-142, ISSN:0923-7534 DOI

Lo Russo, Giuseppe; Crinò, Lucio; Galetta, Domenico; Ardizzoni, Andrea; Cortesi, Enrico; Cappuzzo, Frederico; Bordi, Paola; Calabrò, Luana; Barbieri, Fausto; Santo, Antonio; Altavilla, Giuseppe; Cartenì, Giacomo; Mini, Enrico; Vasile, Enrico; Morgillo, Floriana; Scoppola, Alessandro; Bengala, Carmelo; Fasola, Gianpiero; Tedde, Natale; Piantedosi, Francovito (2017). MA14.06 Nivolumab in Never Smoker Patients with Advanced Squamous NSCLC: Results from the Italian Expanded Access Programme (EAP). JOURNAL OF THORACIC ONCOLOGY, vol. 12, pp. S424-S425, ISSN:1556-0864 DOI

Mini E, Nobili S, Mazzei T (2017). Farmaci antineoplastici: Farmaci antiormonali.. In: Vari. Farmacologia – Principi di base e applicazioni terapeutiche - III edizione, pp. 878-886 Edizioni Minerva Medica, ISBN:978-88-7711-881-3.

Mini E, Nobili S, Mazzei T (2017). Farmaci antineoplastici - Farmaci inibitori della trasduzione del segnale - Farmaci inibitori di protein chinasi. In: Vari. Farmacologia – Principi di base e applicazioni terapeutiche - III edizione, pp. 889-902, Torino: Edizioni Minerva Medica, ISBN:978-88-7711-881-3.

Nobili S, Mini, E, Mazzei T, Vannacci A (2017). Adverse drug reactions in oncoLogy: intEnsive monitoring program on biotechnological anD taRget therapies in Oncologic patientS-ALEXANDROS observational study. DRUG SAFETY, vol. 40, pp. 993-993, ISSN:0114-5916

Mini E., Nobili S., Novelli A., Mazzei T. (2017). Farmaci antimicrobici - Glicopeptidi. In: Vari. Farmacologia – Principi di base e applicazioni terapeutiche - III edizione, pp. 737-745, Torino: Edizioni Minerva Medica, ISBN:978-88-7711-881-3.

Mini E, Nobili S, Mazzei T (2017). Farmaci antineoplastici - Farmaci inibitori della trasduzione del segnale - Generalità. In: Vari. Farmacologia – Principi di base e applicazioni terapeutiche - III edizione, pp. 887-889, Torino: Edizioni Minerva Medica, ISBN:978-88-7711-881-3.

Maggini V, Gallo E, Landini I, Lapucci A, Nobili S, Mini E, Firenzuoli F (2017). P118 A preliminary study for evaluation of cannabis - chemotherapy interactions on human colon cancer cells. BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, vol. 17, pp. 115-115, ISSN:1472-6882 DOI

Galiulo M, Convertino I, Blandizzi C, Tassi R, Diacciati S, Nobili S, Capogrosso Sansone A, Marino A, Mini E, Mazzei T, Vannacci A, Parrilli M, Corona T, Tuccori M (2017). Adverse drug reactions in oncoLogy: intEnsive monitoring program on drug toXicity of biotechnological medicatioNs anD taRget therapies in Oncologic patientS - the ALEXANDROS observational study. DRUG SAFETY, vol. 40, pp. 993-993, ISSN:0114-5916 DOI

Rigacci, L; Perrone, G; Nobili, S; Kovalchuk, S; Puccini, B; Tassi, R; Brugia, M; Landini, I; Mannelli, L; Benelli, G; Napoli, C; Cencini, E; Fabbri, A; Iovino, L; Petrini, M; Birtolo, S; Melosi, A; Santini, S; Bernardeschi, P; Bosi, A; Mini, E (2017). Role of genetic polymorphisms on R-CHOP efficacy in diffuse large B-cell lymphoma patients: an interim analysis of a multicenter prospective pharmacogenetics study.. HEMATOLOGICAL ONCOLOGY, vol. 35, pp. 291-292, ISSN:1099-1069 DOI

Emile, Jf; Julié, C; Le Malicot, K; Lepage, C; Tabernero, J; Mini, E; Folprecht, G; Van Laethem JL, ; Dimet, S; Boulagnon-Rombi, C; Allard, Ma; Penault-Llorca, F; Bennouna, J; Laurent-Puig, P; Taieb, J. (2017). Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX.. EUROPEAN JOURNAL OF CANCER, vol. 82, pp. 16-24, ISSN:0959-8049 DOI

Landini, I; Lapucci, A; Pratesi, A; Massai, L; Napoli, C; Perrone, G; Pinzani, P; Messori, L; Mini, E; Nobili, S. (2017). Selection and characterization of a human ovarian cancer cell line resistant to auranofin. ONCOTARGET, vol. 8, pp. 96062-96078, ISSN:1949-2553

Giovannetti, L; Piazzini, V; Coronnello, M; Mini, E; Bergonzi Maria, C; Bilia Anna, R (2017). LIPOSOMES LOADED WITH BERBERINE HYDROCHLORIDE: DEVELOPMENT, OPTIMISATION AND IN VITRO CITOTOXICITY. PLANTA MEDICA, vol. 4, pp. 0-0, ISSN:0032-0943 DOI

L. Rigacci; G. Perrone; S. Nobili; S. Kovalchuk; B. Puccini; R. Tassi; M. Brugia; I. Landini; L. Mannelli; G. Benelli; C. Napoli; E. Cencini; A. Fabbri; L. Iovino; M. Petrini; S. Birtolo; A. Melosi; S. Santini; P. Bernardeschi; A. Bosi; E. Mini (2017). Role of genetic polymorphisms on R-CHOP efficacy in diffuse large B-cell lymphoma patients: an interim analysis of a multicenter prospective pharmacogenetics study.. HAEMATOLOGICA, vol. 102, pp. 574-574, ISSN:0390-6078

Mini, E; Landini, I; Lucarini, L; Lapucci, A; Napoli, C; Perrone, G; Tassi, R; Masini, E; Moroni, F; Nobili, S. (2017). The Inhibitory Effects of HYDAMTIQ, a Novel PARP Inhibitor, on Growth in Human Tumor Cell Lines With Defective DNA Damage Response Pathways.. ONCOLOGY RESEARCH, vol. 25, pp. 1441-1451, ISSN:0965-0407 DOI

Mini, E.; D’ Aurizio, R.; Perrone, G.; Magi, A.; Lapucci, A.; Tassi, R.; Napoli, C.; Picariello, L.; Landini, I.; Nobili, S. (2016). RNA sequencing reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy. EUROPEAN JOURNAL OF CANCER, vol. 61, pp. S199-S199, ISSN:0959-8049 DOI

Leto, Isabella; Coronnello, Marcella; Righeschi, Chiara; Maria Camilla Bergonzi, ; Mini, Enrico; Bilia, Anna Rita (2016). Enhanced Efficacy of Artemisinin Loaded in Transferrin-Conjugated Liposomes versus Stealth Liposomes against HCT-8 Colon Cancer Cells. CHEMMEDCHEM, pp. 1-8, ISSN:1860-7187 DOI

Di Cesare Mannelli, Lorenzo; Zanardelli, Matteo; Landini, Ida; Pacini, Alessandra; Ghelardini, Carla; Mini, Enrico; Bencini, Andrea; Valtancoli, Barbara; Failli, Paola (2016). Effect of the SOD mimetic MnL4 on in vitro and in vivo oxaliplatin toxicity: Possible aid in chemotherapy induced neuropathy. FREE RADICAL BIOLOGY & MEDICINE, vol. 93, pp. 67-76, ISSN:0891-5849 DOI

Serratrice, M; Maiore, L; Zucca, A; Stoccoro, S; Landini, I; Mini, E; Massai, L; Ferraro, G; Merlino, A; Messori, L; Cinellu, Ma (2016). Cytotoxic properties of a new organometallic platinum(II) complex and its gold(I) heterobimetallic derivatives.. DALTON TRANSACTIONS, vol. 45, pp. 279-590, ISSN:1477-9226 DOI

Mini E, Nobili S, Novelli A, Mazzei T (2016). GLICOPEPTIDI. In: Vincenzo Cuomo, Carlo Riccardi, Francesco Rossi. Farmacologia. Principi di base e applicazioni terapeutiche, pp. 737-744, Torino: Edizioni Minerva Medica spa, ISBN:9788877118813.

Novelli A, Cassetta MI, Mini E, Mazzei T (2016). FLUOROCHINOLONI. In: Vincenzo Cuomo, Carlo Riccardi, Francesco Rossi. Farmacologia. Principi di base e applicazioni terapeutiche, pp. 725-726, Torino: Edizioni Minerva Medica spa, ISBN:9788877118813.

Novelli A, Fallani S, Mini E, Mazzei T (2016). AMINOGLUCOSIDI. In: Vincenzo Cuomo, Carlo Riccardi, Francesco Rossi. Farmacologia. Principi di base e applicazioni terapeutiche, pp. 715-724, Torino: Edizioni Minerva Medica spa, ISBN:9788877118813.

Laurent-Puig, P.; Balogoun, R.; Cayre, A.; Le Malicot, K.; Tabernero, J.; Mini, E.; Folprecht, G.; van Laethem, J-L.; Thaler, J.; Petersen, L. Nørgård; Sanchez, E.; Bridgewater, J.; Ellis, S.; Locher, C.; Lagorce, C.; Ramé, J-F.; Lepage, C.; Penault-Llorca, F.; Taieb, J. (2016). ERBB2 alterations a new prognostic biomarker in stage III colon cancer from a FOLFOX based adjuvant trial (PETACC8). ANNALS OF ONCOLOGY, vol. 27, pp. 47-47, ISSN:0923-7534 DOI

Emile, Jean-François; Le Malicot, Karine; Tabernero, Josep; Mini, Enrico; Folprecht, Gunnar; Van Laethem, Jean-Luc; Julie, Catherine; Allard, Marc Antoine; Bennouna, Jaafar; Lepage, Come; Laurent-Puig, Pierre; Taïeb, Julien (2016). Validation of the prognostic impact of lymphocyte infiltration (LI) in patients (pts) with stage III colon cancer (CC) treated with adjuvant FOLFOX+/- cetuximab: A PETACC8 translational study. JOURNAL OF CLINICAL ONCOLOGY, vol. 34, pp. 553-553, ISSN:0732-183X DOI

Vitali, M.; Crinò, L.; Logroscino, A.F.; Ardizzoni, A.; Caponnetto, S.; Landi, L.; Bordi, P.; Luana, C.; Barbieri, F.; Santo, A.; Santarpia, M.; Carteni, G.; Mini, E.; Vasile, E.; Morgillo, F.; De Galitiis, F.; Conca, R.; Macerelli, M.; Tedde, N.; Vitiello, F. (2016). Preliminary efficacy and safety data of nivolumab in never smoker patients with advanced squamous NSCLC: Experience from Italian sites participating in the Expanded Access Programme (EAP). ANNALS OF ONCOLOGY, vol. 27, pp. 416-416, ISSN:0923-7534 DOI

Taieb, J.; Le Malicot, K.; Balogoum, R.; Tabernero, J.; Mini, E.; Folprecht, G.; van Laethem, J-L.; Emile, J-F.; Mulot, C.; Fratté, S.; Levaché, C-B.; Saban-Roche, L.; Thaler, J.; Petersen, L. Nørgård; Sanchez, E.; Bridgewater, J.; Perkins, G.; Lepage, C.; Zaanan, A.; Laurent-Puig, P. (2016). Adjuvant FOLFOX+ cetuximab vs FOLFOX in full RAS and BRAF wild type stage III colon cancer patients: Results from the PETACC8 trial. ANNALS OF ONCOLOGY, vol. 27, pp. 49-49, ISSN:0923-7534 DOI

Taieb, J; Zaanan, A; Le Malicot, K; Julié, C; Blons, H; Mineur, L; Bennouna, J; Tabernero, J; Mini, E; Folprecht, G; Van Laethem, Jl; Lepage, C; Emile, Jf; Laurent-Puig, P (2016). Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab. A Post Hoc Analysis of the PETACC-8 Trial. JAMA ONCOLOGY, pp. 2378-2385, ISSN:2374-2437 DOI

Garziera, M; Catamo, E; Crovella, S; Montico, M; Cecchin, E; Lonardi, S; Mini, E; Nobili, S; Romanato, L; Toffoli, G (2016). Association of the HLA-G 3′UTR polymorphisms with colorectal cancer in Italy: a first insight. INTERNATIONAL JOURNAL OF IMMUNOGENETICS, vol. 43, pp. 32-39, ISSN:1744-3121 DOI

Mini, E; Landini, I; Napoli, C; Nobili, S; Perrone, G; Lapucci, A (2016). Pharmacological modulation of protein kinase C for overcoming drug resistance in colorectal cancer. Preliminary results of in vitro studies.. ANNALS OF ONCOLOGY, vol. 27, pp. 45-45, ISSN:0923-7534 DOI

Mini, E; D’Aurizio, R; Perrone, G; Magi, A; Lapucci, A; Tassi, R; Napoli, C; Picariello, L; Landini, I; Brugia, M; Mazzei, T; Tonelli, F; Nobili, S (2016). A transcriptomic profile predicts clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy. ANNALS OF ONCOLOGY, vol. 27, pp. 575-575, ISSN:0923-7534 DOI

Tassi, R; Mini, E; D'Aurizio, R; Perrone, G; Magi, A; Lapucci, A; Napoli, C; Picariello, L; Brugia, M; Landini, I; Mazzei, T; Tonelli, F; Nobili, S (2016). Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy. ANNALS OF ONCOLOGY, vol. 27, pp. 43-43, ISSN:0923-7534 DOI

Taieb, J; Le Malicot, K; Shi, Q; Penault Lorca, F; Bouché, O; Tabernero, J; Mini, E; Goldberg, Rm; Folprecht, G; Luc Van Laethem, J; Sargent, Dj; Alberts, Sr; Francois Emile, J; Laurent Puig, P; Sinicrope, Fa (2016). Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.. JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 109, pp. 1-12, ISSN:0027-8874 DOI

Tassi, R.; Mini, E.; D'Aurizio, R.; Perrone, G.; Magi, A.; Lapucci, A.; Napoli, C.; Picariello, L.; Brugia, M.; Landini, I.; Mazzei, T.; Tonelli, F.; Nobili, S. (2016). D13Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy. ANNALS OF ONCOLOGY, vol. 27, pp. iv43-iv43, ISSN:0923-7534 DOI

Cialdai, Francesca; Landini, Ida; Capaccioli, Sergio; Nobili, Stefania; Mini, Enrico; Lulli, Matteo; Monici, Monica (2015). In vitro study on the safety of near infrared laser therapy in its potential application as postmastectomy lymphedema treatment. JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY, vol. 151, pp. 285-296, ISSN:1011-1344 DOI Accesso ONLINE all'editore

Garziera, M; Bidoli, E; Cecchin, E; Mini, E; Nobili, S; Lonardi, S; Buonadonna, A; Errante, D; Pella, N; D'Andrea, M; De Marchi, F; De Paoli, A; De Mattia, E; Zanusso, C; Toffoli, G (2015). HLA-G 3’UTR +2960 14-bp INDEL (Ins/Del) polymorphism is associated to improved DFS of stage II-III CRC patients.. ANNALS OF ONCOLOGY, vol. 26, pp. 42-43, ISSN:0923-7534 DOI

Nobili, S; Galletta, A; Brugia, M; Tassi, R; Petreni, P; Landini, I; Mini, E (2015). Emerging drugs in refractory colorectal cancer. FUTURE MEDICINAL CHEMISTRY, vol. 7, pp. 1491-1501, ISSN:1756-8919 DOI

Rigacci, L; Perrone, G; Nobili, S; Kovalchuk, S; Puccini, B; Lancia, F; Tassi, R; Brugia, M; Landini, I; Mannelli, L; Benelli, G; Napoli, C; Cencini, E; Fabbri, A; Iovino, L; Petrini, M; Birtolo, S; Melosi, A; Martini, V; Santini, S; Breschi, C; Bernardeschi, P; Bengala, C; Bosi, A; Mini, E (2015). Role of Genetic Polymorphisms on Response to R-CHOP regimen in Diffuse Large B-cell Lymphoma Patients: an Interim Analysis of a Multicenter Prospective Pharmacogenetic Study. BLOOD, vol. 126, pp. 2483-2483, ISSN:1528-0020

Garziera, M; Bidoli, E; Cecchin, E; Mini, E; Nobili, S; Lonardi, S; Buonadonna, A; Errante, D; Pella, N; D'Andrea, M; De Marchi, F; De Paoli, A; Zanusso, C; De Mattia, E; Tassi, R; Toffoli, G. (2015). HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment. PLOS ONE, vol. 10, pp. 1-17, ISSN:1932-6203 DOI

Gamberi, Tania; Magherini, Francesca; Fiaschi, Tania; Landini, Ida; Massai, Lara; Valocchia, Elisa; Bianchi, Laura; Bini, Luca; Gabbiani, Chiara; Nobili, Stefania; Mini, Enrico; Messori, Luigi; Modesti, Alessandra (2015). Proteomic analysis of the cytotoxic effects induced by the organogold(III) complex Aubipyc in cisplatin-resistant A2780 ovarian cancer cells: further evidence for the glycolytic pathway implication. MOLECULAR BIOSYSTEMS, vol. 11, pp. 1653-1667, ISSN:1742-206X DOI Accesso ONLINE all'editore

Taieb, Julien; Le Malicot, Karine; Penault-Llorca, Frederique Madeleine; Bouche, Olivier; Shi, Qian; Thibodeau, Stephen N.; Tabernero, Josep; Mini, Enrico; Goldberg, Richard M.; Folprecht, Gunnar; Van Laethem, Jean-Luc; Sargent, Daniel J.; Alberts, Steven R.; Laurent-Puig, Pierre; Sinicrope, Frank A. (2015). Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts) treated with adjuvant FOLFOX+/- cetuximab: A pooled analysis of 3934 pts from the PETACC8 and N0147 trials. JOURNAL OF CLINICAL ONCOLOGY, vol. 33, pp. 3507-3507, ISSN:0732-183X DOI

Taieb, J.; Le Malicot, K.; Penault-Llorca, F.; Bouche, O.; Shi, Q.; Thibodeau, S.; Tabernero, J.; Mini, E.; Zaanan, Z.; Goldberg, R.; Folprecht, G.; Van Laethem, J.L.; Sargent, D.; Alberts, S.; Laurent Puig, P.; Sinicrope, F. (2015). Prognostic value of BRAFV600E and KRAS exon 2 mutations in microsatellite stable stage III colon cancers from patients treated with FOLFOX + /- cetuximab: A pooled analysis from PETACC8 and N0147 trials. ANNALS OF ONCOLOGY, vol. 26, pp. iv110-iv110, ISSN:0923-7534 DOI

Zaanan, A.; Shi, Q.; Taieb, J.; Alberts, S.; Smyrk, T.; Julie, C.; Zawadi, A.; Tabernero, J.; Mini, E.; Goldberg, R.; Folprecht, G.; Van Laethem, J.L.; Le Malicot, K.; Sargent, D.; Laurent Puig, P.; Sinicrope, F. (2015). Analysis of DNA mismatch repair and clinical outcome in stage III colon cancers from patients treated with adjuvant FOLFOX +/- cetuximab in the PETACC8 and NCCTG N0147 adjuvant trials. ANNALS OF ONCOLOGY, vol. 26, pp. iv116-iv116, ISSN:0923-7534 DOI

Zaanan, Aziz; Shi, Qian; Taieb, Julien; Alberts, Steven R.; Smyrk, Thomas C.; Julie, Catherine; Zawadi, Ayman; Tabernero, Josep; Mini, Enrico; Goldberg, Richard M.; Folprecht, Gunnar; Van Laethem, Jean L.; Le Malicot, Karine; Sargent, Daniel J.; Laurent-Puig, Pierre; Sinicrope, Frank A. (2015). Analysis of DNA mismatch repair (MMR) and clinical outcome in stage III colon cancers from patients (pts) treated with adjuvant FOLFOX +/- cetuximab in the PETACC8 and NCCTG N0147 adjuvant trials. JOURNAL OF CLINICAL ONCOLOGY, vol. 33, pp. 3506-3506, ISSN:0732-183X DOI

Stivarou, T; Cipolleschi, Mg; D'Amico, M; Mannini, A; Mini, E; Rovida, E; Dello Sbarba, P; Olivotto, M; Marzi, I (2015). The complex metabolic network gearing the G1/S transition in leukemic stem cells: Hints to a rational use of antineoplastic agents.. ONCOTARGET, vol. 6, pp. 31985-31996, ISSN:1949-2553 DOI Accesso ONLINE all'editore

Toffoli, G; Giodini, L; Buonadonna, A; Berretta, M; De Paoli, A; Scalone, S; Miolo, G; Mini, E; Nobili, S; Lonardi, S; Pella, N; Lo Re, G; Montico, M; Roncato, R; Dreussi, E; Gagno, S; Cecchin, E. (2015). Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines.. INTERNATIONAL JOURNAL OF CANCER, vol. 137, pp. 2971-2980, ISSN:0020-7136 DOI

Taieb, J.; Zaanan, A.; Malicot, K. Le; Julie, C.; Blons, H.; Mineur, L.; Tabernero, J.; Mini, E.; Folprecht, G.; Laethem, J.L. Van; Lepage, C.; Emile, J.F.; Laurent-Puig, P. (2015). 2167 Microsatellite status predicts BRAF V600E and KRAS exon 2 mutations prognostic value in stage III colon cancers (CC) patients treated with adjuvant FOLFOX +/- cetuximab. A post-hoc analysis of the PETACC8 trial. EUROPEAN JOURNAL OF CANCER, vol. 51, pp. S389-S389, ISSN:0959-8049 DOI

Riganti, C; Mini, E; Nobili, S (2015). Editorial: multidrug resistance in cancer: pharmacological strategies from basic research to clinical issues.. FRONTIERS IN ONCOLOGY, vol. 5, pp. 105-107, ISSN:2234-943X DOI

Mini E, Landini I, Lucarini L, Nobili S, Masini E, Moroni F (2015). In vitro cell growth inhibitory effects of HYDAMTIQ, a novel PARP inhibitor, on human tumor cell lines with defective DNA damage response pathways. In: EACR- AACR-SIC Special Conferences Anticancer Drug Action and Drug Resistance: from Cancer Biology to the Clinic, Florence, Italy, Giugno 20-23, 2015, American Association for Cancer Research, pp. 144-144.

Tassi, R; Perrone, G; Brugia, M; Simi, L; Petreni, P; Mori, E; Landini, I; Pazzagli, M; Mazzei, T; Mini, E; Nobili, S (2015). Fluoropyrimidine-related toxicity in gastrointestinal cancer patients. Assessment of risk factors.. ANNALS OF ONCOLOGY, vol. 26, pp. 43-44, ISSN:0923-7534 DOI

Cecchin, E; Giodini, L; Buonadonna, A; Berretta, M; De Paoli, A; Scalone, S; Miolo, G; Mini, E; Nobili, S; Mazzei, T; Lonardi, S; Zagonel, V; Pella, N; Fasola, G; Tirelli, U; Montico, M; Roncato, R; Toffoli, G (2015). Pre-emptive pharmacogenetic testing implementation for chemotherapy dosage optimization: the translational experience at CRO of Aviano.. ANNALS OF ONCOLOGY, vol. 26, pp. 151-151, ISSN:0923-7534 DOI

Cecchin E; Perrone G; Nobili S; Polesel J; De Mattia E; Zanusso C; Petreni P; Lonardi S; Pella N; D'Andrea M; Errante D; Rizzolio F; Mazzei T; Landini I; Mini E; Toffoli G. (2015). MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin. PHARMACOGENOMICS JOURNAL, vol. 14, pp. 219-225, ISSN:1470-269X DOI

Blons H; Emile JF; Le Malicot K; Julié C; Zaanan A; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Thaler J; Bridgewater J; Nørgård-Petersen L; Van Cutsem E; Lepage C; Zawadi MA; Salazar R; Laurent-Puig P; Taieb J. (2014). Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.. ANNALS OF ONCOLOGY, vol. 25, pp. 2378-2385, ISSN:0923-7534 DOI

Wolfgang J. Parak;Marek Osinski;Kenji I. Yamamoto;Francesca Tatini;Fulvio Ratto;Sonia Centi;Ida Landini;Stefania Nobili;Ewa Witort;Franco Fusi;Sergio Capaccioli;Enrico Mini;Roberto Pini (2014). Specific markers, micro-environmental anomalies and tropism: Opportunities for gold nanorods targeting of tumors in laser-induced hyperthermia. In: Colloidal Nanoparticles for Biomedical Applications IX, San Francisco, CA, USA, 1-6 Febbraio 2014, SPIE, vol. 8955, pp. 895519-1-895519-3. DOI Accesso ONLINE all'editore

Centi S; Tatini F; Ratto F; Gnerucci A; Mercatelli R; Romano G; Landini I; Nobili S; Ravalli A; Marrazza G; Mini E; Fusi F; Pini R. (2014). In vitro assessment of antibody-conjugated gold nanorods for systemic injections. JOURNAL OF NANOBIOTECHNOLOGY, vol. 12, pp. 55-65, ISSN:1477-3155 DOI Accesso ONLINE all'editore

Silvia Dei; Marcella Coronnello; Elisa Floriddia; Gianluca Bartolucci; Cristina Bellucci; Luca Guandalini; Dina Manetti; Maria Novella Romanelli; Milena Salerno; Ivan Bello; Enrico Mini; Elisabetta Teodori (2014). Multidrug resistance (MDR) reversers: High activity and efficacy in a series of asymmetrical N,N-bis(alkanol)amine aryl esters. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 87, pp. 398-412, ISSN:0223-5234 DOI Accesso ONLINE all'editore

Correale P; Botta C; Rotundo MS; Guglielmo A; Conca R; Licchetta A; Pastina P; Bestoso E; Ciliberto D; Cusi MG; Fioravanti A; Guidelli GM; Bianco MT; Misso G; Martino E; Caraglia M; Tassone P; Mini E; Mantovani G; Ridolfi R; Pirtoli L; Tagliaferri P (2014). Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized phase III trial. JOURNAL OF IMMUNOTHERAPY, vol. 37, pp. 26-35, ISSN:1524-9557

Francesca Tatini;Ida Landini;Federica Scaletti;Lara Massai;Sonia Centi;Fulvio Ratto;Stefania Nobili;Giovanni Romano;Franco Fusi;Luigi Messori;Enrico Mini;Roberto Pini (2014). Size dependent biological profiles of PEGylated gold nanorods. JOURNAL OF MATERIALS CHEMISTRY. B, vol. 2, pp. 6072-6080, ISSN:2050-750X DOI Accesso ONLINE all'editore

Taïeb, Julien; Emile, Jean-François; Le Malicot, Karine; Zaanan, Aziz; Tabernero, Josep; Mini, Enrico; Rougier, Philippe; VAN Laethem, Jean Luc; Bridgewater, John A.; Folprecht, Gunnar; Salazar, Ramon; Zawadi, Ayman; Van Cutsem, Eric; Lepage, Come; Laurent-Puig, Pierre; Blons, Helene (2014). Prognostic value of KRAS exon 2 gene mutations in stage III colon cancer: Post hoc analyses of the PETACC8 trial. JOURNAL OF CLINICAL ONCOLOGY, vol. 32, pp. 3549-3549, ISSN:0732-183X DOI

Blons, H.; Emile, J.; Le Malicot, K.; Zaanan, A.; Tabernero, J.; Mini, E.; Folprecht, G.; van Laethem, J.; Thaler, J.; Bridgewater, J.A.; Petersen, L.; Van Cutsem, E.; Lepage, C.; Salazar, R.; Laurent-Puig, P.; Taieb, J. (2014). PPROGNOSTIC VALUE OF KRAS MUTATIONS IN STAGE III COLON CANCER: POST-HOC ANALYSES OF THE PETACC8 PHASE III TRIAL. ANNALS OF ONCOLOGY, vol. 25, pp. iv196-iv196, ISSN:0923-7534 DOI

Taieb, J.; Emile, J. F.; Le Malicot, K.; Zaanan, A.; Tabernero, J.; Mini, E.; Folprecht, G.; Van Laethem, J. L.; Thaler, J.; Bridgewater, J.; Petersen, L.; Van Cutsem, E.; Lepage, C.; Salazar, R.; Laurent-Puig, P.; Blons, H. (2014). PROGNOSTIC VALUE OF KRAS MUTATIONS IN STAGE III COLON CANCER: POST-HOC ANALYSES OF THE PETACC8 PHASE III TRIAL. ANNALS OF ONCOLOGY, vol. 25, pp. ii115-ii115, ISSN:0923-7534 DOI

Taieb, J; Tabernero, J; Mini, E; Subtil, F; Folprecht, G; Van Laethem, Jl; Thaler, J; Bridgewater, J; Petersen, Ln; Blons, H; Collette, L; Van Cutsem, E; Rougier, P; Salazar, R; Bedenne, L; Emile, Jf; Laurent-Puig, P; Lepage, C (2014). Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.. THE LANCET ONCOLOGY, pp. 862-873, ISSN:1470-2045 DOI

Nobili S; Napoli C; Puccini B; Landini I; Perrone G; Brugia M; Benelli G; Doria M; Martelli M; Finolezzi E; Di Rocco A; Del Fava E; Rigacci L; Di Lollo S; Bosi A; Mini E. (2014). Identification Of Pharmacogenomic Markers Of Clinical Efficacy In A Dose-Dense Therapy Regimen (R-Chop14) In Diffuse Large B Cell Lymphoma. LEUKEMIA & LYMPHOMA, vol. 55, pp. 2071-2078, ISSN:1042-8194 DOI

Nobili S; Tassi R; Landini I; Perrone G; Napoli C; Mini E (2014). Druggable Targets in Pancreatic Adenocarcinoma. FORUM ON IMMUNOPATHOLOGICAL DISEASES AND THERAPEUTICS, vol. 5, pp. 195-214, ISSN:2151-8017

Bajetta E; Floriani I; Di Bartolomeo M; Labianca R; Falcone A; Di Costanzo F; Comella G; Amadori D; Pinto C; Carlomagno C; Nitti D; Daniele B; Mini E; Poli D; Santoro A; Mosconi S; Casaretti R; Boni C; Pinotti G; Bidoli P; Landi L; Rosati G; Ravaioli A; Cantore M; Di Fabio F; Marchet A; Rulli E; Cropalato Di Tullio M; Galli F; Biagioli E; De Simone I; Mangano S; Tonato M; Zucca E; Valsecchi MG; De Placido S; Catena L; Schiavo M; Proserpio I; Bordonaro R; Cordio S; Burrafato G; Bochicchio AM; Aieta M; Fazio N; Spada F; Amoroso V; Marini G; Soto Parra H; Novello G; Massidda B; Ionta MT; Comandè M; Venezia R; Bertolini A; Menatti E; Zanlorenzi L; Colombo A; Iop A; Bonura S; Mazza E; Viganò M; Ardizzoia A; Dell'Oro S; Lo Re G; Santeufemia D; Buonadonna A; Luisi D; Ucci G; Di Lucca G; Bonetti A; Bergamo F; Alù M; Vastola F; Marchetti P; Corsi DC; Massa E; Di Pinto G; Duro M; Oliani C; Franchini M; Inzoli A; Gebbia N; Repetto L; Rota S; Frontini L; Quadri A; De Grossi S; Cazzaniga ME; Villa F; Foa P; Ferrari D; Rabbi C; Barni S; Petrelli F; Giordano M; Luchena G; Pirovano M; Nasisi A; Catalano V; Giordan P; Zaniboni A; Leone F; Ferrario S; Beretta GD; Menichetti ET; Conte D; Mari D; Giannicola R; Pierantoni C; Luporini AG; Ragazzini MA; Tassinari D; Nicolini M; Frassineti GL; Turci D; Zumaglini F; Tamberi S; Piancastelli A; Cruciani G; Bejtja E; Minuti G; Orlandi M; Mambrini A; Ciarlo A; Cavaciocchi D; Del Monte F; Ricci S; Brunetti IM; Lencioni M; Sisani M; Sozzi P; Granetto C; Chiara S; Galetto AS; Ribecco AS; DeCensi A; Ciuffreda L; Baldini EE; Camisa R; Todeschini R; Rimassa L; Carnaghi C; Pressiani T; Rondini E; Gnoni R; Gasperoni S; Cavanna L; Palladino MA; Mattioli R; Laici G; Pucci F; Alessio MD; Bernardini I; Tomasello G; Baldino G; Rossetti R; Giaquinta S; Rijas Llimpe FL; Brandes AA; Marzola M; Competiello S; Montesarchio V; Rea A; Genua G; Licenziato M; Silvestro L; Montano M; Sarobba MG; Sanna G; Filippelli G; Dima G; Greco E; Roselli M; Natale D; Condemi G; Fumi G; Tafuto S; Masullo P; Tiberio G; de Manzoni G; Nobili S; Fiorentini G; Mazzanti R; Perrotta E; De Stefano A; Cartenì G; Otero M (2014). Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer.. ANNALS OF ONCOLOGY, vol. -, pp. ---, ISSN:0923-7534 DOI

C. Righeschi; M. Coronnello; A. Mastrantoni; B. Isacchi; M. C. Bergonzi; E. Mini; A.R. Bilia (2014). Strategy to provide a useful solution to effective delivery of dihydroartemisinin: development, characterization and in vitro studies of liposomal formulations. COLLOIDS AND SURFACES. B, BIOINTERFACES, vol. 116, pp. 121-127, ISSN:0927-7765

Gamberi T; Massai L; Magherini F; Landini I; Fiaschi T; Scaletti F; Gabbiani C; Bianchi L; Bini L; Nobili S; Perrone G; Mini E; Messori L; Modesti A (2014). Proteomic analysis of A2780/S ovarian cancer cell response to the cytotoxic organogold(III) compound Aubipy(c.). JOURNAL OF PROTEOMICS, vol. 103, pp. 103-120, ISSN:1874-3919 DOI

Messori L; Marchetti L; Massai L; Scaletti F; Guerri A; Landini I; Nobili S; Perrone G; Mini E; Leoni P; Pasquali M; Gabbiani C. (2014). Chemistry and Biology of Two Novel Gold(I) Carbene Complexes as Prospective Anticancer Agents. INORGANIC CHEMISTRY, vol. 35, pp. 2395-2403, ISSN:0020-1669 DOI

Taïeb J; Tabernero J; Mini E; Subtil F; Folprecht G; Van Laethem JL; Thaler J; Bridgewater JA; Sanches E; Petersen L; Collette L; Van Cutsem E; Le Malicot K; Rougier P; Salazar R; Bedenne L; Emile JF; Laurent-Puig P; Lepage C. (2013). Subgroup analyses results of the PETACC8 phase III trial comparing adjuvant FOLFOX4 with or without cetuximab (CTX) in resected stage III colon cancer (CC). JOURNAL OF CLINICAL ONCOLOGY, pp. 1-1, ISSN:0732-183X

Guidi F; Modesti A; Landini I; Nobili S; Mini E; Bini L; Puglia M; Casini A; Dyson PJ; Gabbiani C; Messori L (2013). The molecular mechanisms of antimetastatic ruthenium compounds explored through DIGE proteomics. JOURNAL OF INORGANIC BIOCHEMISTRY, vol. 118, pp. 94-99, ISSN:0162-0134 DOI

F. Orlandi; M. Coronnello; C. Bellucci; S. Dei; L. Guandalini; D. Manetti; C. Martelli; M. N. Romanelli; S. Scapecchi; M. Salerno; H. Menif; I. Bello; E. Mini; E. Teodori (2013). New structure–activity relationship studies in a series of N,N-bis(cyclohexanol)amine aryl esters as potent reversers of P-glycoprotein-mediated multidrug resistance (MDR). BIOORGANIC & MEDICINAL CHEMISTRY, vol. 21, pp. 456-465, ISSN:0968-0896 DOI Accesso ONLINE all'editore

Serratrice M; Cinellu MA; Maiore L; Pilo M; Zucca A; Gabbiani C; Guerri A; Landini I; Nobili S; Mini E; Messori L. (2012). Synthesis, Structural Characterization, Solution Behavior, and in Vitro Antiproliferative Properties of a Series of Gold Complexes with 2-(2'-Pyridyl)benzimidazole as Ligand: Comparisons of Gold(III) versus Gold(I) and Mononuclear versus Binuclear Derivatives. INORGANIC CHEMISTRY, vol. 51, pp. 3161-3171, ISSN:0020-1669 DOI

Salazar R; Mini E; Folprecht G; Subtil F; van Laethem J; Thaler J; Bridgewater JA; Van Cutsem E; Lepage C; Taieb J (2012). Adjuvant FOLFOX4 plus or minus cetuximab (cmab) in patients (pts) with kras mutant (mkras) resected stage III colon cancer (cc). Results from the PETACC8 Intergroup Trial. ANNALS OF ONCOLOGY, vol. 23 (Suppl 9), pp. 178-179, ISSN:0923-7534

Taieb J; Tabernero J; Mini E; Subtil f; Folprecht G; van Laethem JL; Thaler J; Bridgewater JA; van Cutsem E; Rougier P; Collette L; Praet M; Schneider M; Bouché O; Lepage C; Girault C; Emile JF; Laurent-Puig P. (2012). Adjuvant FOLFOX4 with or without cetuximab (CTX) in patients (pts) with resected stage III colon cancer (CC): DFS and OS results and subgroup analyses of the PETACC8 Intergroup Phase III Trial.. ANNALS OF ONCOLOGY, vol. 23 (suppl 4), pp. 9-9, ISSN:0923-7534

Nobili S; Landini I; Mazzei T; Mini E (2012). Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression. MEDICINAL RESEARCH REVIEWS, vol. 32, pp. 1220-1262, ISSN:0198-6325 DOI

Bajetta E; Floriani I; Bartolomeo M; Labianca R; Falcone A; Di Costanzo F; Comella G; Amadori D; Martoni A; Tortora G; Nitti D; Daniele B; Mini E; Rulli E; Cropalato di Tullio M; Santoro A; Casaretti R; Boni C; Pinotti G.; Bidoli P; Rosati G; Ravaioli A; Cantore M (2012). ITACA-S (Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach) Trial: comparison of a sequential treatment with irinotecan (cpt-11) + 5-fluorouracil (5-FU)/folinic acid (LV) followed by docetaxel and cisplatin versus a 5-FU/LV regimen as postoperative treatment for radically resected gastric cancer. TUMORI, vol. 3, pp. 1-1, ISSN:0300-8916

F. Guidi; M. Puglia; C. Gabbiani; I. Landini; T. Gamberi; D. Fregona; M.A. Cinellu; S. Nobili; E. Mini; L. Bini; P.A. Modesti; A. Modesti; L. Messori (2012). 2D-DIGE analysis of ovarian cancer cell responses to cytotoxic gold compounds. MOLECULAR BIOSYSTEMS, vol. 8, pp. 985-993, ISSN:1742-206X DOI

F.Guidi; I.Landini;M. Puglia;F.Magherini;C.Gabbiani;M.A.Cinellu;S.Nobili;T.Fiaschi;L.Bini;E.Mini;L.Messori;A.Modesti (2012). Proteomic Analysis of Ovarian Cancer Cell Responses to Cytotoxic Gold Compounds. METALLOMICS, vol. 4, pp. 307-314, ISSN:1756-5901 DOI

Taieb J; Tabernero J; Mini E; Subtil F; Folprecht G; Van Laethem JL; Thaler J; Bridgewater J; Sanches E; Nørgård Petersen L; Rougier P; Collette L; Praet M; Girault C; Schneider M; Squifflet P; Laurent-Puig P; Van Cutsem E; Bedenne L; Lepage C. (2012). Adjuvant FOLFOX4 +/- cetuximab in kras wildtype patients with resected stage III colon cancer results from the PETACC8 Intergroup Trial. ANNALS OF ONCOLOGY, vol. 23 Suppl 4, pp. 17-17, ISSN:0923-7534

Maiore L; Cinellu MA; Nobili S; Landini I; Mini E; Gabbiani C; Messori L (2012). Gold(III) complexes with 2-substituted pyridines as experimental anticancer agents: Solution behavior, reactions with model proteins, antiproliferative properties. JOURNAL OF INORGANIC BIOCHEMISTRY, vol. 108, pp. 123-127, ISSN:0162-0134 DOI

Crea F; Nobili S; Paolicchi E; Perrone G; Napoli C; Landini I; Danesi R; Mini E (2011). Epigenetics and chemoresistance in colorectal cancer: An opportunity for treatment tailoring and novel therapeutic strategies. DRUG RESISTANCE UPDATES, vol. 14, pp. 280-296, ISSN:1368-7646 DOI

Codacci-Pisanelli G; Frati L; Mini E (2011). Three cheers for targeted therapy in non-small cell lung cancer... When we hit the target!. JOURNAL OF CHEMOTHERAPY, vol. 23, pp. 245-246, ISSN:1973-9478

M. Vignoli; S. Nobili; C. Napoli; A.L. Putignano; M. Morganti; L. Papi; R. Valanzano; F. Cianchi; F. Tonelli; T. Mazzei; E. Mini; M. Genuardi. (2011). Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil. PHARMACOLOGICAL RESEARCH, vol. 64, pp. 242-248, ISSN:1043-6618 DOI

Nobili S; Napoli C; Landini I; Morganti M; Cianchi F; Valanzano R; Tonelli F; Cortesini C; Mazzei T; Mini E (2011). Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer. INTERNATIONAL JOURNAL OF CANCER, vol. 128, pp. 1935-1945, ISSN:0020-7136 DOI

S. Nobili; L. Bruno; I. Landini; C. Napoli; P. Bechi; F. Tonelli; CA. Rubio; E. Mini; G. Nesi (2011). Genomic and genetic alterations influence the progression of gastric cancer. WORLD JOURNAL OF GASTROENTEROLOGY, vol. 17(3), pp. 290-299, ISSN:1007-9327 DOI

Mügge C; Rothenburger C; Beyer A; Görls H; Gabbiani C; Casini A; Michelucci E; Landini I; Nobili S; Mini E; Messori L; Weigand W. (2011). Structure, solution chemistry, antiproliferative actions and protein binding properties of non-conventional platinum(II) compounds with sulfur and phosphorus donors.. DALTON TRANSACTIONS, vol. 40, pp. 2006-2016, ISSN:1477-9234 DOI

Maiore L; Cinellu MA; Michelucci E; Moneti G; Nobili S; Landini I; Mini E; Guerri A; Gabbiani C; Messori L. (2011). Structural and solution chemistry, protein binding and antiproliferative profiles of gold(I)/(III) complexes bearing the saccharinato ligand.. JOURNAL OF INORGANIC BIOCHEMISTRY, vol. 105, pp. 348-355, ISSN:0162-0134 DOI

Napoli C; Nobili S; Landini I; Perrone G; Valenti A; Brugia M; Puccini B; Antognoli G; Doria M; Martelli M; Finolezzi E; Rigacci L; Di Lollo S; Bosi A; Mini E (2011). Pharmacogenomic Markers of Clinical Efficacy in a Dose-Dense Therapy Regimen (R-CHOP14) in Diffuse Large B Cell Lymphoma. BLOOD, vol. 118, pp. 2478-2478, ISSN:0006-4971

Correale, P.; Rotundo, M.S.; Botta, C.; Guglielmo, A.; Licchetta, A.; Conca, R.; Tassone, P.; Ridolfi, R.; Mini, E.; Tagliaferri, P. (2011). 6106 POSTER Immune-boost Treatment With Gemcitabine, Oxaliplatin, Levofolinate, 5-flurouracil, Granulocyte/macrophage Colony-stimulating-factor (GM-CSF) and Aldesleukine Enhances Progression-free and Overall-survival Over FOLFOX Chemotherapy in Metastatic Colorectal Cancer Patients – Early Results From the GOLFIG-2 Phase III Trial. EUROPEAN JOURNAL OF CANCER, vol. 47, pp. S424-S424, ISSN:0959-8049 DOI

G. Tonini; M. Baccini; D. Cavalieri; E. Mini; P. Dolara; A. Biggeri (2010). Penalized survival analysis in genome expression experiments. BIOMEDICAL STATISTICS AND CLINICAL EPIDEMIOLOGY, vol. 1, pp. 35-46, ISSN:1972-5809

Napoli C; Nobili S; Landini I; Perrone G; Puccini B; Antognoli G; Doria M; Martelli M; Finolezzi E; Rigacci L; Di Lollo S; Bosi A; Mini E (2010). Pharmacogenomic markers of clinical efficacy in a dose-dense therapy regimen (R-CHOP14) in diffuse large B cell lymphoma: preliminary results. HAEMATOLOGICA, vol. 95 (Suppl 3), pp. S95-S95, ISSN:0390-6078

Martelli, Cecilia; Coronnello, MARCELLA MARIA; Dei, Silvia; Manetti, Dina; Orlandi, Francesca; Scapecchi, Serena; Romanelli, MARIA NOVELLA; Salerno, M.; Mini, Enrico; Teodori, Elisabetta (2010). Structure-activity relationships studies in a series of N,N-bis(alkanol)amine aryl esters as P-glycoprotein (Pgp) dependent multidrug resistance (MDR) inhibitors. JOURNAL OF MEDICINAL CHEMISTRY, vol. 53, pp. 1755-1762, ISSN:0022-2623 DOI Accesso ONLINE all'editore

Mini E.; Nobili S.; Novelli A.; Mazzei T (2010). Chemioterapici Antimicrobici - Glicopeptidi. In: F. Rossi, C. Riccardi, V. Cuomo. Farmacologia - Principi di base e applicazioni terapeutiche, pp. 672-679, Torino: Edizioni Minerva Medica, ISBN:9788877116994.

Novelli A; Fallani S; Mini E; Mazzei T. (2010). Chemioterapici Antimicrobici – Aminoglucosidi.. In: F. Rossi, C. Riccardi, V. Cuomo. Farmacologia - Principi di base e applicazioni terapeutiche, pp. 649-660, Torino: Edizioni Minerva Medica, ISBN:9788877116994.

Mini E.; Nobili S.; Mazzei T. (2010). Farmaci Antineoplastici - Farmaci antiormonali. In: F. Rossi, C. Riccardi, V. Cuomo. Farmacologia - Principi di base e applicazioni terapeutiche, pp. 788-795, Torino: Edizioni Minerva Medica, ISBN:9788877116994.

Mini E.; Nobili S.; Mazzei T. (2010). Farmaci Antineoplastici - Farmaci inibitori della trasduzione del segnale. In: F. Rossi, C. Riccardi, V. Cuomo. Farmacologia - Principi di base e applicazioni terapeutiche, pp. 797-806, Torino: Edizioni Minerva Medica, ISBN:9788877116994.

Mazzei T; Novelli A; Mini E; Periti P. (2010). Chemioterapici Antimicrobici – Penicilline, cefalosporine ed altre -lattamine. In: F. Rossi, C. Riccardi, V. Cuomo. Farmacologia - Principi di base e applicazioni terapeutiche, pp. 626-639, Torino: Edizioni Minerva Medica, ISBN:9788877116994.

Mini E.; Nobili S.; Mazzei T. (2010). Farmaci Antineoplastici - Antimetaboliti. In: F. Rossi, C. Riccardi, V. Cuomo. Farmacologia - Principi di base e applicazioni terapeutiche, pp. 767-776, Torino: Edizioni Minerva Medica, ISBN:9788877116994.

Tonelli F; Leo F; Nobili S; Mini E; Batignani G (2010). Prognostic factors in primary and iterative surgery of colorectal liver metastases. JOURNAL OF CHEMOTHERAPY, vol. 22, pp. 358-363, ISSN:1973-9478

Novelli A; Cassetta MI; Arrigucci S; Mini E; Mazzei T (2010). Chemioterapici Antimicrobici – Fluorochinoloni. In: F. Rossi, C. Riccardi, V. Cuomo. Farmacologia - Principi di base e applicazioni terapeutiche, pp. 660-672, Torino: Edizioni Minerva Medica, ISBN:9788877116994.

Caffo O; Fallani S; Marangon E; Nobili S; Cassetta MI; Murgia V; Sala F; Novelli A; Mini E; Zucchetti M; Galligioni E (2010). Pharmacokinetic study of gemcitabine, given as prolonged infusion at fixed dose rate, in combination with cisplatin in patients with advanced non-small-cell lung cancer.. CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol. 65, pp. 1197-1202, ISSN:0344-5704 DOI

G. Toffoli; E. Cecchin; G. Gasparini; M. D'Andrea; G. Azzarello; U. Basso; E. Mini; S. Pessa; E. De Mattia; G. Lo Re; A. Buonadonna; S. Nobili; P. De Paoli; F. Innocenti (2010). Genotype-Driven Phase I Study of Irinotecan Administered in Combination With Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer. JOURNAL OF CLINICAL ONCOLOGY, vol. 28, pp. 866-871, ISSN:0732-183X DOI

Magherini F; Modesti A; Bini L; Puglia M; Landini I; Nobili S; Mini E; Cinellu MA; Gabbiani C; Messori L. (2010). Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study.. JBIC, vol. 15, pp. 573-582, ISSN:0949-8257 DOI

Nobili S; Mini E; Landini I; Gabbiani C; Casini A; Messori L. (2010). Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies.. MEDICINAL RESEARCH REVIEWS, vol. 30, pp. 550-580, ISSN:0198-6325 DOI

NOBILI S.; LIPPI D.; WITORT E.; DONNINI M.; BAUSI L.; MINI E.; CAPACCIOLI S (2009). Natura compounds for cancer treatment and prevention. PHARMACOLOGICAL RESEARCH, vol. 6, pp. 365-378, ISSN:1043-6618

Vignoli M; Nobili S; Napoli C; Putignano AL; Morganti M; Papi L; Valanzano R; Cianchi F; Tonelli F; Mazzei T; Mini E; Genuardi M (2009). Influence of TYMS expression and genotype on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil. EUROPEAN JOURNAL OF HUMAN GENETICS, vol. 17 (suppl 2), pp. 187-187, ISSN:1018-4813

Vignoli M; Nobili S; Napoli C; Putignano AL; Morganti M; Papi L; Valanzano R ; Cianchi F; Tonelli F; Mazzei T; Genuardi M; Mini E. (2009). Influence of TYMS gene expression and genotype on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil. ANNALS OF ONCOLOGY, vol. 20 (Suppl 8), pp. viii124-viii125, ISSN:0923-7534

Mini, Enrico*; Nobili, Stefania (2009). Pharmacogenetics: Implementing personalized medicine. CLINICAL CASES IN MINERAL AND BONE METABOLISM, vol. 6, pp. 17-24, ISSN:1724-8914 Accesso ONLINE all'editore

Mini E; Nobili S; Napoli C; Landini I; Morganti M; Cianchi F; Valanzano R; Tonelli F; Mazzei T. (2009). Identification of pharmacogenomic markers of 5-fluorouracil-based chemotherapy in colorectal cancer. ANNALS OF ONCOLOGY, vol. 20 (Suppl 8), pp. viii122-viii123, ISSN:0923-7534

F. Scaglione; E. Bertazzoni Minelli; A. De Sarro; S. Esposito; D. Legnani; T. Mazzei; E. Mini; D. Passali; F. Pea ; S. Stefani; I. Viano; A. Novelli (2009). The Charta of Milan: basic criteria for the appropriate and accurate use of antibiotics:recommendations of the Italian Society of Chemotherapy. JOURNAL OF CHEMOTHERAPY, vol. 21, pp. 475-481, ISSN:1120-009X DOI

Martelli, Cecilia; Alderighi, Daniela; Coronnello, MARCELLA MARIA; Dei, Silvia; Frosini, Maria; Bozec, Benedicte Le; Manetti, Dina; Neri, Annalisa; Romanelli, MARIA NOVELLA; Salerno, Milena; Scapecchi, Serena; Mini, Enrico; Sgaragli, Giampietro; Teodori, Elisabetta (2009). N,N-bis(cyclohexanol)amine aryl esters: a new class of highly potent Pgp-dependent multidrug resistance (MDR) inhibitors. JOURNAL OF MEDICINAL CHEMISTRY, vol. 52, pp. 807-817, ISSN:0022-2623 DOI

Nobili S; Lippi D; Witort E; Donnini M; Bausi L; Mini E; Capaccioli S. (2009). Natural compounds for cancer treatment and prevention. PHARMACOLOGICAL RESEARCH, vol. 59, pp. 365-378, ISSN:1043-6618

Van Cutsem E; Labianca R; Bodoky G; Barone C; Aranda E; Nordlinger B; Topham C; Tabernero J; André T; Sobrero AF; Mini E; Greil R; Di Costanzo F; Collette L; Cisar L; Zhang X; Khayat D; Bokemeyer C; Roth AD; Cunningham D. (2009). Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. JOURNAL OF CLINICAL ONCOLOGY, vol. 27, pp. 3117-3125, ISSN:0732-183X DOI

Landini I; Napoli C; Nobili S; Morganti M; Rigacci L; Bosi A; Mini E (2008). In vitro activity of folate antagonists against methotrexate-resistant CCRF-CEM human T-leukemia sublines and relationships with folate pathway gene expression profiles. HAEMATOLOGICA, vol. 93 (Suppl 2), pp. S49-S50, ISSN:0390-6078

Nobili S; Mini E (2008). Alternative approaches to overcome multidrug resistance. In: Nicola Antonio Colabufo. Multidrug Resistance: Biological and Pharmaceutical Advances in Antitumour Treatment, pp. 101-139 Research Signpost, ISBN:9788130802589.

G. Ciciani; M. Coronnello; G. Guerrini; S.Selleri; M.Cantore; P. Failli; E. Mini; A. Costanzo (2008). Synthesis of new pyrazolo[5,1-c][1,2,4]benzotriazines, pyrazolo[5,1-c]pyrido[4,3-e][1,2,4]triazines and their open analogues as cytotoxic agents in normoxic and hypoxic conditions.. BIOORGANIC & MEDICINAL CHEMISTRY, vol. 16, pp. 9409-9419, ISSN:1464-3391 DOI

S. NOBILI; E. MINI (2008). Overcoming multidrug resistance: alternative approaches to P-glycoprotein modulators. In: -. Multidrug resistance: biological and pharmaceutical advance in the antitumour treatment, pp. 101-139, BARI: NICOLA COLABUFO, ISBN:9788130802589. Accesso ONLINE all'editore

I. Popov; A. Carrato; A. Sobrero; M. Vincent; D. Kerr; R. Labianca; A. Raffaele Bianco; M. El-Serafi; L. Bedenne; B. Paillot; E. Mini; E. Sanches; J. Welch; L. Collette; M. Praet; J. Wils (2008). Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1).. EUROPEAN JOURNAL OF CANCER, vol. 44, pp. 2204-2211, ISSN:0959-8049

A. CASINI; C. HARTINGER; C. GABBIANI ; E. MINI; P.J. DYSON; B.K. KEPPLER; L. MESSORI (2008). GOLD(III) COMPOUNDS AS ANTICANCER AGENTS: RELEVANCE OF GOLD-PROTEIN INTERACTIONS FOR THE MECHANISM OF ACTION. JOURNAL OF INORGANIC BIOCHEMISTRY, vol. 102, pp. 564-575, ISSN:0162-0134, Elsevier Science Incorporated / NY Journals:Madison Square Station, PO Box 882:New York, NY 10159:(212)633-3730, EMAIL: usinfo-f@elsevier.com, INTERNET: http://www.elsevier.com, Fax: (212)633-3680: DOI

Luceri C, Castagnini C, Bigagli E, Toti S, Landini I, Napoli C, Nobili S, Mini E, Dolara P (2008). Comparative genomic hybridization study of genetic changes associated with 5-fluorouracil resistance in HCT-8 colon cancer cell lines: correlations with the expression profiles. In: International Symposium on Cancer genotypes and Cancer phenotypes, Florence, Italy, Luglio 4-5, 2008, -, pp. 53-53.

Napoli C, Nobili S, Morganti M, Landini I, Cianchi F, Valanzano R, Tonelli F, Mazzei T, Mini E (2008). Identification of pharmacogenomic markers of 5-fluorouracil-based chemotherapy in colorectal cancer. In: International Symposium on Cancer genotypes and Cancer phenotypes, Florence, Italy, Luglio 4-5, 2008, -, pp. 62-62.

S. Nobili; D. Checcacci; F. Filippelli; S. Del Buono; V. Mazzocchi; T. Mazzei; E. Mini (2008). Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic Acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy.. JOURNAL OF CHEMOTHERAPY, vol. 20, pp. 622-631, ISSN:1120-009X

L. Bruno; G. Nesi; S. Nobili; M. Veltri; L. R. Girardi; D. Boni; C. Santomaggio; B. Neri; V. Boddi; P. Bechi; E. Mini; C. Cortesini (2008). Postoperative chemotherapy in resected gastric cancer: results of a single center experience.. JOURNAL OF CHEMOTHERAPY, vol. 20, pp. 497-502, ISSN:1120-009X Accesso ONLINE all'editore

Toffoli G, Cecchin E, D'Andrea M, Azzarello G, Buonadonna A, Mini E, Tumolo S, Pessa S, Pasetto LM (2008). A pharmacogenetics UGT1A1 dose-escalation study of irinotecan in colorectal cancer (CRC) patients (pts) treated with the FOLFIRI regimen.. In: Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology, Orlando, FL, USA, January 25–27, 2008, Amer Society of Clinical Oncology, pp. 409-409.

Landini I, Napoli C, Nobili S, Morganti M, Rigacci L, Bosi A, Mini E (2008). In vitro activity of folate antagonists against methotrexate-resistant CCRF-CEM human T-leukemia sublines and relationships with folate pathway gene expression profiles. In: International Symposium on Cancer genotypes and Cancer phenotypes, Florence, Italy, Luglio 4-5, 2008, -, pp. 61-61.

Pratesi N, Simi L, Sestini R, Nobili S, Vignoli M, Landini I, Cianchi F, Valanzano R, Genuardi M, Mini E, Orlando C (2008). The clinical role of PIK3CA mutations in colorectal cancer. In: International Symposium on Cancer genotypes and Cancer phenotypes, Florence, Italy, Luglio 4-5, 2008, -, pp. 69-69.

Vignoli M, Nobili S, Napoli C. Putignano AL, Morganti M, Papi L, Mini E, Genuardi M (2008). Thymidylate synthase and orotate phosphoribosyl-transferase gene expression and genotype as predictors for clinical outcome in colorectal cancer patients treated with 5-fluorouracil. In: International Symposium on Cancer genotypes and Cancer phenotypes, Florence, Italy, Luglio 4-5, 2008, -, pp. 104-104.

Lisa Simi; Nicola Pratesi; Marina Vignoli; Roberta Sestini; Fabio Cianchi; Rosa Valanzano; Stefania Nobili; Enrico Mini; Mario Pazzagli; Claudio Orlando (2008). High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer.. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, vol. 130, pp. 247-253, ISSN:0002-9173 DOI

Marangon E, Sala F, Caffo O, D'Incalci M, Galligioni E, Fallani S, Nobili S, Cassetta M, Mini E, Zucchetti M (2007). Administering gemcitabine as fixed-dose-rate infusion in combination with cisplatin, potentially effective target plasma concentrations are achieved in patients with advanced non-small cell lung cancer. CANCER RESEARCH, vol. 67, pp. 1560-1560, ISSN:1538-7445

Cecilia Martelli; Elisabetta Teodori; Silvia Dei; Marcella Coronnello; Enrico Mini; Giampietro Sgaragli; Daniela Alderighi; Milena Salerno (2007). Isomeric N,N-dicyclohexane-4-ol-amine aryl esters: chemical and pharmacological development of highly potent and efficacious Pgp-dependent MDR inhibitors. In: Frontiers in CNS and Oncology Medicinal Chemistry, Siena, 7-9-ottobre 2007, Italian Chemical Society and American Chemical Society, pp. 33-33.

D. Cavalieri; P. Dolara; E. Mini; C. Luceri; C. Castagnini; S. Toti; K. Maciag; C. De Filippo; S. Nobili; M. Morganti; C. Napoli; G. Tonini; M. Baccini; A. Biggeri; F. Tonelli; R. Valanzano; C. Orlando; S. Gelmini; F. Cianchi; L. Messerini; L. Luzzatto (2007). Analysis of Gene Expression Profiles Reveals Novel Correlations With the Clinical Course of Colorectal Cancer. ONCOLOGY RESEARCH, vol. 16, pp. 535-548, ISSN:0965-0407, Elsevier Science Limited:Oxford Fulfillment Center, PO Box 800, Kidlington Oxford OX5 1DX United Kingdom:011 44 1865 843000, 011 44 1865 843699, EMAIL: asianfo@elsevier.com, tcb@elsevier.co.UK, INTERNET: http://www.elsevier.com, http://www.elsevier.com/locate/shpsa/, Fax: 011 44 1865 843010:

Murgia V; Caffo O; Caldara A;; Cassetta MI; Fallani S; Marangon E; Nobili S; Novelli A; Zucchetti M; d'Incalci M; Mini E; Galligioni E (2007). Plasma and intracellular pharmacokinetic (PK) study of prolonged infusion (PI) of gemcitabine (G) in combination with bolus cisplatin (C), in advanced nonsmall cell lung cancer: Preliminary results. ANNALS OF ONCOLOGY, vol. 18 suppl 11, pp. xi30-xi30, ISSN:0923-7534 DOI

S. Nobili; I. Landini; B. Giglioni; E. Mini (2006). Pharmacological strategies for overcoming multidrug resistance.. CURRENT DRUG TARGETS, vol. 7, pp. 861-879, ISSN:1389-4501 DOI Accesso ONLINE all'editore

A. TEMPESTINI; B. CACIAGLI; M. MORGANTI; E. WITORT; S. NOBILI; L. PAPUCCI; N. SCHIAVONE; M. DONNINI; I. LANDINI; A. LAPUCCI; F. PERNA; M. LULLI; T. MAZZEI; A. SOBRERO; E. MINI; S. CAPACCIOLI (2006). MOLECULAR CHARACTERIZATION OF ESTABLISHED HUMAN COLON CARCINOMA CELL LINES (HCT-8) MADE RESISTANT TO 5-FLUOROURACIL BY DIFFERENT SELECTION SCHEDULES. ONCOLOGY RESEARCH, vol. 16, pp. 143-156, ISSN:0965-0407, Elsevier Science Limited:Oxford Fulfillment Center, PO Box 800, Kidlington Oxford OX5 1DX United Kingdom:011 44 1865 843000, 011 44 1865 843699, EMAIL: asianfo@elsevier.com, tcb@elsevier.co.UK, INTERNET: http://www.elsevier.com, http://www.elsevier.com/locate/shpsa/, Fax: 011 44 1865 843010:

Mazzei T, Mini E, Novelli A (2006). Professor Piero Periti 1921-2005. JOURNAL OF CHEMOTHERAPY, vol. 18, pp. 123-123, ISSN:1120-009X DOI

Mini E; Nobili S; Tonelli F. (2006). Terapia del carcinoma colorettale. Terapia medica adiuvante. . Enciclopedia Medica Italiana Aggiornamento III della Seconda Edizione - Tomo 1, pp. 787-789, Torino: L. Vella - USES Edizioni Scientifiche (UTET), ISBN:9788803000533.

A. Casini; M.A. Cinellu; G. Minghetti; C. Gabbiani; M. Coronnello; E. Mini; L. Messori (2006). Structural and Solution Chemistry, Antiproliferative Effects, and DNA and Protein Binding Properties of a Series of Dinuclear Gold(III) Compounds with Bipyridyl Ligands. JOURNAL OF MEDICINAL CHEMISTRY, vol. 49, pp. 5524-5531, ISSN:0022-2623

E. Mini; S. Nobili; B. Caciagli; I. Landini; T. Mazzei (2006). Cellular pharmacology of gemcitabine.. ANNALS OF ONCOLOGY, vol. 17 Suppl 5, pp. 7-12, ISSN:0923-7534 DOI Accesso ONLINE all'editore

Mini E; Nobili S; Tonelli F (2006). Terapia del carcinoma colorettale. Terapia del CCR in fase avanzata. . Enciclopedia Medica Italiana Aggiornamento III della seconda edizione Tomo 1, pp. 789-793, Torino: L. Vella - USES Edizioni Scientifiche (UTET), ISBN:9788803000533.

E. Mini; S. Nobili (2005). Febbre. In: G. Lelli. Sintomi "segnale" in oncologia clinica fisiopatologia, diagnosi e terapia, pp. 41-50, Ferrara: Monduzzi Editore, ISBN:9788832360233.

E. Mini; S. Nobili; T. Mazzei (2005). Farmaci antineoplastici - Farmaci antiormonali. In: F. Rossi, V. Cuomo, G. Riccardi. Farmacologia - Principi di base e applicazioni terapeutiche, pp. 713-720, Torino: Edizioni Minerva Medica, ISBN:9788877114976.

E. Mini; S. Nobili; T. Mazzei (2005). Farmaci antineoplastici - Antimetaboliti. In: F. Rossi, C. Riccardi, V. Cuomo. Farmacologia - Principi di base e applicazioni tecniche, pp. 691-704, Torino: Edizioni Minerva Medica, ISBN:9788877114976.

E. Mini; S. Nobili; T. Mazzei (2005). Farmaci antineoplastici - Farmaci inibitori della trasduzione del segnale. In: F. Rossi, V. Cuomo, C. Riccardi. Farmacologia - Principi di base e applicazioni terapeutiche, pp. 722-726, Torino: Edizioni Minerva Medica, ISBN:9788877114976.

M. CORONNELLO; G. CICIANI; E. MINI; G. GUERRINI; B. CACIAGLI; S. SELLERI; A. COSTANZO; T. MAZZEI (2005). Cytotoxic activity of 3-nitropyrazolo[5,1-c][1,2,4]benzotriazine derivatives: a new series of anti-proliferative agents.. ANTI-CANCER DRUGS, vol. 16, pp. 645-651, ISSN:0959-4973 DOI

R. Ottanà; S. Carotti; R. Maccari; I. Landini; G. Chiricosta; B. Caciagli; MG Vigorita; E. Mini (2005). In vitro antiproliferative activity against human colon cancer cell lines of representative 4-thiazolidinones. Part I.. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 15, pp. 3930-3933, ISSN:0960-894X DOI Accesso ONLINE all'editore

E.Mini; S.Nobili; A.Novelli; T.Mazzei (2005). Glicopeptidi. In: F.Rossi, V.Cuomo, C.Riccardi. Farmacologia: principi di base e applicazioni terapeutiche, pp. 611-618, Torino.: Edizioni Minerva Medica., ISBN:9788877114976.

A.Novelli; M.I.Cassetta; E.Mini; T.Mazzei (2005). Fluorochinoloni.. In: F.Rossi, V.Cuomo, C.Riccardi.. Farmacologia: principi di base e applicazioni terapeutiche, pp. 600-610, torino: Edizioni Minerva Medica, ISBN:9788877114976.

T.Mazzei; A.Novelli; E.Mini; P.Periti (2005). Penicilline, cefalosporine e altre beta-lattamine.. In: F.Rossi, V.Cuomo, C.Riccardi. Farmacologia: principi di base e applicazioni terapeutiche, pp. 563-578, Torino.: Edizioni Minerva Medica., ISBN:9788877114976.

A.Novelli; S.Fallani; E.Mini; T.Mazzei (2005). Aminoglucosidi. In: F.Rossi, V.Cuomo, C.Riccardi. Farmacologia: principi di base e applicazioni terapeutiche., pp. 589-599, torino: Edizioni Minerva Medica., ISBN:9788877114976.

CORONNELLO M.; MINI E.; CACIAGLI B.; CINELLU; M.A.; BINDOLI A.; GABBIANI C.; L. MESSORI (2005). MECHANISMS OF CYTOTOXICITY OF SELECTED ORGANOGOLD(III) COMPOUNDS. JOURNAL OF MEDICINAL CHEMISTRY, vol. 48, pp. 6761-6765, ISSN:0022-2623, American Chemical Society:1155 Sixteenth Street Northwest:Washington, DC 20036:(800)227-5558, EMAIL: service@acs.org, INTERNET: http://www.pubs.acs.org, Fax: (614)447-3671: DOI

U. Pradal; A. Delmarco; M. Morganti; M. Cipolli; E. Mini; G. Cazzola (2005). Long-term azithromycin in cystic fibrosis: another possible mechanism of action?. JOURNAL OF CHEMOTHERAPY, vol. 17, pp. 393-400, ISSN:1120-009X DOI Accesso ONLINE all'editore

Morganti M; Ciantelli M; Giglioni B; Putignano AL; Nobili S; Papi L; Landini I; Napoli C; Valanzano R; Cianchi F; Boddi V; Tonelli F; Cortesini C; Mazzei T; Genuardi M; Mini E (2005). Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers. EUROPEAN JOURNAL OF CANCER, vol. 41, pp. 2176-2183, ISSN:0959-8049 DOI

Pinto C, Di Fabio F, Gentile AL, Mini E, Giaquinta S, Rojas Llimpe FL, Mutri V, Piana E, Mazzei T, Martoni A (2005). ADVANCED COLORECTAL CANCER (ACRC) IN ELDERLY PATIENTS: EVALUATION OF THREE DIFFERENT OXALIPLATIN-BASED CHEMOTHERAPY REGIMENS - Session D: Colo-rectal Cancer. ANNALS OF ONCOLOGY, vol. 16, pp. vii47-vii47, ISSN:0923-7534 DOI

Nobili S; Del Buono S; Mazzocchi V; Filippelli F; Checcacci D; Giglioni B; Mazzei T; Mini E (2004). Bimonthly chemotherapy (CHT) with oxaliplatin (OHP), irinotecan (CPT11), infusional 5-fluorouracil/folinic acid (FU/FA) in patients with metastatic colorectal cancer pretreated with CPT11- or OHP-based CHT. ANNALS OF ONCOLOGY, vol. 15 suppl 2, pp. 65-65, ISSN:0923-7534

Nobili S; Del Buono S; Mazzocchi V; Filippelli F; Giglioni B; Mazzei T; Mini E (2004). Biweekly (BW) chemotherapy (CHT) with oxaliplatin (OHP), irinotecan (CPT11), infusional 5-fluorouracil/folinic acid (FU/FA) in patients (PTS) with metastatic colorectal cancer (MCRC) pretreated with CPT11- or OHP-based CHT.. JOURNAL OF CHEMOTHERAPY, vol. 16 (suppl 1), pp. 213-213, ISSN:1120-009X

Morganti M; Ciantelli M; Giglioni B; Putignano AL; Nobili S; Papi L; Landini I; Napoli C; Valanzano R; Cianchi F; Boddi V; Tonelli F; Cortesini C; Mazzei T; Genuardi M; Mini E. (2004). Correlation between thymidylate synthase (TS) mRNA expression and TS gene promoter polymorphisms in primary colorectal cancer patients. ANNALS OF ONCOLOGY, vol. 15, pp. 61-61, ISSN:0923-7534

Morganti M, Ciantelli M, Giglioni B, Putignano AL, Nobili S, Papi L, Landini I, Napoli C, Valanzano R, Cianchi F, Boddi V, Tonelli F, Cortesini C, Mazzei T, Genuardi M, Mini E (2004). Correlation between thymidylate synthase (TS) mRNA expression and TS gene promoter polymorphysms in primary colorectal cancer patients.. CANCER RESEARCH, vol. 67, pp. 866-867, ISSN:1538-7445

A. Tempestini; E. Witort; L. Papucci; N. Schiavone; M. Donnini; A. Lapucci; F. Perna; M. Morganti; B. Caciagli; I. Landini; A. Sobrero; E. Mini; S. Capaccioli (2004). Molecular characterization of established human colorectal carcinoma cell lines (HCT-8) made resistant to 5-fluorouracil (5-FU) by different selective schedules. JOURNAL OF CHEMOTHERAPY, vol. 16 (Suppl 1), pp. 177-177, ISSN:1120-009X DOI

L. Bruno, D. Boni, G. Nesi, C. Santomaggio, V. Boddi, P. Bechi, E. Mini, C. Cortesini (2004). Chemotherapy after surgery for gastric cancer: a case-control study. JOURNAL OF CHEMOTHERAPY, vol. 16, pp. 216-216, ISSN:1973-9478 DOI

Di Fabio F; Mini E; Gentile AL; Nobili S; Angelelli B; Giaquinta S; Rojas Llimpe FL; Pinto C;Mazzei T; Martoni A (2004). Neurotoxicity of oxaliplatin (OXA) in advanced colorectal cancer (ACRC) chemotherapy: evaluation of three consecutive prospective studies. ANNALS OF ONCOLOGY, vol. 15 suppl 2, pp. 58-58, ISSN:0923-7534

Saccardi R; Tyndall A; Coghlan G; Denton C; Edan G; Emdin M; Farge D; Fassas A; Finke J; Furst D; Lassus M; Mancardi G; Miniati I; Mini E; Pagliai F; Passweg J; Pignone A; van Laar JM; Bocelli-Tyndall C; Matucci-Cerinic M. (2004). Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis. BONE MARROW TRANSPLANTATION, vol. 34, pp. 877-881, ISSN:0268-3369 DOI

L. MESSORI; MARCON G.; CINELLU M.A.; CORONNELLO M.; MINI E.; GABBIANI C.; ORIOLI P. (2004). Solution Chemistry and Cytotoxic Properties of Novel Organogold(III) Compounds. BIOORGANIC & MEDICINAL CHEMISTRY, vol. 12, pp. 6039-6043, ISSN:0968-0896, Elsevier Science Limited:Oxford Fulfillment Center, PO Box 800, Kidlington Oxford OX5 1DX United Kingdom:011 44 1865 843000, 011 44 1865 843699, EMAIL: asianfo@elsevier.com, tcb@elsevier.co.UK, INTERNET: http://www.elsevier.com, http://www.elsevier.com/locate/shpsa/, Fax: 011 44 1865 843010: DOI

R.Mazzanti;AL.Giallombardo;E.Mini;S.Nobili;B.Neri;U.Arena; P.Pantaleo;V.Fabbroni;M.Ghilardi;R.Gattai;L.Bandettini (2004). Treatment of locally advanced hepatocellular carcinoma by hepatic intra-artery chemotherapy: a pilot study.. DIGESTIVE AND LIVER DISEASE, vol. 36, pp. 278-285, ISSN:1590-8658 DOI

Novelli A; Mini E; Mazzei T. (2004). Pharmacological interactions between antibiotics and other drugs in the treatment of lower respiratory tract infections (chapter 15). In: M. Cazzola, F. Blasi and S. Ewig. Antibiotics and the lung, pp. 229-254 M. Cazzola, F. Blasi and S. Ewig, ISBN:9781904097723.

Morganti, M; Ciantelli, M; Giglioni, B; Putignano, Al; Nobili, S; Papi, L; Landini, I; Napoli, C; Valanzano, R; Cianchi, F; Boddi, V; Tonelli, F; Cortesini, C; Mazzei, T; Genuardi, M; Mini, E. (2004). Correlation between thymidylate synthase (TS) mRNA expression and TS gene promoter polymorphisms in primary colorectal cancer patients. JOURNAL OF CHEMOTHERAPY, vol. 16 (Suppl. 1), pp. 205-205, ISSN:1973-9478

Mini E.; Nobili S; Del Buono S; Mazzocchi V; Filippelli F; Giglioni B; Mazzei T (2004). Biweekly (BW) chemotherapy (CHT) with oxaliplatin (OHP), irinotecan (CPT11), infusional 5-fluorouracil/folinic acid (FU/FA) in patients (pts) with metastatic colorectal cancer (MCRC) pretreated with CPT11- or OHP-based CHT. JOURNAL OF CLINICAL ONCOLOGY, vol. 22, pp. 3065-3065, ISSN:0732-183X

Gentile AL; Pinto C; Mini E; Nobili S; Di Fabio F; Mazzei T; Martoni A (2003). Neurotoxicity in advanced colorectal cancer (ACRC) patients treated with three different oxaliplatin (OXA) regimens. ANNALS OF ONCOLOGY, vol. 14, pp. 49-49, ISSN:0923-7534

Landini I; Carotti S; Caciagli B; Morganti M; Napoli C; Nobili S; Giglioni B; Boddi V; Mazzei T; Mini E (2003). Sequence-dependent interactions between oxaliplatin and 5-fluorouracil in human colon carcinoma cell lines. JOURNAL OF CHEMOTHERAPY, vol. 15 (Suppl 1), pp. 36-36, ISSN:1973-9478

Nobili S; Mazzocchi V; Del Buono S.; Scicolone S; Giglioni B; Mazzei T; Mini E (2003). Biweekly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy. JOURNAL OF CHEMOTHERAPY, vol. 15 (Suppl 1), pp. 69-69, ISSN:1973-9478

Mini E; Nobili S; Mazzocchi V; Del Buono S; Scicolone S; Giglioni B; Mazzei T (2003). Biweekly (BW) chemotherapy (CHT) with oxaliplatin (OHP), irinotecan (CPT-11), infusional 5-fluorouracil/folinic acis (FU/FA) in patients (PTS) with metastatic colorectal cancer (MCRC) pretreated with CPT-11- or OHP-based CHT. JOURNAL OF CLINICAL ONCOLOGY, vol. 22, pp. 1503-1503, ISSN:0732-183X

Morganti M; Ciantelli M; Giglioni B; Nobili S.; Papi L.; Landini I.; Napoli C.; Valanzano R.; Cianchi F; Boddi V.; Tonelli F; Cortesini C; Mazzei T; Genuardi M; Mini E (2003). Thymidylate Synthase (TS) mRNA expression and TS gene promoter polymorphism in primary colorectal cancer (CRC) patients (PTS) receiving post-operative fluorouracil (5-FU)-based chemotherapy (CT). JOURNAL OF TUMOR MARKER ONCOLOGY, vol. 18, pp. 171-171, ISSN:0886-3849

A. MARTONI; E. MINI; C. PINTO; AL. GENTILE; S. NOBILI; P. DENTICO; A. MARINO; S. SCICOLONE; B. ANGELELLI; T. MAZZEI (2003). OXALIPLATIN PLUS RALTITREXED IN THE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER: A PHASE II STUDY. ANTICANCER RESEARCH, vol. 23, pp. 687-691, ISSN:0250-7005, International Institute of Anticancer Research:John G Delinassios, 1st Km Kapandritiou-Kalamou Road, Kapandriti Attiki 19014 Greece:011 30 2 2950 53389, 011 30 2950 52945, EMAIL: journals@iiar-anticancer.org, INTERNET: http://www.iiar-anticancer.org, Fax: 011 30 2 2950 53389, 011 30 2 2950 52945:

G. TOFFOLI; A. RUSSO; F. INNOCENTI; G. CORONA; S. TUMOLO; F. SARTOR; E. MINI; M. BOIOCCHI (2003). EFFECT OF METHYLENETETRAHYDROFOLATE REDUCTASE 677-->T POLYMORPHISM ON TOXICITY AND HOMOCYSTEINE PLASMA LEVEL AFTER CHRONIC METHOTREXATE TREATMENT OF OVARIAN CANCER PATIENTS. INTERNATIONAL JOURNAL OF CANCER, vol. 103, pp. 294-299, ISSN:0020-7136

Mini E.; Morganti M.; Napoli C.; Valanzano R.; Cianchi F.; Messerini A; Nobili S; Boddi V; Tonelli F; Cortesini C; Toffoli G; Mazzei T (2002). The role of thymidylate synthase (TS) expression in prognosis and outcome of 5-fluorouracil (5-FU)-based chemotherapy in patients (pts) with colorectal cancer (CC). JOURNAL OF CLINICAL ONCOLOGY, vol. 21, pp. 2266-2266, ISSN:0732-183X

Mazzei T.; Carotti S.; Landini I.; Caciagli B.; Nobili S.; Mini E (2002). Sequence-dependent interactions between oxaliplatin (OHP) and 5-fluorouracil (5-FU) in human colon carcinoma cell lines. JOURNAL OF CLINICAL ONCOLOGY, vol. 21, pp. 2183-2183, ISSN:0732-183X

F. Prignano; M. Coronnello; N. Pimpinelli; P. Cappugi; E. Mini; B. Giannotti (2002). Immunophenotypical markers, ultrastructure and chemosensitivity profile of metastatic melanoma cells.. CANCER LETTERS, vol. 186, pp. 183-192, ISSN:0304-3835

P. Periti; T. Mazzei; E Mini (2002). Clinical pharmacokinetics of depot leuprorelin.. CLINICAL PHARMACOKINETICS, vol. 41, pp. 485-504, ISSN:0312-5963 Accesso ONLINE all'editore

C. De Filippo; C. Luceri; G. Caderni; M. Pacini; L. Messerini; A. Biggeri; E. Mini; F. Tonelli; F. Cianchi; P. Dolara (2002). Mutations of the APC gene in human sporadic colorectal cancers. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol. 37, pp. 1048-1053, ISSN:0036-5521

Martoni A.; Mini E.; Pinto C.; Gentile AL; Nobili S; Marino A; Dentico P; Angelelli B; Scicolone S; Piana E; Mazzei T (2002). Phase II study of oxaliplatin (OHP) and raltitrexed (RTX) in chemonaive and pretreated advanced colorectal cancer (ACRC) patients. JOURNAL OF CLINICAL ONCOLOGY, vol. 21, pp. 689-689, ISSN:0732-183X

MARCON G.; CAROTTI S.; CORONNELLO M.; L. MESSORI; MINI E.; ORIOLI P.; MAZZEI T.; CINELLU M.A.; MINGHETTI G. (2002). Gold(III) Complexes with Bipyridyl Ligands: Solution Chemistry, Cytotoxicity and DNA Binding Properties. JOURNAL OF MEDICINAL CHEMISTRY, vol. 45, pp. 1672-1677, ISSN:0022-2623, American Chemical Society:1155 Sixteenth Street Northwest:Washington, DC 20036:(800)227-5558, EMAIL: service@acs.org, INTERNET: http://www.pubs.acs.org, Fax: (614)447-3671:

A. Di Paolo; R. Danesi; F. Vannozzi; A. Falcone; E. Mini; L. Cionini; T. Ibrahim; D. Amadori; M. Del Tacca (2002). Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer.. CLINICAL PHARMACOLOGY & THERAPEUTICS, vol. 72, pp. 627-637, ISSN:1532-6535

Luceri C.; De Filippo C.; Guglielmi F.; Caderni G.; Messerini L.; Biggeri A.; Mini E.; Tonelli F.; Cianchi F.; Dolara P. (2002). Microsatellite instability in a population of sporadic colorectal cancers: correlation between genetic and pathological profiles.. DIGESTIVE AND LIVER DISEASE, vol. 34, pp. 553-559, ISSN:1590-8658

Mini E, Caciagli B, Carotti S, Landini I, Morganti M, Nobili S, Coronnello M, Toffoli G, Jansen G, Peters GJ, Priest DG, Mazzei T (2002). Mechanisms of methotrexate (MTX) resistance in human colon carcinoma cells DLD-1. In: 93rd Annual Meeting American Association for Cancer Research (AACR), San Francisco, CA, USA, April 6-10, 2002., Waverly Press, pp. 3864-3864.

De Filippo, C; Luceri, C; Caderni, G; Pacini, M; Messerini, L; Biggeri, A; Mini, E; Tonelli, F; Cianchi, F; Dolara, P (2002). Mutations of the APC gene in human sporadic colorectal cancers. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol. 37, pp. 1048-1053, ISSN:0036-5521 DOI

B. Neri; G. Cini; L. Doni; C. Fulignati; M. Turrini; D. Pantalone; E. Mini; C. De Luca Cardillo; L.M. Fioretto; A.S. Ribecco; R. Moretti; M. Scatizzi; G. Zocchi; A. Quattrone (2002). Weekly gemcitabine plus Epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II study. BRITISH JOURNAL OF CANCER, vol. 87, pp. 497-501, ISSN:0007-0920 DOI Accesso ONLINE all'editore

De Filippo C.; Luceri C.; Caderni G.; Pacini M.; Messerini L.; Biggeri A.; Mini E.; Tonelli F.; Cianchi F.; Dolara P. (2002). Mutations of the APC gene in human sporadic colorectal cancers.. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol. 37, pp. 1048-1053, ISSN:0036-5521

Carotti S.; Landini I.; Caciagli B.; Nobili S.; Mazzei T.; Mini E (2001). Sequence-dependent interactions between oxaliplatin and 5-fluorouracil in human colon carcinoma cell lines. ANNALS OF ONCOLOGY, vol. 12 suppl 4, pp. 86-86, ISSN:0923-7534

Mini E.; Caciagli B.; Carotti S.; Landini I.; Morganti M.; Nobili S.; Mazzei T.; Toffoli G.; Jansen G.; Peters G.J.; Priest D.J (2001). Multiple mechanisms of methotrexate (MTX) resistance in human colon carcinoma cells DLD-1.. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, vol. 17, pp. S20-S20, ISSN:0924-8579

E. Mini; F. Grassi; P. Cherubino; S. Nobili; P. Periti (2001). Preliminary results of a survey of the use of antimicrobial agents as prophylaxis in orthopedic surgery.. JOURNAL OF CHEMOTHERAPY, vol. 13 Spec No 1, pp. 73-79, ISSN:1120-009X Accesso ONLINE all'editore

M. Coronnello; G. Marcon; S. Carotti; B. Caciagli; E. Mini; T. Mazzei; P. Orioli; L. Messori (2001). Cytotoxicity, DNA damage, and cell cycle perturbations induced by two representative gold(III) complexes in human leukemic cells with different cisplatin sensitivity. ONCOLOGY RESEARCH, vol. 12, pp. 361-370, ISSN:0965-0407

A. Martoni; E. Mini; C. Pinto; S. Nobili; A. L. Gentile; P. Dentico; B. Angelelli; S. Scicolone; E. Piana; T. Mazzei (2001). Oxaliplatin and protracted continuous 5-fluorouracil infusion in patients with pretreated advanced colorectal carcinoma.. ANNALS OF ONCOLOGY, vol. 12, pp. 519-524, ISSN:0923-7534 Accesso ONLINE all'editore

A. Di Paolo; R. Danesi; A. Falcone; L. Cionini; F. Vannozzi; G. Masi; G. Allegrini; E. Mini; G. Bocci; P. F. Conte; M. Del Tacca (2001). Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients.. ANNALS OF ONCOLOGY, vol. 12, pp. 1301-1306, ISSN:0923-7534

Prignano F.; Coronnello M.; Pimpinelli N.; Cappugi P.; Mini E.; Giannotti B (2001). Ultrastructural and chemosensitivity features of primary metastatic melanoma cells: preliminary results.. MELANOMA RESEARCH, vol. 11/suppl.1, pp. S202-, ISSN:0960-8931

Pinto C.; Mini E.; Gentile A.L.; Nobili S.; Marino A.; Dentico P.; Angelelli B.; Scicolone S.; Piana E.; Iovi F.; Mazzei T.; Martoni A (2001). Oxaliplatin (OHP) and raltitrexed (RTX) in advanced colorectal cancer (ACRC) patients: a phase II study. JOURNAL OF CLINICAL ONCOLOGY, vol. 20, pp. 2204-2204, ISSN:0732-183X

Giordana Marcon; Stefania carotti; Marcella Coronnello; Enrico Mini; Teresita Mazzei; Luigi Messori; Pierluigi Orioli (2001). Gold(III) complexes as potential antitumor agents: cytotoxic properties and interaction with DNA of some selected gold(III) compounds. ANTICANCER RESEARCH, vol. 21, pp. 1601-1601, ISSN:0250-7005

Mini E.; Pinto C.; Gentile A.L.; Marino A.; Angelelli B.; Piana E.; Martoni A.; Nobili S.; Dentico P.; Scicolone S.; Mazzei T (2001). Oxaliplatin (OHP) and raltitrexed (RTX) in advanced colorectal cancer (ACRC) patients (PTS): preliminary results of a phase II study. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, vol. 17, pp. S21-S21, ISSN:0924-8579

Mini E, Grassi F, Cherubino P, Periti P (2001). Preliminary results of a survey of the use of antimicrobial agents as prophylaxis in orthopedic surgery. In: Fourth Symposium on the Control of Surgical Infections, Florence, Italy,, Aprile 19-21, 2001, -, pp. 44-44.

A. Martoni; E. Mini; C. Pinto; A. Gentile; T. Mazzei (2001). [Oxaliplatin: combinations with thymidylate synthetase inhibitors: two consecutive phase II studies]. TUMORI, vol. 87, pp. A25-A26, ISSN:0300-8916

Caciagli B, Carotti S, Landini I, Morganti M, Nobili S, Coronnello M, Jansen G, Peters GJ, Toffoli G, Priest DG, Mini E (2001). Mechanisms of methotrexate (MTX) resistance in human colon carcinoma cells DLD-1. In: 22nd Meeting of EORTC-PAMM Group, Verona, Italy, Gennaio 31 – Febbraio 3, 2001, -, pp. 42-42.

Pinto C.; Mini E.; Gentile A.L.; Marino A.; Nobili S.; Dentico P.; Angelelli B.; Carpani B.; Scicolone S.; Mazzei T.; Martoni A (2001). Neurotoxicity in patients treated with oxaliplatin (OHP) combination chemotherapy for advanced colorectal cancer (ACRC) in two consecutive phase II studies. ANNALS OF ONCOLOGY, vol. 12 suppl 4, pp. 8-8, ISSN:0923-7534

Mini E.; Caciagli B.; Carotti S.; Landini I.; Morganti M.; Nobili S.; Coronnello M.; Toffoli G.; Jansen G.; Peters G.J.; Priest D.G.; Mazzei T (2001). Multiple mechanisms of methotrexate (MTX) resistance in human colon carcinoma cells DLD-1. PHARMACOLOGICAL RESEARCH, vol. 43 suppl A, pp. 133-133, ISSN:1043-6618

Peri A; Bonaccorsi L; Muratori M; Luconi M; Baldi E; Granchi S; Pesciullesi A;Mini E; Cioppi F; Forti G; Serio M; Miele L; Maggi M (2000). Uteroglobin reverts the transformed phenotype in the endometrial adenocarcinoma cell line HEC-1A by disrupting the metabolic pathways generating platelet-activating factor. INTERNATIONAL JOURNAL OF CANCER, vol. 88, pp. 525-534, ISSN:0020-7136 DOI

M. Morganti; M. Coronnello; B. Caciagli; C. Biondi; A. Quattrone; S. Capaccioli; T. Mazzei; E. Mini (2000). Modulation of dihydrofolate reductase gene expression in methotrexate-resistant human leukemia CCRF-CEM/E cells by antisense oligonucleotides.. ANTI-CANCER DRUGS, vol. 11, pp. 285-294, ISSN:0959-4973 Accesso ONLINE all'editore

Napoli C.; Morganti P.; Bruno L.; Nobili S.; Cortesini C.; Mazzei T.; Mini E (2000). Preliminary results of thymidylate synthase (TS) and folylpolyglutamate synthetase (FPGS) gene expression analysis by polymerase chain reaction (PCR) in gastric cancer patients (PTS). ANNALS OF ONCOLOGY, vol. 11, pp. 16-16, ISSN:0923-7534

Luceri, C; Guglielmi, F; De Filippo, C; Caderni, G; Mini, E; Biggeri, A; Napoli, C; Tonelli, F; Cianchi, F; Dolara, P (2000). Clinicopathologic features and FHIT gene expression in sporadic colorectal adenocarcinomas. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol. 35, pp. 637-641, ISSN:0036-5521 DOI

TOFFOLI G.; CORONA G; TOLUSSO B; SARTOR F; SORIO R; E. MINI; BOIOCCHI M (2000). RESISTANCE TO METHOTREXATE IN SKOV3 CELL LINES AFTER CHRONIC EXPOSURE TO CARBAMAZEPINE IS ASSOCIATED WITH A DECREASED EXPRESSION OF FOLATE RECEPTOR.. INTERNATIONAL JOURNAL OF CANCER, vol. 85, pp. 683-690, ISSN:0020-7136, John Wiley & Sons Incorporated:Customer Service, 111 River Street:Hoboken, NJ 07030:(800)225-5945, (201)748-6000, EMAIL: societyinfo@wiley.com, INTERNET: http://www.wiley.com, Fax: (212)748-6551:

Messori L.; Caciagli B.; Carotti S.; Coronnello M.; Marcon G.; Mazzei T.; Mini E (2000). Solution chemistry and DNA binding properties of cytotoxic gold(III) complexes.. JOURNAL OF CHEMOTHERAPY, pp. 139-139, ISSN:1120-009X

Periti, P; Mini, E; Grassi, F; Cherubino, P (2000). [Antibiotic prophylaxis of postoperative infection in orthopedics. Results of an epidemiologic survey in Italy conducted by the Journal of Chemotherapy]. JOURNAL OF CHEMOTHERAPY, vol. 12 Suppl 2, pp. 28-38, ISSN:1120-009X DOI

L. Messori; F. Abbate; G. Marcon; P. Orioli; M. Fontani; E. Mini; T. Mazzei; S. Carotti; T. O'Connell; P. Zanello (2000). Gold(III) complexes as potential antitumor agents: solution chemistry and cytotoxic properties of some selected gold(III) compounds.. JOURNAL OF MEDICINAL CHEMISTRY, vol. 43, pp. 3541-3548, ISSN:0022-2623

E. Mini; S. Nobili; P. Periti (2000). Does surgical prophylaxis with teicoplanin constitute a therapeutic advance?. JOURNAL OF CHEMOTHERAPY, vol. 12 Suppl 5, pp. 40-55, ISSN:1120-009X

S. CAROTTI; G. MARCON; M. MARUSSICH; T. MAZZEI; L. MESSORI; E. MINI; P. ORIOLI (2000). Cytotoxicity and DNA binding properties of a chloro glycylhistidinate gold(III) complex (GHAu).. CHEMICO-BIOLOGICAL INTERACTIONS, vol. 125, pp. 29-38, ISSN:0009-2797

Mini E.; Pinto C.; Angelelli B.; Dentico P.; Piana E.; Nobili S.; Gentile A.L.; Scicolone S.; Mazzei T.; Martoni A (2000). Phase II study of oxaliplatin (OHP) and protracted 5-fluorouracil (5FU) infusion in pretreated metastatic colorectal cancer (MCRC) patients. ANNALS OF ONCOLOGY, vol. 11 suppl 2, pp. 73-73, ISSN:0923-7534

I. Noci; M. Coronnello; P. Borri; E. Borrani; M. Giachi; O. Chieffi; M. Marchionni; M. Paglierani; A. M. Buccoliero; A. Cherubini; A. Arcangeli; E. Mini; G. Taddei (2000). Inhibitory effect of luteinising hormone-releasing hormone analogues on human endometrial cancer in vitro.. CANCER LETTERS, vol. 150, pp. 71-78, ISSN:0304-3835

Napoli C.; Morganti M.; Bruno L.; Nobili S.; Cortesini C.; Mazzei T.; Mini E (2000). Expression of thymidylate synthase (TS) and folylpolyglutamate synthetase (FPGS) genes by polymerase chain reaction (PCR) in gastric cancer patients (PTS): preliminary results. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, pp. 249-249, ISSN:0306-5251

Pinto C; Mini E; Petronelli A; Dentico P; Piana E; Nobili S; Gentile A; Scicolone S; Mazzei T; Martoni A (2000). Oxaliplatin (OHP) and Protracted 5-Fluorouracil (5 FU) Infusion in Pretreated Metastatic Colorectal Cancer (MCRC) Patients: A Phase II Study. JOURNAL OF CLINICAL ONCOLOGY, vol. 19, pp. 1172-1172, ISSN:0732-183X

Luceri C, De Filippo C, Caderni G, Mini E, Napoli C, Tonelli F, Cortesini C, Dolara P (1999). Molecular analysis of the FHIT gene in human sporadic colon cancers.. In: 90th Annual Meeting of the American Association of Cancer Research, Philadelphia, PA, USA,, 10-14 Aprile, 1999, AACR, pp. 273-273.

Bigdeli M, Apolone G, Torri V, Bedenne L, Bianco AR, Carrato A, Kerr D, Labianca R, Mini E, Paillot B, Pignatti F, Vincent M, Wils J (1999). Economic evaluation alongside The Pan-European Trial in Adjuvant Colon Cancer (PETACC-1). In: EORTC-FFCD Joint Meeting on Liver and Gastro-Intestinal Tract Cancers, Paris, France, Giugno 23-26, 1999, -, pp. 137-137.

E Mini , C Biondi, M Morganti, C Napoli, P Mazzoni, F Cianchi, F Tonelli, C Cortesini, S Capaccioli, F Ficari, A Quattrone, S Rossi, T Mazzei (1999). Marked variation of thymidylate synthase and folylpolyglutamate synthetase gene expression in human colorectal tumors.. ONCOLOGY RESEARCH, vol. 11, pp. 437-445, ISSN:1555-3906

P. Periti; G. Stringa; E. Mini (1999). Comparative multicenter trial of teicoplanin versus cefazolin for antimicrobial prophylaxis in prosthetic joint implant surgery. Italian Study Group for Antimicrobial Prophylaxis in Orthopedic Surgery.. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, vol. 18, pp. 113-119, ISSN:0934-9723

Caciagli B.; Carotti S.; Morganti M.; Landini I.; Nobili S.; Mazzei T.; Toffoli G.; Mini E (1999). Preliminary characterization of methotrexate (MTX) resistance mechanisms in human colon carcinoma cells DLD-1. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, vol. 44, pp. 162-162, ISSN:0305-7453

Neri B, Mini E, Fioretto L, Francescani D, Medi F (1999). Dose-finding study of gemcitabine and epirubicin in patients with advanced pancreatic cancer.. In: 35th Annual Meeting of the American Society of Clinical Oncology, Atlanta, Georgia, USA, May 15-18, 1999, Amer Society of Clinical Oncology, pp. 1128-1128.

Caciagli B.; Carotti S.; Morganti M.; Landini I.; Nobili S.; Mazzei T.; Toffoli G.; Mini E (1999). Preliminary characterization of methotrexate (MTX) resistance mechanisms in human colon carcinoma cells DLD-1. PHARMACOLOGICAL RESEARCH, vol. 39, pp. 99-99, ISSN:1043-6618

Mini E; Mazzei T; Nobili S; Periti P (1999). High-dose intravenous quinolones: efficacy and safety in lower respiratory tract infection therapy. JOURNAL OF CHEMOTHERAPY, vol. 11 (Suppl 2), pp. 52-52, ISSN:1973-9478

Morganti M.; Coronnello M.; Napoli C.; Quattrone A.; Mazzei T.; Capaccioli S.; Mini E (1999). Modulation of fluorodeoxyuridine cytotoxicity in human adenocarcinoma HCT-8 cells by antisense oligonucleotides targeted to thymidylate synthase.. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, pp. 161-161, ISSN:0305-7453

E. Mini; P. Pinzani; G. Amunni; A. Villanucci; T. Mazzei; M. Pazzagli (1999). Correlation of in vitro drug sensitivity and clinical response in ovarian carcinoma using an ATP-luminescence tumor chemosensitivity assay. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, vol. 44 (Suppl A), pp. 160-160, ISSN:0305-7453

P. Calamai; S. Carotti; A. Guerri; T. Mazzei; L. Messori; E. Mini; P. Orioli; G.P. Speroni (1998). Cytotoxic effects of gold(III) complexes on established human tumor cell lines sensitive and resistant to cisplatin.. ANTI-CANCER DRUG DESIGN, vol. 13, pp. 67-80, ISSN:0266-9536

Mini E, Biondi C, Morganti M, Napoli C, Mazzoni P, Cianchi F, Rossi S, Tonelli F, Cortesini C, Mazzei T (1998). Marked variation thymidylate synthase (TS) and folylpolyglutamate synthetase (FPGS) gene expression in human colorectal cancer. In: 34th Annual Meeting of the American Society of Clinical Oncology, Los Angeles, CA, USA, Maggio 16-19, 1998, American Society of Clinical Oncology, pp. 298-298.

Biondi C, Morganti M, Napoli C, Mazzoni P, Cianchi F, Rossi S, Tonelli F, Cortesini C, Mazzei T, Mini E (1998). Quantitation of intratumoral thymidylate synthase (TS) and folylpolyglutamate synthetase (FPGS) gene expression by the Polymerase Chain Reaction (PCR): marked variation among human colorectal cancer patients. In: 10th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, The Netherlands, Giugno 16-19, 1998, -, pp. 162-162.

Calamai, P; Carotti, S; Guerri, A; Mazzei, T; Messori, L; Mini, E; Orioli, P; Speroni, G P (1998). Cytotoxic effects of gold(III) complexes on established human tumor cell lines sensitive and resistant to cisplatin. ANTI-CANCER DRUG DESIGN, vol. 13, pp. 67-80, ISSN:0266-9536

P. Periti; E. Mini; G. Mosconi (1998). Antimicrobial prophylaxis in orthopaedic surgery: the role of teicoplanin.. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, vol. 41, pp. 329-340, ISSN:0305-7453

P. Borri; M. Coronnello; I. Noci; A. Pesciullesi; A. Peri; R. Caligiani; M. Maggi; F. Torricelli; G. Scarselli; O. Chieffi; T. Mazzei; E. Mini (1998). Differential inhibitory effects on human endometrial carcinoma cell growth of luteinizing hormone-releasing hormone analogues.. GYNECOLOGIC ONCOLOGY, vol. 71, pp. 396-403, ISSN:0090-8258

G. Cini; M. Coronnello; E. Mini; B. Neri (1998). Melatonin's growth-inhibitory effect on hepatoma AH 130 in the rat.. CANCER LETTERS, vol. 125, pp. 51-59, ISSN:0304-3835

Mazzei T.; Bellacci A.; Pesciullesi A.; Galli A.; Carlà V.; Nobili S.; Caciagli B.; Pace M.; Mini E (1998). Pharmacokinetic monitoring of melphalan (L-PAM) during hyperthermic perfusion in patients (PTS) with melanoma of the limbs. JOURNAL OF CLINICAL ONCOLOGY, vol. 17, pp. 228-228, ISSN:0732-183X

Carotti S, Guerri A, Mazzei T, Messori L, Mini E, Orioli P (1998). Gold(III) compounds as potential antitumor agents: cytotoxicity and DNA binding of some selected gold(III) complexes. In: 10th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, The Netherlands, Giugno 16-19, 1998, -, pp. 29-29.

P. Periti; F. Tonelli; E. Mini (1998). Selecting antibacterial agents for the control of surgical infection: mini-review.. JOURNAL OF CHEMOTHERAPY, vol. 10, pp. 83-90, ISSN:1120-009X

R. MAURITZ; M.W. BEKKENK; M.G. ROTS; R. PIETERS; E. MINI; C.H. VAN ZANTWIJK; A.J. VEERMAN; G.J. PETERS; G. JANSEN (1998). EX VIVO ACTIVITY OF METHOTREXATE VERSUS NOVEL ANTIFOLATE INHIBITORS OF DIHYDROFOLATE REDUCTASE AND THYMIDYLATE SYNTHASE AGAINST CHILDHOOD LEUKEMIA CELLS. CLINICAL CANCER RESEARCH, vol. 4, pp. 2399-2410, ISSN:1078-0432, American Association of Cancer Research:150 South Independence Mall West, #826:Philadelphia, PA 19106:(215)440-9300, EMAIL: pubs@aacr.org, INTERNET: http://www.aacr.org, Fax: (215)440-7228:

P. Calamai; S. Carotti; A. Guerri; L. Messori; E. Mini ; P. Orioli; G.P. Speroni (1997). Biological properties of two gold(III) complexes: AuCl3(Hpm) and AuCl2(pm). JOURNAL OF INORGANIC BIOCHEMISTRY, vol. 66, pp. 103-109, ISSN:0162-0134

Pesciullesi A.; Bellacci A.; Carla V.; Galli A.; Nobili S.; Mini E.; Pace M.; Mazzei T. (1997). Pharmacokinetics of melphalan (L-PAM) during hyperthermic perfusion in patients with melanoma of the limbs. PHARMACOLOGICAL RESEARCH, vol. 35, pp. 232-233, ISSN:1043-6618

Biondi C.; Morganti M.; Carotti S.; Pesciullesi A.; Caciagli B.; Mini E.; Mazzei T. (1997). Quantitative analysis by polymerase chain reaction (PCR) of genes involved in resistance to cytotoxic antimetabolites. PHARMACOLOGICAL RESEARCH, vol. 35, pp. 233-234, ISSN:1043-6618

E. Mini; S. Nobili; P. Periti (1997). Methicillin-resistant staphylococci in clean surgery. Is there a role for prophylaxis?. DRUGS, vol. 54 Suppl 6, pp. 39-52, ISSN:0012-6667

P. Pinzani; S. Carotti; A. Gerli; M. Pazzagli; T. Mazzei; E. Mini (1997). Evaluation of methotrexate sensitivity in human leukemia cell lines by an adenosine triphosphate bioluminescence assay. ANTI-CANCER DRUGS, vol. 8, pp. 767-777, ISSN:0959-4973

Pesciullesi A.; Bellacci A.; Carlà V.; Galli A.; Nobili S.; Mini E.; Pace M.; Mazzei T (1997). Pharmacokinetic monitoring of melphalan (L-PAM) during hyperthermic perfusion in patients with melanoma of the limbs. PHARMACOLOGICAL RESEARCH, vol. 35, pp. 232-233, ISSN:1043-6618

Tonelli F, Periti P, Mazzei T, Mini E, Ficari F, Valanzano R, Mazzoni P (1996). A randomized multicenter study comparing 5-fluorouracil (5-FU) and l-folinic acid (L-LV) alone or with levamisole (LEV) or interferon alpha2a (IFNalpha2a) as adjuvant therapy for colorectal cancer. In: Thirty-Second Annual Meeting of the American Society of Clinical Oncology, Philadelphia, PA, USA, Maggio 18-21, 1986, American Society of Clinical Oncology, pp. 226-226.

A. Valeri; E. Mini; P. Tonelli; I. Agostino; B. Neri; S. Nobili; D. Borrelli; T. Mazzei (1996). Treatment of unresecable liver metastases from colorectal carcinoma with hepatic arterial and systemic chemotherapy. JOURNAL OF CHEMOTHERAPY, vol. 8(4), pp. 216-218, ISSN:1120-009X

Morganti M.; Caciagli B.; Coronnello M.; Carotti S.; Biondi C.; Quattrone A.; Capaccioli S.; Mazzei T.; Mini E. (1996). Modulazione dei livelli di mRNA della diidrofolico reduttasi mediante oligonucleotidi antisenso in cellule leucemiche umane (CCRF-CEM/E) con superespressione di questo enzima.. JOURNAL OF CHEMOTHERAPY, vol. 8/suppl.3, pp. 73-73, ISSN:1120-009X

Morganti M.; Caciagli B.; Coronnello M.; Quattrone A.; Capaccioli S.; Mazzei T.; Mini E. (1996). Modulation of dihydrofolate reductase (DHFR) mRNA levels in human leukemia CCRF-CEM/E line overexpressing this enzyme by antisense oligodeoxynucleotides.. TUMORI, vol. 82/suppl.4, pp. 26-26, ISSN:0300-8916

T. Mazzei; E. Mini; P. Mazzoni; F. Ficari; P. Periti; F. Tonelli; and other participants of the Gruppo Oncologico-Chirurgico Cooperativo Italiano (GOCCI) (1996). Adjuvant therapy of colorectal carcinoma with 5-fluorouracil and l-folinic acid alone or combined with levamisole or interferon-alfa2a. Preliminary toxicological results of a multicenter study of the Italian Cooperative Oncological-Surgical Group (GOCCI). JOURNAL OF CHEMOTHERAPY, vol. 8 (Suppl 4), pp. 147-151, ISSN:1120-009X

Tonelli F, Periti P, Mazzei T, Mini E, Ficari F, Valanzano R, Mazzoni P (1995). Adjuvant therapy of colorectal carcinoma with 5-fluorouracil (5-FU) and l-folinic acid (l-LV) alone or combined with levamisole (LEV) or interferon alpha2a (IFN alpha2a). Preliminary toxicological results of a multicenter study of the Gruppo Oncologico-Chirurgico Cooperativo Italiano (GOCCI). In: 31st Annual Meeting of the American Society of Clinical Oncology, Los Angeles, CA, USA, Maggio 20-23, 1995, American Society of Clinical Oncology, pp. 219-219.

Bellacci A, Pesciullesi A, Galli A, Carlà V, Mini E, Mazzei T, Pace M (1995). Pharmacokinetics of melphalan n (L-PAM) in true and mild hyperthermic perfusion in patients with melanoma of the lower limb. A preliminary report. In: 5th International Congress on Anti-Cancer Chemotherapy (Neo-Adjuvant, Adjuvant and Experimental), Paris, France, Gennaio 31-1 Febbraio, 1995, -, pp. 126-126.

Tonelli F, Periti P, Mazzei T, Mini E, Ficari F, Valanzano R, Mazzoni P, Dentico P (1995). Adjuvant therapy of colorectal carcinoma with 5-fluorouracil (5-FU) and l-folinic acid (l-LV) alone or combined with levamisole (LEV) or interferon alpha2a (IFN alpha2a). Preliminary toxicological results of a Multicenter Study of the Gruppo Oncologico-Chirurgico Cooperativo Italiano.. In: 15th Anniversary International Congress. Colorectal cancer: from Gene to Cure, Amsterdam, The Netherlands, Febbraio 9-11, 1995, -, pp. 51-51.

Mini E, Pazzagli M, Pinzani P, Carotti S, Gerli A, Mazzei T (1995). Evaluation of methotrexate (MTX) sensitivity by an ATP bioluminescence assay in human leukemia cells. THE CANADIAN JOURNAL OF INFECTIOUS DISEASES, vol. 6, pp. 476-476, ISSN:1180-2332

Tonelli F, Periti P, Mazzei T, Mini E, Ficari F, Valanzano R, Mazzoni P (1995). Adjuvant therapy of colorectal carcinoma with 5-fluorouracil (5-FU) and l-folinic acid (l-LV) alone or with levamisole (LEV) or interferon alpha2a (IFN alpha2a).. THE CANADIAN JOURNAL OF INFECTIOUS DISEASES, vol. 6, pp. 209-209, ISSN:1180-2332

Tonelli F, Periti P, Mazzei T, Mini E, Ficari F, Valanzano R, Nobili S, Mazzoni P (1995). Adjuvant chemotherapy with 5-fluorouracil (5-FU) and folinic acid (L-LV) for colorectal carcinoma: preliminary results of a randomized multicenter study of the Gruppo Cooperativo Oncologico Tosco-Umbro (GCOTU). In: 15th Anniversary International Congress. Colorectal cancer: from Gene to Cure, Amsterdam, The Netherlands, Febraio 9-11, 1995, -, pp. 49-49.

A. Arcangeli; L. Bianchi; A. Becchetti; L. Faravelli; M. Coronnello; E. Mini; M. Olivotto; E. Wanke (1995). A novel inward-rectifying K+ current with a cell-cycle dependence governs the resting potential of mammalian neuroblastoma cells.. THE JOURNAL OF PHYSIOLOGY, vol. 489 (Pt 2), pp. 455-471, ISSN:0022-3751

T. Mazzei; F. Tonelli; E. Mini; P. Mazzoni; A. Pesciullesi; R. Valanzano; F. Ficari; C. Biondi; P. Periti (1995). Flow cytometric analysis of DNA ploidy and cell proliferation activity in colorectal carcinoma.. ANTICANCER RESEARCH, vol. 15, pp. 2247-2253, ISSN:0250-7005

I. A. Cree; M. Pazzagli; E. Mini; T. Mazzei; E. M. Hunter; L. A. Sutherland; P. Pinzani; A. Gerli; P. E. Andreotti (1995). Methotrexate chemosensitivity by ATP luminescence in human leukemia cell lines and in breast cancer primary cultures: comparison of the TCA-100 assay with a clonogenic assay.. ANTI-CANCER DRUGS, vol. 6, pp. 398-404, ISSN:0959-4973

T.Mazzei;A.Novelli;F.De Lalla;E. Mini;P. Periti (1995). Tissue penetration and pulmonary disposition of tobramycin.. JOURNAL OF CHEMOTHERAPY, vol. 7, pp. 363-370, ISSN:1120-009X

Periti P, Rizzo M, Mazzei T, Mini E (1995). Depot leuprorelin acetate alone or with nilutamide in the treatment of metastatic prostate carcinoma: interim report of a multicenter, double-blind, placebo-controlled study. THE CANADIAN JOURNAL OF INFECTIOUS DISEASES, vol. 6, pp. 293-293, ISSN:1180-2332

Pinzani P, Gerli A, Carotti S, Mini E, Orlando C, Gelmini S, Sestini R, Pazzagli M (1994). ATP chemosensitivity testing: methodology and comparison with other methods. In: Joint Meeting on Laboratory Medicine in Oncology, Naples, Italy, Giugno 12-15, 1994, International Academy of Tumor Marker Oncology, vol. 9, pp. 42-42.

Mini E, Mazzei T, Periti P (1994). Mechanisms of resistance to methotrexate (MTX) in human tumors and pharmacological strategies for its circumvention. In: 9th Mediterranean Congress of Chemotherapy, Milan, Italy, Giugno 12-17, 1994, -, pp. 19-19.

Periti P, Stringa G, Mazzei T, Mini E, Dentico P (1994). Antimicrobial prophylaxis in prosthetic joint implant surgery: a comparative multicenter trial between teicoplanin and cefazolin. In: 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Orlando, FL, USA, Ottobre 4-8, 1994, -, pp. 5-5.

Mini E; Tonelli F (1994). Biochemical modulation of 5-fluorouracil in the treatment of colorectal cancer. In: Cancer in the Elderly. Second International Conference on Geriatric Oncology, Genova, Italy, Settembre 19-21, 1994, -, pp. 170-170.

ROSSO R.; MAZZEI T.; SOBRERO A.; E. MINI; CARTEI G.; CONTE P.; LA BIANCA R.; CARTEI F.; FALCONE A.; PANCERA G.; BARSANTI G.; DI COSTANZO F; GUGLIELMI A.; BOLLI E.; TIXI L.; ASCHELE C.; RIBECCO A.; PERITI P. (1994). PHASE II TRIAL OF 5-FLUOROURACIL AND THE NATURAL L-ISOMER OF FOLINIC ACID IN THE TREATMENT OF ADVANCED COLORECTAL CARCINOMA.. EUROPEAN JOURNAL OF CANCER, vol. 30A(3), pp. 338-343, ISSN:0959-8049, Elsevier Science Limited:Oxford Fulfillment Center, PO Box 800, Kidlington Oxford OX5 1DX United Kingdom:011 44 1865 843000, 011 44 1865 843699, EMAIL: asianfo@elsevier.com, tcb@elsevier.co.UK, INTERNET: http://www.elsevier.com, http://www.elsevier.com/locate/shpsa/, Fax: 011 44 1865 843010:

A. Valeri; E. Mini; P. Tonelli; F. Veneri; B. Neri; D. Borrelli; T. Mazzei (1994). Intra-arterial chemotherapy with 5-fluorouracil and 5-methyltetrahydrofolate in the treatment of unresectable liver metastases from colorectal cancer. ANTICANCER RESEARCH, vol. 14, pp. 2215-2220, ISSN:0250-7005

A. Quattrone; L. Papucci; M. Morganti; M. Coronnello; E. Mini; T. Mazzei; F.P. Colonna; A. Garbesi; S. Capaccioli (1994). Inhibition of MDR1 gene expression by antimessenger oligonucleotides lowers multiple drug resistance. ONCOLOGY RESEARCH, vol. 6, pp. 311-320, ISSN:0965-0407

A. Quattrone; L. Papucci; N. Schiavone; E. Mini; S. Capaccioli (1994). Intracellular enhancement of intact antisense oligonucleotide steady-state levels by cationic lipids. ANTI-CANCER DRUG DESIGN, vol. 9, pp. 549-553, ISSN:0266-9536

Mini E, Mazzei T, Carotti S, Coronnello M, Gerli A, Pesciullesi A, Periti P (1994). Effect of the l and d stereoisomers of 5-formyltetrahydrofolate (LV) and 5-methytetrahydrofolate (5-CH3-H4PteGlu) on fluoropyrimidine cytotoxicity in human leukemic CCRF-CEM cells. In: 18th International Congress of Chemotherapy, Stockholm, Sweden, Giugno 27 – Luglio 2, 1993, -, pp. 1164-1164.

Periti P, Stringa G, Mazzei T, Mini E, Novelli A, Calviani L (1993). A comparison of the prophylactic use of teicoplanin or cefazolin in the prevention of infections complications of hip and knee prosthesis insertion. In: 18th International Congress of Chemotherapy, Stockholm, Sweden, Giugno 27 – Luglio 2, 1993, -, pp. 1442-1442.

Mini, E; Novelli, A; Coronnello, M; Fallani, S; Pesciullesi, A; Periti, P (1993). In vitro effects of brodimoprim on human polymorphonuclear leukocyte functions. Preliminary results. JOURNAL OF CHEMOTHERAPY, vol. 5, pp. 499-501, ISSN:1120-009X

Coronnello M.; Pesciullesi A.; Carotti S.; Gerli A.; Morganti M.; Biondi C.; Mini E.; Mazzei T (1993). Flow cy¬tometric evaluation of the in¬hibitory effects of li¬posome-entrapped methotrexate (MTX) on lymphocyte proliferation and polymorphonuclear (PMN) leukocyte functions.. EUROPEAN JOURNAL OF HISTOCHEMISTRY, vol. 37/suppl.2, pp. 84-84, ISSN:1121-760X

Novelli A, Mazzei T, Mini E, Cassetta MI, Fallani S, Periti P (1993). Pharmacokinetics and blister fluid penetration of ticarcillin/clavulanate in adults. In: 18th International Congress of Chemotherapy, Stockholm, Sweden, Giugno 27 – Luglio 2, 1993, -, pp. 817-817.

Mini E.; Carotti S.; Gerli A.; Coronnello M.; Pe¬sciullesi A.; Morganti M.; Biondi C.; Ghione M.; Mazzei T. (1993). Valutazione dell'indice terapeu¬tico in vi¬tro di un vettore liposomiale veicolante metotrexato (MTX) in cellule leucemiche umane CCRF-CEM in immu¬nociti umani nor¬mali.. TUMORI, vol. 79/suppl.3, pp. 141-141, ISSN:0300-8916

T.Mazzei;E.Mini;A.Novelli;P.Periti (1993). Chemistry and mode of action of macrolides.. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, vol. 31 Suppl C, pp. 1-9, ISSN:0305-7453

E. Mini; A. Novelli; M. Coronnello; S. Fallani; A. Pesciullesi; P. Periti (1993). In vitro effects of brodimoprim on human polymorphonuclear leukocyte functions. Preliminary results. JOURNAL OF CHEMOTHERAPY, vol. 5(6), pp. 499-501, ISSN:1120-009X, ESIFT Srl:Casella Postale 147, I 50018 Scandicci Fi Italy:011 39 055 4271516, EMAIL: mary@jchemother.it, Fax: 011 39 055 4271280:

S. Capaccioli; G. Di Pasquale; E. Mini; T. Mazzei; A. Quattrone (1993). Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 197, pp. 818-825, ISSN:0006-291X

T. Bergan; A. Stockis; S. Kaftezis; H. Schmid; F. Scaglione; M. Maciocchi; E. Wiedekamm; G. Villa; S. Reggio; E. Mini; T. Mazzei; F. Paradisi (1993). Clinical pharmacology. Discussion. JOURNAL OF CHEMOTHERAPY, vol. 5, pp. 502-503, ISSN:1120-009X

P. Periti; T. Mazzei; E. Mini; A. Novelli (1993). Adverse effects of macrolide antibacterials.. DRUG SAFETY, vol. 9, pp. 346-364, ISSN:0114-5916

Sobrero A, Rosso R, Bolli E, Tixi L, Falcone A, Conte PF, Pancera G, La Bianca R, Di Costanzo F, Pronzato P, Mini E, Periti P (1992). Phase II study of 5-FU plus 6-S-leucovorin (6S-LV) in advanced colorectal cancer. In: 28th Annual Meeting of the American Society of Clinical Oncology, San Diego, CA, USA, Maggio 20-23, 1992, American Society of Clinical Oncology, pp. 187-187.

P.PERITI;T.MAZZEI;E.MINI;A.NOVELLI (1992). Pharmacokinetic drug interaction of macrolides. CLINICAL PHARMACOKINETICS, vol. 23, pp. 106-131, ISSN:0312-5963

Mazzei, T; Novelli, A; Mini, E; Periti, P (1992). [Plasma and tissue antibiotic concentrations: what is their prognostic value?]. ANNALI ITALIANI DI MEDICINA INTERNA, vol. 7, pp. 67s-73s, ISSN:0393-9340

P.Periti;G.Stringa;L.Donati;T.Mazzei;E.Mini;A.Novelli (1992). Teicoplanin--its role as systemic therapy of burn infections and as prophylaxis for orthopaedic surgery. Italian Study Groups for Antimicrobial Prophylaxis in Orthopaedic Surgery and Burns.. EUROPEAN JOURNAL OF SURGERY, vol. S 567, pp. 3-8, ISSN:1102-4151

Periti P, Novelli A, Mazzei T, Mini E, Fallani S (1991). Comparative in vitro activity of ciprofloxacin against methicillin-resistant staphylococci. In: 17th International Congress of Chemotherapy, Berlin, Federal Republic of Germany, Giugno 23-28, 1991, -, pp. 626-626.

Periti P, Novelli A, Mini E, Mazzei T, Cassetta MI (1991). Clinical pharmacokinetics of cefpodoxime proxetil in older patients. In: 17th International Congress of Chemotherapy, Berlin, Federal Republic of Germany, Giugno 23-28, 1991, -, pp. 250-250.

Periti P, Stringa G, Donati L, Mazzei T, Mini E, Novelli A (1991). Teicoplanin: its role as systemic burn therapy and as prophylaxis for orthopedic surgery. In: 17th International Congress of Chemotherapy, Berlin, Federal Republic of Germany, Giugno 23-28, 1991, -, pp. 545-545.

E. Mini; R. Stanyon; M. Coronnello; A. Gerli; T. Mazzei; P. Periti (1991). Chromosomal characterization of methotrexate-resistant human T-lymphoblast leukemia cells (CCRF-CEM) with impaired polyglutamylation.. TUMORI, vol. 77, pp. 95-99, ISSN:0300-8916

Mini E.; Mazzei T.; Carotti S.; Coronnello M.; Gerli A.; Pesciullesi A.; Periti P (1991). Characterization and selective pharmacologic circumven¬tion of metho¬trexate (MTX) resi¬stance in leukemia cells. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, vol. suppl.2, pp. S11-S11, ISSN:0277-5379

Mini E; Bertino JR (1991). Modulation of 5-fluorouracil by metabolites and antimetabolites. In: T-C Chou, DC Rideut. Synergism and Antagonism in Chemotherapy, pp. 449-506 Academic Press, Inc, ISBN:9780121740900.

Periti P, Novelli A, Mazzei T, Mini E, Casetta MI (1991). Clinical pharmacokinetics and tissue penetration of cefpirome in the elderly. In: 17th International Congress of Chemotherapy, Berlin, Federal Republic of Germany, Giugno 23-28, 1991, -, pp. 268-268.

Mini E, Mazzei T, Ribecco A, Periti P (1991). Phase I study of LY186641 given on alternative weeks to patients (pts) with solid tumors. In: 27th Annual Meeting of the American Society of Clinical Oncology, Houston, TX, USA, Maggio 19-21, 1991, American Society of Clinical Oncology, pp. 110-110.

P. Periti; F. Pannuti; G. R. Della; T. Mazzei; E. Mini; A. Martoni; P. Preti; L. Ercolino; L. Pavesi; A. Ribecco (1991). Combination chemotherapy with cyclophosphamide, fluorouracil, and either epirubicin or mitoxantrone: a comparative randomized multicenter study in metastatic breast carcinoma.. CANCER INVESTIGATION, vol. 9, pp. 249-255, ISSN:0735-7907

F. Boccardo; A. U. Decensi; D. Guarneri; G. Martorana; L. Fioretto; E. Mini; M. P. Macaluso; L. Giuliani; L. Santi; P. Periti (1991). Anandron (RU 23908) in metastatic prostate cancer: preliminary results of a multicentric Italian study.. CANCER DETECTION AND PREVENTION, vol. 15, pp. 501-503, ISSN:0361-090X

Mini E.; Bernabei P.A.; Gerli A.; Carotti S.; Coronnello M.; Pesciullesi A.; Mazzei T (1991). Citotossicità comparativa di metotrexato (MTX) e trimetrexato (TMTX) in cellule leucemiche umane.. TUMORI, vol. 77/suppl.3, pp. 166-166, ISSN:0300-8916

E.MINI;A. NOVELLI;P.PERITI (1991). Concentration-effect relationship for antimicrobial drugs.. JOURNAL OF CHEMOTHERAPY, vol. 3 (supp 1), pp. 149-154, ISSN:1120-009X, ESIFT Srl:Casella Postale 147, I 50018 Scandicci Fi Italy:011 39 055 4271516, EMAIL: mary@jchemother.it, Fax: 011 39 055 4271280:

D.E. MCCLOSKEY; J.J. MCGUIRE; C.A. RUSSELL; B.G. ROWAN; J.R. BERTINO; G. PIZZORNO; E. MINI (1991). DECREASED FOLYLPOLYGLUTAMATE SYNTHETASE ACTIVITY AS A MECHANISM OF METHOTREXATE RESISTANCE IN CCRF-CEM HUMAN LEUKEMIC SUBLINES. THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 266, pp. 6181-6187, ISSN:0021-9258 Accesso ONLINE all'editore

Mini E; Bertino JR (1991). Mechanism of action, pharmacokinetics and modulation of 5-fluorouracil cytotoxicity: clinical and biochemical considerations.. In: A. Abad. Medical Treatment of Colon and Rectum Cancer, pp. 46-74 Grapicas Monterreina S.A.

E. MINI; F. TRAVE; Y.M. RUSTUM; J.R. BERTINO (1990). ENHANCEMENT OF THE ANTITUMOR EFFECTS OF 5-FLUOROURACIL BY FOLINIC ACID.. PHARMACOLOGY & THERAPEUTICS, vol. 47, pp. 1-19, ISSN:0163-7258, Elsevier Science Limited:Oxford Fulfillment Center, PO Box 800, Kidlington Oxford OX5 1DX United Kingdom:011 44 1865 843000, 011 44 1865 843699, EMAIL: asianfo@elsevier.com, tcb@elsevier.co.UK, INTERNET: http://www.elsevier.com, http://www.elsevier.com/locate/shpsa/, Fax: 011 44 1865 843010:

Periti P, Mazzei T, Mini E, Ribecco A, Aglietti A (1990). Phase I study of LY186641, a diarylsulfonylurea given on alternative weeks to patients with solid tumours. ANNALS OF ONCOLOGY, vol. 1, pp. 40-40, ISSN:0923-7534

E. Mini; M. Coronnello; S. Carotti; A. Gerli; A. Pesciullesi; B. A. Moroson; T. Mazzei; P. Periti; J. R. Bertino (1990). Biochemical modulation of fluoropyrimidines by antifolates and folates in an in vitro model of human leukemia.. JOURNAL OF CHEMOTHERAPY, vol. 2 Suppl 1, pp. 17-27, ISSN:1120-009X

T. Mazzei; E. Mini; M. Rizzo; P. Periti (1990). Human pharmacokinetic and pharmacodynamic profiles of leuprorelin acetate depot in prostatic cancer patients.. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, vol. 18 Suppl 1, pp. 42-56, ISSN:0300-0605

M. Rizzo; T. Mazzei; E. Mini; R. Bartoletti; P. Periti (1990). Leuprorelin acetate depot in advanced prostatic cancer: a phase II multicentre trial.. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, vol. 18 Suppl 1, pp. 114-125, ISSN:0300-0605

Mini, E; Periti, P (1989). [Medical therapy of malignant melanoma]. ANNALI ITALIANI DI CHIRURGIA, vol. 60, pp. 257-263, ISSN:0003-469X

E. Mini; A. Novelli; T. Mazzei; P. Periti (1989). Comparative in vitro activity of the new oxazolidinones DuP 721 and DuP 105 against staphylococci and streptococci.. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, vol. 8, pp. 256-260, ISSN:0934-9723

E.Mini;T.Mazzei;E.F.Reali;A.Novelli;P.Periti (1989). Pharmacokinetics of teicoplanin during cardiopulmonary bypass surgery.. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH, vol. 9, pp. 287-292, ISSN:0251-1649

A.Novelli;T.Mazzei;E.F.Reali;E.Mini;P.Periti (1989). Clinical pharmacokinetics and tissue penetration of teicoplanin.. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH, vol. 9, pp. 233-237, ISSN:0251-1649

P. Periti; E. Mini (1989). Drug resistance in cancer: an overview of the clinical aspects.. JOURNAL OF CHEMOTHERAPY, vol. 1, pp. 5-9, ISSN:1120-009X

P. Periti; T. Mazzei; E. Mini; A. Novelli (1989). Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part II).. CLINICAL PHARMACOKINETICS, vol. 16 (5), pp. 261-282, ISSN:0312-5963

Mini E.; Coronnello M.; Carotti S.; Pesciullesi A.; Mazzei T.; Periti P (1989). Effetti di esposizioni alter¬nate a trimetressato (TMTX) e metotres¬sato (MTX) sulla insorgenza di resistenza agli antifolici in un modello di leucemia T-linfoblastica umana (CCRF-CEM) in vitro.. TUMORI, vol. 75/suppl.4, pp. 51-51, ISSN:0300-8916

Stanyon R.; Mini E.; Coronnello M.; Gerli A.; Mazzei T.; Periti P. (1989). Analisi cariologica di linee cellulari leucemiche umane CCRF-CEM resistenti al metotressato (MTX) per alterata poliglutammilazione.. TUMORI, vol. 75/suppl.4, pp. 53-53, ISSN:0300-8916

P. Periti; T. Mazzei; E. Mini; A. Novelli (1989). Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part I).. CLINICAL PHARMACOKINETICS, vol. 16, pp. 193-214, ISSN:0312-5963

T. Mazzei; E. Mini; M. Eandi; E. F. Reali; L. Fioretto; R. Bartoletti; M. Rizzo; G. Calabrò; P. Periti (1989). Pharmacokinetics, endocrine and antitumour effects of leuprolide depot (TAP-144-SR) in advanced prostatic cancer: a dose-response evaluation.. DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH, vol. 15, pp. 373-387, ISSN:0378-6501

P. A. Bernabei; E. Mini; V. Gattei; F. C. Agostino; R. Bezzini; R. Saccardi; V. Santini; M. Coronnello; T. Mazzei; P. Rossi Ferrini (1989). Induction of differentiation of HL-60 cells along the monocytic pathway by 5-methyltetrahydrofolate.. JOURNAL OF CHEMOTHERAPY, vol. 1, pp. 359-364, ISSN:1120-009X

Novelli A, Mazzei T, Reali EF, Balocchini E, Melani A, Mini E, Periti P (1988). Clinical pharmacokinetics and tissue penetration of teicoplanin. In: 8th International Symposium on Future Trends in Chemotherapy, Tirrenia, Pisa, Italy, Marzo 28-30, 1988, -, pp. 203-203.

Mini E, Mazzei T, Rizzo M, Periti P (1988). Pharmacokinetics and endocrine effects of leuprolide depot. In: 6th Mediterranean Congress of Chemotherapy, Taormina-Giardini Naxos, Italy, Maggio 22-27, 1988, -, pp. 69-69.

Mini E, Mazzei T, Periti P (1988). Pharmacokinetics and metabolism of hormonal drugs: clinical implications. In: International Symposium of Hormonotherapy in Oncology, Bologna, Italy,, Marzo 23-25, 1988, -, pp. 1988-1988.

Mini E, Reali EF, Silvestri V, Montesi G, Novelli A, Periti P (1988). Pharmacokinetics of teicoplanin during cardiopulmonary bypass surgery. In: 8th International Symposium on Future Trends in Chemotherapy, Tirrenia, Pisa, Italy, Marzo 28-30, 1988, -, pp. 201-201.

Mazzei T, Mini E, Eandi M, Reali EF, Fioretto L, Magni M, Periti P (1988). Pharmacokinetics and endocrine effects of leuprolide depot in advanced prostatic cancer: a dose-response analysis. In: 8th International Symposium on Future Trends in Chemotherapy, Tirrenia, Pisa, Italy, Marzo 28-30, 1988, -, pp. 204-204.

Mini E (1988). Resistance to fluoropyrimidines. In: 6th Mediterranean Congress of Chemotherapy, Taormina-Giardini Naxos, Italy, Maggio 22-27, 1988, -, pp. 16-16.

P. Periti; T. Mazzei; F. Orlandini; E. Mini (1988). Comparison of the antimicrobial prophylactic efficacy of cefotaxime and cephazolin in obstetric and gynaecological surgery. A randomised multicentre study.. DRUGS, vol. 35 Suppl 2, pp. 133-138, ISSN:0012-6667

E. Mini; G. Pizzorno; M. Coronnello; J. J. McGuire; T. Mazzei; P. Periti; J. R. Bertino (1988). Impaired methotrexate polyglutamylation in a human leukemia cell line resistant to short-term, high-dose methotrexate.. PHARMACOLOGICAL RESEARCH COMMUNICATIONS, vol. 20, pp. 445-446, ISSN:0031-6989

Mini E.; Mazzei T.; Coronnello M.; Bertino J.R.; Periti P (1988). Compa¬rative effects of two non-classical antifolates, tri¬metrexate (TMQ) and triazinate (TZT), on 5-fluoroura¬cil (FUra) cytotoxicity against human CCRF-CEM leukemia cells.. ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH PROCEEDINGS, vol. 29, pp. 475-475, ISSN:0197-016X

G. Pizzorno; E. Mini; M. Coronnello; J. J. McGuire; B. A. Moroson; A. R. Cashmore; R. N. Dreyer; J. T. Lin; T. Mazzei; P. Periti; J.R Bertino (1988). Impaired polyglutamylation of methotrexate as a cause of resistance in CCRF-CEM cells after short-term, high-dose treatment with this drug.. CANCER RESEARCH, vol. 48, pp. 2149-2155, ISSN:0008-5472

Mini E, Pizzorno G, Mazzei T, Moroson BA, Cashmore AR, Bertino JR (1987). Impaired polyglutamylation as a mechanism of resistance to methotrexate (MTX) in human leukemia CCRF-CEM cells to high-dose short-term exposure to this drug. In: 78th Annual Meeting of the American Association for Cancer Research, Atlanta, GE, USA, Maggio 20-23, 1987, American Association for Cancer Research, pp. 285-285.

Periti P, Mazzei T, Novelli A, Reali EF, Mini E (1987). Comparative tissue penetration of betalactam antibiotics. In: International Symposium on the Control of Hospital Infections, Rome, Italy, Aprile 27-29, 1987, -, pp. 113-113.

Periti P, Mazzei T, Orlandini F, Mini E (1987). Comparative randomized multicenter study of cefotetan and cefazolin i.v. as antimicrobial prophylaxis in gynecological and obstetric surgery. In: International Symposium on the Control of Hospital Infections, Rome, Italy, Aprile 27-29, 1987, -, pp. 118-118.

J.R. Bertino; A. Sobrero; E. Mini; B.A. Moroson; A. Cashmore (1987). Design and rationale for novel antifolates. In: National Cancer Institute (U.S.). NCI monographs : a publication of the National Cancer Institute, pp. 87-91, Bethesda, MD: U.S. National Cancer Institute.

Bernabei PA, Mini E, Agostino FC, Gattei V, Bezzini ER, Santini V, Saccardi R, Mazzei T, Rossi Ferrini P (1987). 5-methyltetrahydrofolate (mTHF) induces monocytes differentiation in HL60 cells. In: 4th International Symposium on Therapy of Acute Leukemias, Rome, Italy, Febbraio 7-12, 1987, -, pp. 458-458.

E.Mini; T.Mazzei; P.Periti; E.F.Reali; P.Bordonaro; E.Balocchini; B.Ninu (1987). Microbiological and pharmacokinetic evaluation of cefonicid, a long-acting cephalosporin. CHEMIOTERAPIA, vol. 6, pp. 243-246, ISSN:0392-906X

Mini E, Mazzei T, Palminiello A, Bordonaro P, Mazzola L, Periti P (1987). Tissue penetration of the new macrolide roxithromycin (RU 28965, ROX) into the lung. In: 15th International Congress of Chemotherapy, Istanbul, Turkey, Luglio 19-24, 1987, -, pp. 102-102.

Periti, P; Mini, E (1987). Immunomodulation by cancer chemotherapeutic agents. CHEMIOTERAPIA, vol. 6, pp. 399-402, ISSN:0392-906X

Mini, E; Mazzei, T; Periti, P; Reali, E F; Bordonaro, P; Balocchini, E; Ninu, B (1987). Microbiological and pharmacokinetic evaluation of cefonicid, a long-acting cephalosporin. CHEMIOTERAPIA, vol. 6, pp. 243-246, ISSN:0392-906X

Bertino JR; Mini E (1987). Does modulation of 5-fluorouracil by metabolites of antimetabolites work in the clinic?. In: KR Harrap, TA Connors. New Avenues in Developmental Cancer Chemotherapy, pp. 163-184 Academic Press, Inc, ISBN:9780123260208.

Periti P; Mini E (1987). Immunomodulation by cancer chemotherapeutic agents. In: B Bizzini, E Bonmassar. Advances in Immunomodulation, pp. 301-306, Roma, Italia: Pythagora Press, ISBN:9788885852068.

Bertino, J R; Sobrero, A; Mini, E; Moroson, B A; Cashmore, A (1987). Design and rationale for novel antifolates. NCI monographs : a publication of the National Cancer Institute., vol. -, pp. 87-91

Periti P, Mini E, Mazzei T, Fioretto L, Magni M, Bartoletti R, Rizzo M (1987). Preliminary results of a phase II multicenter study on the clinical efficacy and safety to the LH-RH analog leuprolide in the treatment of prostatic carcinoma. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, vol. 10, pp. 53-53, ISSN:0391-4097

Romanini A, Russello O, Rosso R, Nicolin A, Mini E, Moroson BA, Bertino JR, Sobrero A (1987). Sequence-dependent synergism between trimetrexate and 5-fluorouracil in a human colon carcinoma cell line. In: 78th Annual Meeting of the American Association for Cancer Research, American Association for Cancer Research, pp. 291-291.

E. Mini; T. Mazzei; M. Coronnello; L. Criscuoli; M. Gualtieri; P. Periti; J. R. Bertino (1987). Effects of 5-methyltetrahydrofolate on the activity of fluoropyrimidines against human leukemia (CCRF-CEM) cells.. BIOCHEMICAL PHARMACOLOGY, vol. 36, pp. 2905-2911, ISSN:0006-2952

E. Mini; B. A. Moroson; J. R. Bertino (1987). Cytotoxicity of floxuridine and 5-fluorouracil in human T-lymphoblast leukemia cells: enhancement by leucovorin.. CANCER TREATMENT REPORTS, vol. 71, pp. 381-389, ISSN:0361-5960

Scanlon KJ, Nee Deels C, Lu Y, Lin C, Newman E, Leong L, Mini E (1986). Biochemical basis for cisplatinum and 5-fluorouracil synergism in human tumors. In: 77th Annual Meeting of the American Association for Cancer Research, Los Angeles, CA, USA, Maggio 7-10, 1986, American Association for Cancer Research, pp. 291-291.

Periti P, Mazzei T, Mini E, Fioretto L, Pannuti F, Martoni A, Cellerino R, Miseria S (1986). Phase I clinical trial of a new alkylating agent, PTT-119. In: 14th International Cancer Congress, Budapest, Hungary, Agosto 21-27, 1986, -, pp. 454-454.

Mini E, Luciani E, Bordonaro P, Periti P (1986). Microbiological and pharmacokinetic evaluation of cefonicid. In: 5th Mediterranean Congress of Chemotherapy, Cairo, Egypt,, Ottobre 26 - Novembre 1, 1986, -, pp. 58-58.

Mini E, Mazzei T, Coronnello M, Criscuoli L, Gualtieri M, Periti P (1986). Efficacy of 3-(p-fluorofenyl)-L-alanyl-3-m-bis(2-chloroethyl)amino-phenyl-L-methionine ethoxy HCl (PTT-119) on human leukemia cell lines. In: 14th International Cancer Congress, Budapest, Hungary, Agosto 21-27, 1986, -, pp. 393-393.

E. MINI; DOMBROWSKI J.; MOROSON B.A.; BERTINO J.R. (1986). CYTOTOXIC EFFECTS OF HYPERTHERMIA AND 5-FLUOROURACIL AND THEIR COMBINATION ON A HUMAN LEUKEMIA T-LYMPHOBLAST CELL LINE, CCRF-CEM.. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, vol. 22, pp. 927-934, ISSN:0277-5379 Accesso ONLINE all'editore

Mini E.; Mazzei T.; Coronnello M.; Gualtieri M.; Cri¬scuoli L.; Periti P (1986). Sviluppo di linee cellulari leu¬cemiche umane resistenti al metotres¬sato (MTX). Ri¬sultati preliminari con un modello in studio in vitro alternativo. TUMORI, vol. 72/suppl.6, pp. 670-670, ISSN:0300-8916

Periti P; Mini E (1986). Clinical and bacteriological evaluation of cefonicid in comparison with cefotaxime and cefuroxime. In: Symposium of the European Society of Clinical Microbiology, Palma de Majorca, Spain, Maggio 26-28, 1986, -, pp. 242-242.

Mini E.; Mazzei T.; Gualtieri M.; Criscuoli L.; Coronnello M.; Periti P (1986). Citotossicità comparativa del 3-(p-fluorofenil)-L-alanilmetionina etilestere clori¬drato, PTT-119, e del melfalan (L-PAM) in cellule tu¬morali umane.. TUMORI, pp. 670-670, ISSN:0300-8916

Bertino JR; Srimatkandada S; Carman MD; Jastreboff M; Melhman L; Medina WD; Mini E; Moroson BA; Cashmore AR; Dube SK (1986). Drug resistance: new approaches to treatment. In: P Chandra. New Experimental Modalities in the Control of Neoplasia, pp. 183-193 Plenum Publishing Corporation, New York, ISBN:9781468452426.

Martoni A, Mazzei T, Mini E, Fioretto L, Miseria S, Preti P, Cellerino R, Pannuti F, Robustelli Della Cuna G, Periti P (1986). Phase I trial of a novel alkylating agent. CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol. 23, pp. 48-48, ISSN:0344-5704

Bertino JR, Rodenhuis S, Lin J, Cashmore A, Moroson BA, Mini E, Sobrero A (1986). Trimetrexate, a second generation antifolate. In: 5th NCI-EORTC Symposium on New Drug in Cancer Therapy, Amsterdam, The Netherlands, Ottobre 22-24, 1986, -, pp. 11-11.

E. Mini; T. Mazzei; M. Coronnello; L. Criscuoli; M. Gualtieri; P. Periti (1986). Efficacy of 3-(p-fluorofenyl)-L-alanyl-3-m-bis(2-chloroethyl)amino-phenyl-L-methionine ethoxy HCl (PTT-119) on human leukemia cell lines. In: 14th International Cancer Congress, Budapest, Hungary, Au¬gust 21-27, 1986, vol. A, pp. 393-393.

Sobrero A, Mini E, Moroson BA, Love T, Sherwood RF, Bertino JR (1985). Enhancement of cytotoxic effects of trimetrexate by carboxypeptidase G (CPG) on human tumor cell lines. CLINICAL RESEARCH, vol. 33, pp. 578-578, ISSN:0009-9279

P. Periti; G. R. della; F. Pannuti; T. Mazzei; P. Preti; A. Martoni; E. Mini (1985). First-line combination chemotherapy with mitoxantrone and cyclophosphamide in advanced breast cancer.. INVESTIGATIONAL NEW DRUGS, vol. 3, pp. 167-171, ISSN:0167-6997

Mini, E; Mazzei, T; Coronnello, M; Criscuoli, L; Gualtieri, M; Periti, P (1985). Enhancement of fluoropyrimidine cytotoxicity by 5-methyltetrahydrofolate in a human leukemia cell line, CCRF-CEM. CHEMIOTERAPIA, vol. 4, pp. 454-459, ISSN:0392-906X

Mini E, Moroson BA, Bertino JR (1985). Leucovorin (LV)-fluoropyrimidine synergy in the human leukemic lymphoblast cell line CCRF-CEM. In: 76th Annual Meeting of the American Association for Cancer Research, Houston, TX, USA, Maggio 22-25, 1985, American Association for Cancer Research, pp. 324-324.

Bertino JR, Mini E, Sobrero A, Moroson BA, Love T (1985). Clinical achievements and prospects in biochemical modulation. In: The 8th Annual Bristol-Meyers Symposium on Cancer Chemotherapy, London, UK, Settembre 4-5, 1985, -, pp. 37-37.

Periti P, Robustelli Della Cuna G, Pannuti F, Mazzei T, Preti P, Martoni A, Mini E (1985). Mitoxantrone (dihydro-anthracenedione, DHAD) combined with cyclophosphamide (CYC) as first line chemotherapy in advanced breast cancer. In: 3rd European Conference on Clinical Oncology and Cancer Nursing, Stockholm, Sweden, Giugno 16-20, 1985, -, pp. 82-82.

Mini E, Mazzei T, Periti P (1985). Fluoropyrimidine-folate synergy in human leukemia-lymphoma cells in culture. In: 3rd European Conference on Clinical Oncology and Cancer Nursing, Stockholm, Sweden, Giugno 16-20, 1985, -, pp. 127-127.

E. MINI; MOROSON B.A.; FRANCO C.T.; BERTINO J.R. (1985). CYTOTOXIC EFFECTS OF FOLATE ANTAGONISTS AGAINST METHOTREXATE-RESISTANT HUMAN LEUKEMIC LYMPHOBLAST CCRF-CEM CELL LINES.. CANCER RESEARCH, vol. 45, pp. 325-330, ISSN:0008-5472, American Association of Cancer Research:150 South Independence Mall West, #826:Philadelphia, PA 19106:(215)440-9300, EMAIL: pubs@aacr.org, INTERNET: http://www.aacr.org, Fax: (215)440-7228:

Bertino JR; Mini E (1985). Single agent vs combination chemotherapy in head and neck cancer. In: PB Chretien, ME Johns, DP Shedd, EW Strong, PH Ward. Head and Neck Cancer, pp. 425-427 Decker B.C., Inc., Philadelphia, PA, ISBN:9780941158404.

Bertino JR; Mini E; Sobrero A; Srimatkandada S; Carman M; Jastreboff M; Dube S. (1985). Drug resistant cells as targets for new therapies. In: Gale, Golde. Leukemia: Recent Advances in Biology and Treatment., pp. 529-536 Alan R. Liss, Inc., New York, ISBN:9780845126271.

Mini E, Sobrero A, Moroson BA, Bertino JR (1985). Differential efficacy of trimetrexate (2-diamino-6-methyl-(3,4,5-trimethoxyanilino)methyl)quinazoline, JB-11, TMQ) and methotrexate (MTX) on human colon carcinoma and human leukemia cells in vitro. In: 76th Annual Meeting of the American Association for Cancer Research, Houston, TX, USA, Maggio 22-25, 1985, American Association for Cancer Research, pp. 230-230.

Bertino JR, Mini E, Sawicki WL, Moroson BA, Jastreboff M, McGuire JJ (1985). Effects of trimetrexate on human leukemia cells from patients sensitive and resistant to methotrexate (MTX). In: 21st Annual Meeting of the American Society for Clinical Oncology, Houston, TX, USA, Maggio 19-21, 1985, American Society of Clinical Oncology, pp. 44-44.

J. J. McGuire; E. Mini; P. Hsieh; J. R. Bertino (1985). Role of methotrexate polyglutamates in methotrexate- and sequential methotrexate-5-fluorouracil-mediated cell kill.. CANCER RESEARCH, vol. 45, pp. 6395-6400, ISSN:0008-5472

J. R. Bertino; E. Mini; A. Sobrero; B. A. Moroson; T. Love; M. Jastreboff; M. Carmen; S. Srimatkandada; S. Dube (1985). Methotrexate resistant cells as targets for selective chemotherapy.. ADVANCES IN ENZYME REGULATION, vol. 24, pp. 3-11, ISSN:0065-2571

E. Mini; S. Srimatkandada; W. D. Medina; B. A. Moroson; M. D. Carman; J. R. Bertino (1985). Molecular and karyological analysis of methotrexate-resistant and -sensitive human leukemic CCRF-CEM cells.. CANCER RESEARCH, vol. 45, pp. 317-324, ISSN:0008-5472

J. R. Bertino; S. Srimatkandada; M. D. Carman; E. Mini; M. Jastreboff; B. A. Moroson; S. K. Dube (1985). Mechanisms of drug resistance in human leukemia.. HAEMATOLOGY AND BLOOD TRANSFUSION, vol. 29, pp. 90-95, ISSN:0171-7111

Mazzei T, Mini E, Periti P (1985). 5-methyltetrahydrofolate (MeTHF) enhances fluoropyrimidine cytotoxicity against human leukemia cells in vitro. BRITISH JOURNAL OF PHARMACOLOGY, vol. 86, pp. 561-561, ISSN:0007-1188

Mini E, Dombrowski J, Moroson BA, Bertino JR (1984). Cytotoxic effects of hyperthermia and 5-fluorouracil (FUra) on human leukemic CCRF-CEM cells. In: 75th Annual Meeting of the American Association for Cancer Research, Toronto, Ontario, Canada, Maggio 9-12, 1984, American Association for Cancer Research, pp. 341-341.

Periti, P; Mazzei, T; Lamanna, S; Mini, E (1984). Single-dose ceftriaxone versus multi-dose cefotaxime as short-term antimicrobial prophylaxis in urologic surgery. Preliminary results of a multicenter prospective randomized study. CHEMIOTERAPIA, vol. 3, pp. 295-298, ISSN:0392-906X

Mini, E; Mazzei, T; Coronnello, M; Criscuoli, L; Gualtieri, M; Periti, P (1984). Modulation of fluoropyrimidine cytotoxicity by methotrexate or 5-methyltetrahydrofolate in human leukemia cells in vitro. CHEMIOTERAPIA, vol. 3, pp. 343-349, ISSN:0392-906X

J.H. SCHORNAGEL; P.K. CHANG; L.J. SCIARINI; B.A. MOROSON; E. MINI; A.R. CASHMORE; J.R. BERTINO (1984). SYNTHESIS AND EVALUATION OF 2,4-DIAMINOQUINAZOLINE ANTIFOLATES WITH ACTIVITY AGAINST METHOTREXATE-RESISTANT HUMAN TUMOR CELLS.. BIOCHEMICAL PHARMACOLOGY, vol. 33, pp. 3251-3255, ISSN:0006-2952, Elsevier Science Limited:Oxford Fulfillment Center, PO Box 800, Kidlington Oxford OX5 1DX United Kingdom:011 44 1865 843000, 011 44 1865 843699, EMAIL: asianfo@elsevier.com, tcb@elsevier.co.UK, INTERNET: http://www.elsevier.com, http://www.elsevier.com/locate/shpsa/, Fax: 011 44 1865 843010:

J. R. Bertino; C. D. Kowal; M. E. Klein; J. Dombrowski; E. Mini (1984). The potential for chemotherapy and hyperthermia.. FRONTIERS OF RADIATION THERAPY AND ONCOLOGY, vol. 18, pp. 162-170, ISSN:0071-9676

Mini E; Bertino JR (1984). Methotrexate-5-fluorouracil interactions: pharmacological and clinical aspects. In: Proceedings of the 1st Congress of the Mediterranean Society of Therapy, Florence, Italy, Giugno 10-15, 1984, -, pp. 121-122.

Periti, P; Mazzei, T; Lamanna, S; Mini, E (1984). Single-dose ceftriaxone versus multi-dose cefotaxime antimicrobial prophylaxis in gynecologic and obstetrical surgery. Preliminary results of a multicenter prospective randomized study. CHEMIOTERAPIA, vol. 3, pp. 299-304, ISSN:0392-906X

Bertino JR; Mini E; Sobrero A (1984). Sequential methotrexate and 5-fluorouracil in the treatment of solid tumors.. In: K Kimura, S Fujii, M Ogawa, GP Bodey, P Alberto. Fluoropyrimidines in Cancer Therapy, pp. 251-260 Elsevier Science Publishers B.V., Amsterdam, ISBN:9780444806123.

Mazzei T, Rizzo M, Scarselli G, Mini E (1984). Single-dose ceftriaxone versus multiple-dose cefotaxime antimicrobial prophylaxis in urologic, gynecologic, and obstetrical surgery. A multicenter study. In: 6th International Symposium on Future Trends in Chemotherapy, Tirrenia, Pisa, Italy, Maggio 28-30, 1984, -, pp. 129-129.

Mini E, Medina WD, Srimatkandada S, Moroson BA, Bertino JR (1983). Establishment and characterization of methotrexate resistant human cell lines and effects of folate antagonists. CLINICAL RESEARCH, vol. 31, pp. 509-509, ISSN:0009-9279

Bertino JR; Mini E; Sobrero A (1983). Sequential use of methotrexate (MTX) and 5-fluorouracil (FUra) in the treatment of solid tumors. In: International Symposium on Fluoropyrimidines, Nagoya, Japan, Novembre 3-5, 1983, Exerpta Medica, pp. 20-20.

Mini E.; Bertino J.R. (1983). Sequential methotrexate and 5-fluorouracil: Biochemical pharmacology and therapeutic use. CHEMIOTERAPIA, vol. 2, pp. 147-162, ISSN:0392-906X

J. R. Bertino; E. Mini; D. J. Fernandes (1983). Sequential methotrexate and 5-fluorouracil: mechanisms of synergy.. SEMINARS IN ONCOLOGY, vol. 10(2 Suppl 2), pp. 2-5, ISSN:0093-7754

Periti P.; Ciuffi M.; Coronnello M.; Mazzei T; Mini E (1983). Pharmacokinetics of 5-methyltetrahydrofolate in normal adults. CHEMIOTERAPIA, vol. 2, pp. 83-87, ISSN:0392-906X

Mini E, McGuire JJ, Moroson BA, Bertino JR (1983). Correlation of methotrexate polyglutamate MTX(Glu) formation and cell kill in the human lymphoblast cell line CCRF-CEM. In: 74th Annal Meeting of the American Association for Cancer Research, San Diego, CA, USA, Maggio 25-28, 1983, American Society of Clinical Oncology, pp. 275-275.

McGuire JJ; Mini E; Hsieh P; Bertino JR (1983). Folylpolyglutamate synthetase: relation to methotrexate action and as target for new drug development. In: YC Cheng, B Goz, M Minkoff. Development of Target-Oriented Anticancer Drugs, pp. 97-106 Raven Press, New York, ISBN:9780890041611.

Mini E; Bertino JR (1982). Time and dose relationship for methotrexate (MTX), fluorouracil (FUra) and combination of these drugs for maximum cell kill in human CCRF-CEM cells. In: 73rd Annual Meeting of the American Association for Cancer Research, St. Louis, MO, USA, Aprile 28-Maggio 1, 1982, American Association for Cancer Research, pp. 181-181.

Mazzei T, Cavallo AM, Branconi F, Mini E, Di Gioia E (1982). Ovarian epithelial carcinoma: treatment with cisplatinum + VP16. CHEMIOTERAPIA, vol. 1, pp. 119-119, ISSN:0392-906X

Periti P, Mazzei T, Ciuffi M, Savino L, Spinelli G, Mini E (1982). Pharmacokinetics of oral medroxyprogesterone acetate at moderate doses.. CHEMIOTERAPIA, vol. 1, pp. 126-126, ISSN:0392-906X

Mini E, Moroson BA, Blair OC, McGuire JJ, Bertino JR (1982). Time, dose and sequence relationship of methotrexate (MTX), fluorouracil (FUra) and their combination for optimal cell kill in the human T-lymphoid cell line CCRF-CEM. CHEMIOTERAPIA, vol. 1, pp. 118-118, ISSN:0392-906X

Bonazza M, Cavallo AM, Mini E, Rinnovati A (1981). Evaluation of vindesine in advanced tumors: phase II study.. In: 12th International Congress of Chemotherapy, Florence, Italy, Giugno 19-24, 1981, -, pp. 156-156.

Mazzei T.; Ciuffi M.; Mini E.; Bonazza M. (1981). Comparative human pharmacokinetics of bacampicillin and talampicillin. DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH, vol. 7, pp. 479-483, ISSN:0378-6501

Mazzei T.; Mini E.; Nicoletti P. (1981). Bacteriological pharmacokinetic and clinical study of dibekacin. DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH, vol. 7, pp. 495-502, ISSN:0378-6501 Accesso ONLINE all'editore

Mazzei T.; Ciuffi M.; Cavallo A.M.;Mini E, Nicoletti P, Bonazza M, Catalani C, Coronnello M. (1981). Bacteriological, pharmacokinetic and clinical evaluation of bekanamycin. DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH, vol. 7, pp. 489-494, ISSN:0378-6501

Mini E.; Mazzei T.; Nicoletti P. (1981). Cefazolin/dicloxacillin combination: experimental and clinical aspects. DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH, vol. 7, pp. 585-589, ISSN:0378-6501

Mazzei T, Ciuffi M, Mini E, Bonazza M (1980). Bacampicillin and talampicillin serum and urinary levels when the two antibiotics have been given orally at equimolar doses of ampicillin. In: 4th International Symposium on Future Trends in Chemotherapy, Florence, Italy, Giugno 23-24, 1980, -, pp. 121-121.

Mini E, Mazzei T, Schiatti R, Cavallo AM, Carini M, Rizzo M. (1980). Cefazolin/dicloxacillin combination in the treatment of urinary tract infections. In: 4th International Symposium of Future Trends in Chemotherapy, Florence, Italy, Giugno 23-24, 1980, -, pp. 81-81.

Mazzei T, Ciuffi M, Mini E, Nicoletti P, Cavallo AM, Bonazza M, Catalani C, Criscuoli L (1980). Bacteriological, pharmacokinetic and clinical evaluation of bekanamycin. In: 4th International Symposium on Future Trends in Chemotherapy, Florence, Italy, Giugno 23-24, 1980, -, pp. 68-68.

Mazzei T, Mini E, Nicoletti P, Ciuffi M, Carini M, Bertoni E, Coronnello M, Mainardi GC, Amato M (1980). Bacteriological, pharmacokinetic and clinical study of dibekacin. In: 4th International Symposium on Future Trends in Chemotherapy, Florence, Italy, Giugno 23-24, 1980, -, pp. 69-69.

Mazzei, T; Ciuffi, M; Nicoletti, P; Panero, C; Mainardi, G C; Mini, E; Versari, L (1979). [The role of amikacin in conditions requiring chemotherapy with aminoglycoside antibiotics]. GIORNALE ITALIANO DI CHEMIOTERAPIA, vol. 26, pp. 397-406, ISSN:0017-0445

Mini, E; Mazzei, T; Ciuffi, M; Ruggeri, M; Benini, A; Carniani, E (1979). [Relation of pharmacokinetics and toxicity of methotrexate at high dose]. GIORNALE ITALIANO DI CHEMIOTERAPIA, vol. 26, pp. 387-396, ISSN:0017-0445

Rizzo M, De Carlo G, Amato M, Parri F, Lamanna S, Mini E, Mazzei T (1979). Cefamandole pharmacokinetics in man. DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH, vol. 5, pp. 141-152, ISSN:0378-6501

T. Mazzei; E. Mini; A.M. Cavallo; M. Carini; M. Bonazza; G.C. Vannozzi; G. Zuccati (1979). Chemioterapia oncologica e controllo del dolore cronico mediante farmaci analgesics non narcotics: il ruolo del diflunisal. CHEMIOTERAPIA ONCOLOGICA, vol. anno III, vol 2, pp. 92-109, ISSN:0392-0968

M.Rizzo;C.Bartolozzi;D.CAMMELLI;M.FRANCHINI;G.DE CARLO;G.C.MAINARDI;T.REPETTO;F.PARRI;T.MAZZEI;S.LAMANNA;E.MINI;A.NOVELLI (1979). Clinical pharmacology of bacampicillin: a multidisciplinary study.. DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH, vol. 5 (2-3), pp. 27-32, ISSN:0378-6501

A.LAMANNA;P.NICOLETTI;P.PECILE;A.NOVELLI;E.MINI;P.PERITI (1979). Chemoresistance to fosfomycin: a bacteriological study.. DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH, vol. 5 (2-3), pp. 343-348, ISSN:0378-6501

P.PERITI;T.MAZZEI;E.MINI;A.NOVELLI;P.NICOLETTI;A.LAMANNA (1979). High dose fosfomycin: indications, tolerance and pharmacokinetics.. DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH, vol. 5 (2-3), pp. 373-377, ISSN:0378-6501

A.LAMANNA;P.NICOLETTI;A.NOVELLI;E.MINI;S.MAZZOLI;T.MAZZEI (1979). Dibekacin in vitro activity on recently isolated bacterial strains from various clinical materials.. DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH, vol. 5 (2-3), pp. 259-263, ISSN:0378-6501

P. Nicoletti; A. Novelli; G. Landini; M. Ruggers; T. Mazzei; E. Mini; G. De Carlo; A.M. Cavallo; M. Rizzo; G. Zuccati (1978). Osservazioni laboratoristiche e cliniche sul sinergismo fra fosfomicina e beta lattamine. CHEMIOTERAPIA ANTIMICROBICA, vol. 3, pp. 341-353, ISSN:0391-9862

Mini E (1978). Evaluation of predisposing factors in development of high dose methotrexate toxicity. CHEMIOTERAPIA ONCOLOGICA, vol. 2, pp. 175-175, ISSN:0392-0968

Enrico MINI

Curriculum

CURRICULUM VITAE

Name: Enrico Mini

Date of Birth: February 22, 1952

Place of Birth: Livorno, Italy

ADDRESS

Section of Clinical Pharmacology and Oncology

Department of Health Sciences (UniFI)

EDUCATION

1988: PhD in Pharmacology and Toxicology, UniFI

1980: Specialty in Oncology, University of Modena

1977: MD, with honors, UniFI

CURRENT POSITIONS

Academic:

2011- Director, Specialty School of Medical Oncology, UniFI

2008- Professor of Medical Oncology, UniFI

1992- Head, Laboratory of Cancer Pharmacology and Chemotherapy, UniFI

Clinical:

2014- Director, Unit of Translational Oncology, Careggi University Hospital (AOUC), Florence

PREVIOUS POSITIONS

Academic:

2001-2008: Professor of Pharmacology, Department of Pharmacology, UniFI

1992-2001: Associate Professor of Pharmacology, Department of Pharmacology, UniFI

1988-1992: Lecturer (Cancer Pharmacology), University of Ferrara

1983-1987: Lecturer (Cellular Pharmacology), University of Siena

1981-1985: Research Scientist, Depts Pharmacology and Internal Medicine (Section of Medical Oncology), Yale University School of Medicine, New Haven, CT, USA

Clinical:

2004-2014: Program Director/Attending Physician, Unit of Oncological Pharmacology, AOUC, Florence

1993-2004: Attending Physician, Service of Clinical Pharmacology, Unit of Chemotherapy, AOUC, Florence

VISITING APPOINTMENTS

July-September 2010: Visiting Professor, Dept. Pharmacology, Yale University School of Medicine, New Haven CT, USA

May-July 1989, September 1990: Visiting Scientist, Cornell University Graduate School of Medical Sciences, Laboratory of Molecular Pharmacology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

May 1987, September-October 1987: Visiting Scientist, Departments of Internal Medicine (Section of Medical Oncology) and Pharmacology, Yale University School of Medicine, New Haven CT, USA

HONORS AND AWARDS

1989: UniFI, Italy - Viviana Minozzi Bartolozzi Award

1988-1989: Lady Tata Memorial Trust (LTMT), London, UK - LTMT Award

1988: Italian Society of Pharmacology (SIF), Milan, Italy - Alberico Benedicenti Special Mention Award

1988: National Research Council (CNR), Rome, Italy/National Institute of Health (USA) - Fellowship abroad

1985: International Union against Cancer (UICC), Geneva, Switzerland - International Cancer Research

Technology Transfer (ICRETT) Award

1982-1984: Leukemia Society of America (LSA), New York, NY, USA - Special Fellowship

1981 ,1985, 1986: National Research Council (CNR), Rome, Italy – Fellowship abroad

1980-1981: Italian Association for Cancer Research (AIRC), Milan, Italy - Fellowship abroad

MEMBERSHIP OF COMMITTEES/BOARDS/RESEARCH-STUDY GROUPS

2015-: UniFI Delegate for Oncology Research, Dipartimento Interaziendale di Area Vasta Centro (D.I.A.V.C.) per la Prevenzione, Diagnosi e Cura delle Malattie Oncologiche, Regione Toscana

2015-: Member, Unit of Translational Hematology and Oncology, Center of Excellence for the Study at Molecular Level of Chronic, Degenerative and Neoplastic Diseases to Develop Novel Therapies (DENOTHE), UniFI

2015-: Member, European Organization for Research and Treatment of Cancer (EORTC) – Lung Cancer Group

2015-: Member, Department Committee, Department (DAI) of Oncology - AOUC

2013-: Member and Secretary, Executive Committee, Italian Society of Chemotherapy (SIC)

2012-: Member, Interdepartmental Center ‘Development of Mini-Invasive New Technologies in Oncological Surgery’ (COMIS)

2012-2013: Member, Interdepartmental Center ‘Research on Pharmacoutilization, Pharmacoepidemiology, Pharmacovigilance and Pharmacoeconomy’ (CIRF)

2012: Member, Working Group on Oncological Pharmacology, Italian Society of Pharmacology (SIF)

2007-2011: Member and Secretary, Executive Committee, SIC

2007-2013: Chairman, Cancer Section, International Society of Chemotherapy (ISC) (London)

2007- 2013: Member, Executive Committee, ISC (London)

2005-2007: Member, Executive Committee, SIC

2005-2007: Secretary, Cancer Section, ISC (London)

2004-2012: Member of the Technical-Scientific Committee of Tuscan Cancer Institute, Tuscany Region

1998-: Member, Steering Committee, EORTC, PAN-European Trials in Adjuvant Colon Cancer (PETACC) (Bruxelles)

1998-: Member, EORTC – Gastrointestinal Cancer Group

1997-2001: Member, Executive Committee of the Italian Society of Chemotherapy

1997-2001: Member, Executive Committee, Italian Society of Immunopharmacology

1991-: Secretary, Italian Oncological and Surgical Cooperative Group (GOCCI), Florence

1991-1994: Secretary, Technical-Scientific Committee - Italian Antineoplastic Carriers Consortium (CIVA), Italian National Program on Drugs (Rome)

1987-: Member, EORTC – Pharmacology and Molecular Mechanisms (PAMM) Group

PROFESSIONAL SOCIETIES

American Society for Microbiology (ASM)

European Society of Medical Oncology (ESMO)

European Association for Cancer Research (EACR)

Associazione Italiana di Immunofarmacologia

Società Italiana di Farmacologia (SIF)

European Organisation for Research and Treatment of Cancer (EORTC)

EORTC-Pharmacology and Molecular Mechanisms (PAMM) Group

American Society of Clinical Oncology (ASCO)

American Association for Cancer Research AACR)

Italian Association of Medical Oncology (AIOM)

Italian Society of Chemotherapy (SIC)

MEMBERSHIPS OF EDITORIAL BOARDS

2017-: Editorial Board Member, Cancer Drug Resistance

2015-: Associate Editor, Frontiers in Oncology

2015-: Associate Editor, Frontiers in Pharmacology

2015: Host Editor, Issue ‘Multidrug resistance in cancer: molecular basis, pharmacological strategies and clinical issues’, Frontiers in Oncology

2015 -: Editorial Board Member, Oncology Research

2014 -: Editorial Board Member, Cell Death in Therapy

2014 -: Editorial Board Member, World Cancer Research Journal

2014 -: Editorial Board Member, European Journal of Oncology

2006 -: Associate Editor, Metal-Based Drugs

2002 -: Editor, Journal of Chemotherapy

1997 – 2002: Field Editor - Anticancer Chemotherapy, Journal of Chemotherapy

REVIEWER ACTIVITY

Cancer pharmacology and medical oncology for several peer reviewed key scientific journals and primary national and international granting societies/institutions

RESEARCH GRANTS AWARDED

Prof. Mini’s preclinical and translational research programs are currently supported by Associazione Italiana per la Ricerca sul Cancro, Istituto Toscano Tumori, Ente Cassa di Risparmio di Firenze, Associazione Giacomo Onlus, Gruppo Oncologico Chirurgico Cooperativo Italiano and other private and public research fundings. His research programs have been previously funded by the above and several other institutions (e.g., Ministero dell’Istruzione, dell’Università e della Ricerca (MIUR), Ministero della Salute, Consiglio Nazionale delle Ricerche, Regione Toscana, NATO, Fédération Francophone de Cancérologie Digestive). In particular, Prof. Mini acted as Principal Investigator/Scientific Coordinator in 3 Progetti di Rilevante Interesse Nazionale (PRIN) (n. 2003053403/2003; n. 2005065797/2005; n. 20084TASKL/2008) and as Associated Investigator in 2 PRIN (n. 9806301873_004/1998; n. 9906278347_005/1999) of MIUR. All of them concerned molecular mechanisms of drug resistance in gastrointestinal neoplasms (mainly colorectal cancer), novel pharmacological strategies to revert this phenomenon and identification of potentially predictive biomarkers of drug resistance. Prof. Mini has experience in clinical trials under ICN-GCP and has participated to several national and international clinical trials as a PI, Co-I and national coordinator.

TEACHING ACTIVITY

Currently Prof. Mini holds Medical Oncology courses at the School of Sciences of Human Health (Medicine and Surgery and others 4 healthcare Degree Programs); an Oncology Diagnostics course at the Biotechnologies Degree Program; Oncology courses at various Medical Specialty Schools and Masters, UniFI.

Previously he held Pharmacology courses at Medicine and Surgery and Biotechnologies Degree Programs, at various Medical Specialty Schools (UniFI).

From 2011 he is member of the Council of the Doctorate School in Pharmacology, Toxicology and Innovative Therapies (UniFI).

From 1995 to 2011 he was a member of the Council of the Doctorate School in Molecular and Cellular Physiology, Pharmacology, and Toxicology (University of Siena).

TUTORSHIPS

Prof. Mini has supervised at UniFI, Pharmacology and Toxicology Ph.D. student thesis, M.D., B.S., Pharm. And Biotechnology student thesis, Pharmacology and Medical Oncology Specialty School student thesis work.

MAJOR RESEARCH INTERESTS

Molecular mechanisms of tumor drug resistance and pharmacological strategies to overcome this phenomenon. Pharmacology of antimetabolites and metal-based drugs. Cancer pharmacogenomics and pharmacogenetics. Medical treatment of colorectal cancer. Clinical trials in medical oncology.

INVITED TALKS

Prof. Mini has been invited to give approximately 200 lectures including keynote lectures at national and international congresses or seminars at universities in Italy and abroad.

PUBLICATIONS

Author of more than 150 peer reviewed original articles and more than 40 reviews, editorials, letters (www.ncbi.nlm.nih.gov/entrez/query.fcgi) and book chapters. He has also shared results of his research through approximately 400 communications at national and international meetings.

ORGANIZATIONAL ACTIVITIES

Prof. Mini has organized several national and international congresses, conferences, symposia.